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Some believe it is only great power that can hold evil in check, but that is not what I have 
found.  I found it is the small everyday deeds of ordinary folk that keep the darkness at 
bay.  Small acts of kindness and love.  
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ABSTRACT 
 Abnormal aggregation of microtubule associated protein tau is the defining 
pathological hallmark of tauopathies, which include Alzheimer’s disease (AD) and 
related frontotemporal dementias (FTLD-tau).  However, the cellular events precipitating 
tau pathogenesis in disease are unknown.  Here, we demonstrate a novel mechanism 
regulating tau aggregation in tauopathies.  We have previously shown that RNA binding 
proteins (RBPs) associated with stress granules (SGs) progressively accumulate with tau 
in multiple mouse models of tauopathy, as well as in human AD and FTLD-tau brain 
tissue.  We now present a novel functional role for tau in regulating the biology of SGs in 
neurons.  Tau facilitates the rapid formation of SGs in the soma and dendrites in response 
to exogenous stress, which functions to transiently reprogram protein synthesis to 
promote cell survival (also known as the ‘translational stress response’).  However, the 
chronic interaction of tau with SG proteins in disease, such as with the SG nucleating 
protein T cell intracellular antigen 1 (TIA1), promotes tau misfolding and neurotoxicity, 
which can be modulated in primary neurons by pharmacological or genetic manipulations 
that increase (i.e. puromycin, TIA1 overexpression) or decrease (i.e. cycloheximide, 
  ix 
TIA1 knockdown or knockout) SG formation, respectively.  In order to test whether SGs 
also mediate the progression of tauopathy in vivo, we crossed PS19 transgenic (P301S) 
tau mice with Tia1-/- or C57BL/6J (background strain) mice.  PS19 mice with 
heterozygous reduction in TIA1 (P301S TIA1+/-) developed less SGs compared to 
P301S TIA1+/+ mice, which was associated with marked neuronal protection, improved 
cognitive function, and prolonged lifespan.  The behavioral neuroprotection in P301S 
TIA1+/- mice was associated with decreased accumulation of soluble tau oligomers, and 
occurred despite the increased presence of neurofibrillary tangles.  Our findings suggest 
that TIA1 stabilizes tau in its oligomeric state, preventing its further assembly into 
insoluble fibrils, which are less toxic.  More importantly, the studies described in this 
dissertation identify modulation of RBP aggregation in SGs as a promising therapeutic 
strategy for the treatment of AD and FTLD-tau.  
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PREFACE 
I want to tell you how much I miss my mother.  Bits of her are still there.  I miss 
her most when I’m sitting across from her. 
– Candy Crowley  
  xi 
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INTRODUCTION 
 
Alzheimer’s disease clinical presentation and treatment options 
Alzheimer’s disease (AD) is the most prevalent form of aging-related dementia, 
currently affecting 1 in 9 Americans over the age of 65 with no effective therapies to 
slow the progression of disease (Alzheimer Association, 2016).  The most overt symptom 
of AD is the progressive deterioration of memory and cognitive function that leads to an 
inability to perform everyday tasks.  AD is also associated with a variety of comorbid 
disorders, which include anxiety, depression, and vascular disease (Alzheimer 
Association, 2016; Karran, Mercken, & De Strooper, 2011).  Although the precise cause 
of AD is unknown, the onset and severity of symptoms closely follows the pattern of 
neuronal loss that begins in the entorhinal cortex of the temporal lobe and eventually 
spreads to the entire cerebral cortex (Karran et al., 2011; Tanzi & Bertram, 2005; Yipeng 
Wang & Mandelkow, 2015).  Due to the increasing population of adults over the age of 
65, the number of AD cases is expected to triple by the year 2050, placing a paramount 
importance on the discovery of therapies to modify progression of disease (Alzheimer 
Association, 2016). 
Existing treatment options for AD attempt to alleviate the cognitive and 
behavioral symptoms.  Acetylcholinesterase inhibitors, most commonly doneprezil 
(marketed under the name Aricept), are used to treat the cognitive symptoms at early to 
moderate stages of disease (Szeto & Lewis, 2015).  These drugs target the cholinergic 
deficit caused by the selective vulnerability of cholinergic neurons in early AD by 
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increasing levels of acetylcholine at the synapse.  Acetylcholinesterase inhibitors delay 
the worsening of symptoms for 6 to 12 months, but only show efficacy in approximately 
half of patients and are associated with a variety of side effects (Szeto & Lewis, 2015).  A 
second class of AD drug modulates excitatory neurotransmission in the brain, 
exemplified by the first-in-class drug memantine (marketed under the name of Namenda), 
and is approved for use in moderate to late stage patients.  Memantine is an 
uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) glutamate receptor, 
which inhibits the prolonged influx of calcium ions at excitatory synapses (Lipton, 2005).  
These drugs target the glutamatergic excitotoxicity that has been proposed to play a role 
in neuron loss in AD (Esposito et al., 2013).  Treatment with memantine has been 
reported to delay the deterioration of mood, memory, and other symptoms of late stage 
AD, but like the acetylcholinesterase inhibitors, only shows efficacy in a subset of 
patients and does not modify disease progression (Szeto & Lewis, 2015).  AD treatment 
plans frequently involve co-treatment with antidepressants, anxiolytics, or antipsychotics 
to treat comorbid behavioral symptoms of disease, and almost all cases require significant 
attention by a personal caregiver or admittance to a nursing home that specializes in 
providing care for elderly with dementia (Alzheimer Association, 2016).  Without a 
significant breakthrough in treatment for AD, the societal healthcare cost for the 
treatment of AD is expected to exceed $1 trillion by the year 2050 (Alzheimer 
Association, 2016).   
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Figure 1: Neuropathology of Alzheimer’s disease 
Gallyas silver stain of insoluble beta-sheeted protein aggregates in human Alzheimer’s disease (AD) brain. 
Notice that amyloid plaques accumulate in the extracellular space while neurofibrillary tangles (NFTs) 
accumulate within neurons.  Adapted from (Mandelkow & Mandelkow, 1998). 
 
Alzheimer’s disease pathology and genetics 
Although the underlying cause of AD is unknown, the neuropathology of disease 
and pattern of neuronal loss have been extensively studied.  The AD brain is 
characterized by two distinct pathological protein aggregates: 1) extracellular amyloid 
plaques (also known as senile plaques [SPs]) composed of β-amyloid peptide, and 2) 
intraneuronal neurofibrillary tangles (NFTs) composed of microtubule associated protein 
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tau (MAPT, or tau) (Fig. 1).  β-amyloid (Aβ) peptide is a cleavage product of the amyloid 
precursor protein (APP), which is a ubiquitous transmembrane protein whose primary 
biological function is largely unknown (Steiner, Capell, Leimer, & Haass, 1999).  APP is 
highly expressed at neuronal synapses, and is processed by three proteolytic enzymes 
called secretases.  APP is sequentially cleaved by either α- or β-secretase followed by γ-
secretase (Karran et al., 2011; Steiner et al., 1999; Tanzi & Bertram, 2005; Zhang, 
Thompson, Zhang, & Xu, 2011).  The predominant cleavage product is generated by 
cleavage of APP by α-secretase, while alternative cleavage by β-secretase enzymes (i.e. 
BACE1) generates the 37-49 amino acid Aβ peptide.  Production of Aβ is elevated in the 
AD brain, and Aβ is the primary protein component of the extracellular amyloid plaques 
that accumulate in AD (Tanzi & Bertram, 2005).  Genetic mutations that accelerate the 
production of Aβ cause early-onset familial AD, including mutations in the γ-secretase 
genes Psen1 and Psen2 (which encode the proteins Presenilin 1 and 2 that are subunits of 
the γ-secretase holoenzyme complex) as well as the gene that encodes APP itself (App) 
(Guerreiro & Hardy, 2014; Karch & Goate, 2015).  This has led to the amyloid cascade 
hypothesis which proposes that extracellular amyloid plaques are the initial cause of AD 
pathogenesis (Fig. 2) (J. A. Hardy & Higgins, 1992; Karran et al., 2011; Tanzi & 
Bertram, 2005).  The amyloid cascade hypothesis posits that the presence of extracellular 
amyloid plaques leads to synaptic dysfunction that produces intracellular changes that are 
toxic to neurons.  These changes include the aggregation of tau in NFTs, which then 
leads to neurodegeneration.   
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Figure 2: The amyloid cascade hypothesis 
Schematic representation of the amyloid cascade hypothesis. In Alzheimer’s disease (AD), familial AD 
(FAD) mutations (i.e. in PSEN1/2 or APP) or sporadic aging-related perturbations lead to the accumulation 
of β-amyloid (Aβ) peptide, which produces both soluble Aβ oligomers (Aβ42) and amyloid plaques. The 
aggregate stress from Aβ42 oligomers and plaques induces intracellular changes in neurons, which includes 
hyper-phosphorylation of tau, detachment of tau from microtubules, and destabilization of the microtubule 
cytoskeleton. Free (microtubule unbound) tau then becomes misfolded, allowing tau assembly into paired 
helical filaments (PHFs). As PHFs become mature neurofibrillary tangles, neurons degenerate and cause 
dementia. Adapted from (Karran et al., 2011). 
 
The amyloid cascade hypothesis has been extensively tested in both animal 
models and clinical trials.  Transgenic mice that overexpress the human App and/or 
Psen1/2 mutations linked to familial AD accumulate widespread amyloid plaques and 
develop age-dependent impairment in memory and cognitive function (Götz & Ittner, 
2008; Webster, Bachstetter, Nelson, Schmitt, & Van Eldik, 2014).  However, these mice 
do not develop NFTs and have minimal neuron loss.  Nonetheless, a variety of amyloid 
targeted therapeutics, including secretase inhibitors and anti-Aβ immunotherapies, have 
been shown to effectively reduce amyloid plaques and improve cognition in transgenic 
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mice (Karran et al., 2011; Webster et al., 2014).  Many of these therapeutics have also 
been tested in human patients.  Most notably, treatment with the γ-secretase inhibitor 
semagacestat led to a further deterioration of cognition in Phase III trials despite 
significantly reducing Aβ production (R S Doody et al., 2013).  Further, anti-Aβ 
immunotherapies such as bapineuzumab and solanezumab have shown no positive effect 
over placebo in Phase III clinical trials (Rachelle S Doody et al., 2014; Vandenberghe et 
al., 2016).  These disappointing findings in human studies have prompted researchers to 
reappraise some of the assumptions of the amyloid cascade hypothesis.  Nonetheless, 
many experimental therapeutics targeting Aβ with alternative mechanisms of action are 
still being evaluated in preclinical and clinical trials (Godyn, Jonczyk, Panek, & 
Malawska, 2016; Sevigny, Suhy, et al., 2016).  Notably, aducanumab is an anti-Aβ 
immunotherapy that has elicited promising results in Phase I clinical studies (Sevigny, 
Chiao, et al., 2016).  Aducanumab immunotherapy differs from previous anti-Aβ 
antibodies in two key ways: 1) it was raised specifically against aggregated Aβ isolated 
from human AD brain tissue, rather than against recombinant Aβ peptides or fibrils; and 
2) its target population is restricted to patients with a clinical diagnosis of prodromal or 
mild AD.  Thus, there is renewed optimism that optimization of Aβ–targeted therapeutics 
will deliver an efficacious preventative therapy when administered to the appropriate 
patient population.  Nonetheless, the discovery of new therapies that modify the 
progression of disease after its onset remains an urgent and unmet medical need.   
One of the proposed explanations for the failure of AD therapies in human 
patients is the incomplete understanding of what causes neurons to degenerate in AD.  In 
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fact, a variety of recent findings suggest that the tau protein, and not amyloid plaques, 
represents a more promising therapeutic target (J. Hardy & Selkoe, 2002; Herrup, 2015).  
In healthy individuals, tau is expressed predominantly in the axons of neurons where it 
functions to bind and stabilize microtubules (Mandelkow & Mandelkow, 1998; Yipeng 
Wang & Mandelkow, 2015).  However, in AD and other related forms of dementia, tau 
becomes aberrantly phosphorylated causing it to detach from microtubules and 
mislocalize to the soma and dendrites.  In AD, hyper-phosphorylated and mis-sorted tau 
is known to aggregate into paired helical filaments (PHFs); these PHFs comprise the 
ultrastructural building block for the NFTs that accumulate in degenerating neurons 
(Yipeng Wang & Mandelkow, 2015).  For many years, it has been known that the 
progression of neuron loss and severity of cognitive impairment in human patients is 
highly correlated with the spatiotemporal pattern of NFTs, while largely unrelated to that 
of amyloid plaques (Fig. 3) (Braak & Braak, 1991).  Mutations in the gene encoding tau 
(Mapt) cause Frontotemporal Dementia (FTD) with parkinsonism linked to chromosome 
17 (FTDP-17) (Haugarvoll, Wszolek, & Hutton, 2007), one of several neurodegenerative 
diseases characterized by the abnormal accumulation of NFTs with or without the 
presence of amyloid plaques.  These neurodegenerative disorders are collectively referred 
to as tauopathies (or Frontotemporal Lobar Degeneration with neurofibrillary tau 
pathology [FTLD-tau]), and include FTDP-17, Corticobasal Degeneration, Progressive 
Supranuclear Palsy, and Chronic Traumatic Encephalopathy, among others (Williams, 
2006).  Importantly, Roberson et al. have shown that genetic knockout of tau rescues 
memory loss and excitotoxicity in an amyloid mouse model despite the continued high 
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levels of amyloid plaques (Roberson et al., 2007), indicating that tau is required for 
neuron loss in AD.  Thus, the abnormal aggregation of tau is sufficient to cause 
neurodegeneration, and has emerged as an attractive target for pharmacological 
intervention in AD.  However, the cellular mechanisms precipitating tau aggregation in 
disease remain unknown.  
 
Figure 3:  Cognitive decline in Alzheimer’s disease is caused by neuronal loss, which 
correlates with neurofibrillary tangles 
Graphical representation of the clinical progression of cognitive function, senile plaques (SPs), 
neurofibrillary tangles (NFTs), and neuronal loss in mild cognitive impairment (MCI) and Alzheimer’s 
disease (AD).  Adapted from (Chiba et al. 2013). 
 
A variety of studies have elucidated potential mechanisms of tau aggregation.  
Counterintuitively, tau is one of the most soluble proteins ever described (Jeganathan, 
Von Bergen, Mandelkow, & Mandelkow, 2008).  Due to its lack of hydrophobic residues, 
full length tau is an intrinsically disordered protein in its soluble form, and remains 
natively unfolded over wide variations in pH, ionic strength, solvent polarity, and 
denaturation (Jeganathan et al., 2008).  Only recently have researchers identified 
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biomolecules that induce tau aggregation in vitro.  Polyanionic cofactors, such as heparin 
and dextran sulfate, accelerate the structural transition from random coil to beta-structure 
(Goedert et al., 1996), which can be analyzed by fluorescent dyes such as thioflavin that 
bind to beta-rich structures (Biancalana & Koide, 2010).  However, the physiological 
relevance of these molecules is unknown.  In contrast, RNA is a highly charged 
polyanionic molecule that is abundantly present in high concentrations within the cell.  
Thus, it is notable that RNA has also been demonstrated to induce PHF assembly, in a 
manner dependent upon the microtubule-binding repeat domains and early dimerization 
of tau (Kampers, Friedhoff, Biernat, Mandelkow, & Mandelkow, 1996).   
Post-translational modifications (PTMs) of tau, especially phosphorylation, also 
impact its aggregation properties.  Tau is abnormally hyper-phosphorylated in AD, and 
phosphorylated tau forms PHFs faster than non-phosphorylated tau in vitro (Iqbal et al., 
1998; Minjarez et al., 2013).  Tau protein has 85 putative phosphorylation sites, including 
four KXGS sequences in the microtubule-binding domains that are differentially 
acetylated or phosphorylated (Marcus & Schachter, 2011; Martin, Latypova, & Terro, 
2011), which regulates binding or detachment to tubulin, respectively.  Additional 
residues—such as serine (S) 202, threonine (T) 205, S396, and S404—are selectively 
phosphorylated in AD or FTLD-tau brain tissues, and label PHFs with a high degree of 
specificity.  Both phosphorylation and acetylation of tau, especially in residues in the 
proline-rich and microtubule-binding repeat domains, have been proposed to induce 
conformational changes that promote tau aggregation (Cohen et al., 2011; Martin et al., 
2011; Min et al., 2010; Weaver, Espinoza, Kress, & Davies, 2000) (Fig. 4; Table 1).  
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These conformational changes produce what is referred to as misfolded tau, which is 
widely regarded as a prerequisite to PHF formation (Weaver et al., 2000).  Misfolded tau 
confirmations have also been shown to impair fast axonal transport along microtubules 
(Combs, Hamel, & Kanaan, 2016; Kanaan et al., 2012).  While a variety of kinases, 
phosphatases, acetyltransferases, and chaperones have been linked to the PTMs in tau 
that contribute to disease (Cohen et al., 2011; Fontaine et al., 2015; Marcus & Schachter, 
2011; Martin et al., 2011; Min et al., 2010), the exact sequence of pathological events and 
their requirements for both aggregation and toxicity remain unclear.   
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Figure 4: mRNA and protein domain structure of tau 
A.  The human Mapt gene (encoding the tau protein) contains 16 exons. The six human tau isoforms 
expressed in the brain are generated through alternative splicing of exon 2 (E2), E3, and E10, which 
produce isoforms that include 0, 1, or 2 amino-terminal domains (0N, 1N, or 2N, respectively) and either 3 
or 4 microtubule binding repeat domains (3R or 4R). In the adult brain, levels of the 3R and 4R forms are 
roughly equal and the 2N isoform is underrepresented compared with the others (0N, 1N and 2N tau 
isoforms comprise ~37%, ~54% and ~9%, of total tau, respectively).  B. Tau can be subdivided into two 
major domains. The microtubule assembly domain contains the microtubule binding repeat domains and 
the C-terminal flanking regions, which is responsible for binding to microtubules and for tau aggregation. 
The projection domain is the N-terminal domain that projects away from microtubules. The middle region 
of tau (amino acids 151–243) is a Proline-rich domain that contains multiple Thr-Pro or Ser-Pro motifs that 
are targets of proline-directed kinases such as glycogen synthase kinase 3β (GSK3β), cyclin-dependent 
kinase 5 (CDK5), and p38 mitogen-activated protein kinase (MAPK). In AD and other tauopathies, these 
and other motifs become hyper-phosphorylated and are recognized by several well-characterized phospho-
tau antibodies (AT8, AT180, AT100, 12E8 and PHF1). Mutations in tau are mostly clustered in or near the 
repeat domains, and have been shown to affect alternative splicing of exon 10, binding affinity to 
microtubules, and protein-protein interactions.  Adapted from (Yipeng Wang & Mandelkow, 2015).  
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Table 1: Post-translational modifications in tau 
Summary of the predominant post-translational modifications (PTMs) associated with tau pathology in 
Alzheimer’s disease and related tauopathies.  The work described in the present dissertation uses the 
following antibodies to assess the progression of tau pathophysiology in cultured neurons and in animal 
models: CP13, AT8, PHF1, MC1, TNT1, and TOC1.  
 
While tau aggregation into NFTs has long been regarded as the driver of 
neurodegeneration in tauopathies, a variety of recent studies challenge this assumption.  
Most famously, Santacruz et al. developed a transgenic mouse model (rTg4510 mice) 
overexpressing a human tau mutation (P301L) linked to FTDP-17 under a doxycycline-
repressible promoter to show that NFTs alone are not sufficient to induce 
neurodegeneration (Santacruz et al., 2005).  Santacruz et al. found that rTg4510 mice 
developed an age-dependent accumulation of NFTs, widespread neuronal loss, and 
premature mortality.  Suppression of transgenic tau expression after the presence of NFTs 
by administration of doxycycline reduced levels of soluble tau to endogenous levels; in 
contrast, insoluble NFTs were more stable and persisted despite suppression of the 
transgene.  Surprisingly, despite the persistence of NFTs, doxycycline-treated animals 
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exhibited improved memory performance and increased neuronal survival compared to 
control animals.  This result suggests that the majority of the toxicity associated with tau 
overexpression is due to a soluble rather than insoluble tau species.  More recently, 
several groups have confirmed that soluble tau oligomers, especially dimers and trimers, 
are more toxic than monomers or insoluble fibrils (Lasagna-Reeves et al., 2011).  These 
tau oligomers have been shown to propagate along neuron projections when injected into 
the entorhinal cortex of transgenic tau mice, consistent with the stereotypic spread of tau 
pathology observed in human patients (Hyman, 2014; Kfoury, Holmes, Jiang, Holtzman, 
& Diamond, 2012; Mirbaha, Holmes, Sanders, Bieschke, & Diamond, 2015).  
Inflammatory processes have also been proposed to play an important role in tau 
propagation (Chen, Zhang, & Huang, 2016; Hong, Kim, & Im, 2016).  Further, 18 
different strains of tau oligomers have been isolated from human AD brain tissue, and 
each exhibit distinct biochemical properties and neurotoxicity profiles in vitro and in vivo 
(Kaufman et al., 2016; Sanders et al., 2014).  Thus, while it is now clear that tau 
oligomers are a critical neurotoxic species in AD, the cellular events that lead to their 
accumulation remain poorly understood.   
 
Protein aggregation in neurodegenerative disease 
 Abnormal protein aggregation into oligomers and fibrils is a hallmark of almost 
every neurodegenerative disorder (Tanzi & Bertram, 2005; Lansbury et al. 2006).  
Nonetheless, the clinical features of each disease are distinct.  This has led to the idea that 
neurons, which are highly differentiated and non-dividing cells, are particularly 
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vulnerable to intracellular deficits in protein homeostasis.  As such, the manifestation of a 
specific neurodegenerative disease may depend on which protein(s) aggregates and which 
brain area is affected.  For example, AD results in the pathological accumulation of tau 
initially in the memory centers of the temporal lobe (i.e. the entorhinal cortex and 
hippocampus), which produces memory loss as the most overt clinical feature of disease.  
In contrast, the overwhelming majority of Amyotrophic Lateral Sclerosis (ALS) cases are 
characterized by the pathological accumulation of a protein called Tar DNA binding 
protein 43 kD (TDP-43) within motor neurons of the spinal cord and cortex, which 
produces progressive muscle weakening, motor incoordination, and paralysis.  Thus, 
there is considerable interest in elucidating the cellular processes contributing to 
abnormal protein aggregation in neurodegenerative diseases, as these processes may 
represent shared pathogenic mechanisms amenable to therapeutic intervention.   
 
 
Figure 5: Protein aggregation is a core feature of neurodegenerative disease 
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Schematic of macroscopic and microscopic protein aggregates and the affected brain areas in various 
neurodegenerative diseases: including tau deposits in Alzheimer’s disease (AD) and Frontotemporal 
Dementia (FTD); TDP-43/FUS inclusions in Amyotrophic Lateral Sclerosis (ALS) and FTD; α-synuclein-
positive lewy bodies in Parkinson’s disease (PD) and Lewy Body Dementia (LBD; huntington (htt) protein 
inclusions in Huntington’s disease (HD); and prion protein (PrP) deposits in Prion disease. Adapted from 
(Bertram, Bertram, Tanzi, & Tanzi, 2005). 
 
RNA binding proteins 
RNA binding proteins (RBPs) have diverse roles that regulate all facets of mRNA 
metabolism in neurons.  These proteins are characterized by the presence of two 
conserved domains: RNA recognition motifs (RRMs), which allow RBPs to bind RNA, 
and glycine-rich, low-complexity (LC) domains (also known as intrinsically disordered 
domains [IDRs] or prion-related domains [PRDs]), which confer the ability of reversible 
prion-like aggregation (Gitler & Shorter, 2011; Nussbacher, Batra, Lagier-Tourenne, & 
Yeo, 2015; Ramaswami, Taylor, & Parker, 2013).  In neurons, the functions of RBPs can 
be divided on the basis of their subcellular localization.  The majority of RBP functions 
occur in the nucleus where they regulate transcriptional initiation, alternative splicing, 
and nuclear export (Ash, Vanderweyde, Youmans, Apicco, & Wolozin, 2014; Lagier-
Tourenne, Polymenidou, & Cleveland, 2010; Nussbacher et al., 2015; Wolozin, 2012).  
In the cytoplasm, RBPs and their bound mRNA transcripts associate with molecular 
motors, such as kinesins, and are actively transported along microtubules.  This process is 
critically important in neurons which require extensive transport of mRNAs encoding 
synaptic proteins into processes, axon terminals, and dendritic spines (L. Liu-Yesucevitz 
et al., 2011).  Once at the synapse, RBPs regulate activity-dependent mRNA translation, 
which has been shown to be required for the synaptic plasticity underlying memory (Bliss 
& Collingridge, 1993; Frandemiche et al., 2014; Hoeffer et al., 2012).  Thus, RBPs 
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mediate a variety of nuclear and cytoplasmic processes critical for proper neuronal 
function. 
 
Figure 6: Multifaceted roles for neuronal RNA binding proteins in health and disease 
Proposed physiological roles of RNA binding proteins, using TDP-43 and FUS/TLS as examples. A. 
Summary of major steps in RNA processing from transcription to translation or degradation. B-K. RNA 
binding proteins such as TDP-43 and FUS/TLS have varied roles in transcriptional repression and initiation 
(B-D), alternative splicing (E-G), microRNA processing (H), nucleo-cytoplasmic shuttling (I), nucleation 
and maturation of stress granules (J), RNA transport (K), and local regulation of mRNA 
translation/degradation (K). Mutations in RNA binding proteins that mediate all of these processes have 
been linked to the development of neurodegenerative diseases (Nussbacher et al., 2015). Adapted from 
(Lagier-Tourenne et al., 2010). 
 
In addition to their roles in mRNA metabolism, RBPs also function to rapidly 
reprogram protein synthesis as part of the translational stress response.  Under conditions 
of transient stress, mRNA translation is reprogrammed to repress synthesis of 
housekeeping proteins and selectively upregulate synthesis of stress response proteins 
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(i.e. chaperones and heat shock proteins).  The housekeeping mRNAs become 
sequestered by RBPs that then self-aggregate via their LC domains to form cytoplasmic 
stress granules (SGs) (Anderson & Kedersha, 2008; Gilkes et al., 2004; Protter & Parker, 
2016).  Upon resolution of the cell stress, SGs are rapidly disassembled and normal 
mRNA translation is reinitiated.  Thus, the aggregation of RBPs into SGs is a transient 
and reversible physiological process that protects the cell from apoptosis in the face of a 
temporary stress while preserving the transcriptomic state of the cell that existed prior to 
its onset. 
SGs are highly regulated by various stress signaling pathways (Fig. 7).  Stress-
sensing kinases, including protein kinase R (PKR) and PKR-like endoplasmic reticulum 
kinase (PERK), are activated by specific cell stress conditions (i.e. heat shock, viral 
infection, nutrient deprivation, oxidative stress, unfolded protein response, others), 
leading to downstream phosphorylation of eukaryotic initiation factor 2 alpha (eIF2α) 
(Bentmann, Haass, & Dormann, 2013; N. L. Kedersha, Gupta, Li, Miller, & Anderson, 
1999) (for a detailed description of SGs, please refer to the published reviews from the 
Anderson, Kedersha, Taylor, Parker, and Wolozin laboratories).  eIF2α is a component of 
the eIF2/tRNA/GTP ternary complex that recruits methionine-tRNAs to the 5’-cap of 
processed mRNAs, thereby initiating translation.  However, phosphorylation of eIF2α at 
serine 51 disrupts binding to methionine-tRNA, which results in stalled translational 
initiation, ‘run off’ of actively translating 60S ribosomes, and disassembly of polysomes.  
The remaining untranslated mRNAs are rapidly bound by specific RBPs, including T cell 
intracellular antigen 1 (TIA1), that self-aggregate via their LC domains to form SGs 
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(Gilkes et al., 2004).  Additional proteins, especially those with intrinsically disordered or 
unstructured domains that interact with the LC domains of TIA1, are then recruited to 
form a mature SG via a process called secondary aggregation (Anderson & Kedersha, 
2008; Nancy Kedersha, Ivanov, & Anderson, 2013; Protter & Parker, 2016).  The 
sequestered transcripts are both repressed from active translation and shielded from 
degradation.  In contrast, mRNAs with internal ribosomal entry sites (IRES), such as heat 
shock proteins (i.e. HSP70) and stress response transcription factors (i.e. ATF4), continue 
to be translated; these transcripts do not require the 5’-cap initiation complex to initiate 
protein synthesis and are selectively upregulated.  Upon resolution of the cell stress, 
eIF2α is de-phosphorylated, SGs disassemble, and normal mRNA translation resumes.  
Thus, SGs function to promote cell survival in the face of a transient cell stress by 
dynamically and reversibly reprogramming mRNA translation (Fig. 8).   
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Figure 7: Stress granule life cycle 
Under physiological conditions, ribosomes that translate mRNA into protein are bound to an mRNA 
molecule, forming a polysome. Upon cellular stress, eIF2α is phosphorylated by stress-sensing kinases (i.e. 
PKR, PERK), causing elongating ribosomes to ‘run-off’ the transcript as a result of the reduced availability 
of eIFs, leaving behind a circularized mRNA transcript and 5’-cap pre-initiation complex. SG nucleation is 
initiated by the recruitment of SG-nucleating proteins, such as TIA1 (blue), which triggers the aggregation 
of mRNA particles (mRNPs). Secondary aggregation of additional RNA binding proteins and signaling 
proteins via protein–protein interactions with the low-complexity (LC) domains of TIA1 facilitate 
maturation of the aggregated mRNPs into stress granules (SGs). During recovery from stress, SG proteins 
dissociate from the SG, allowing ribosomes to bind and re-form a translating polysome. Adapted from 
(Bentmann et al., 2013). 
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Figure 8: Summary of stress granule biology 
Stress granules (SGs) form to rapidly re-program protein synthesis in the face of transient stress. Under 
normal physiological conditions (no stress, green), RNA binding proteins (RBPs) associated with SGs 
remain largely in the nucleus, where they are free to mediate transcription and splicing. Under conditions of 
cell stress (red), stress kinases become activated leading to the phosphorylation of eIF2α, which serves as 
the molecular switch that initiates SG formation. SG nucleating proteins such as TIA1 bind mRNA and 
aggregate via self-assembly of their low-complexity (LC) domains, sequestering RBPs and housekeeping 
mRNAs in cytoplasmic granules. mRNA transcripts required for the response to stress are not recruited to 
SGs, and are preferentially translated. Upon resolution of stress, eIF2α is de-phosphorylated, and SGs 
disperse to facilitate normal mRNA translation.  
 
 
RNA binding proteins in neurodegenerative disorders 
Due to the innately aggregation-prone nature of SG biology, it is noteworthy that 
they have been found to associate with the primary pathological aggregates in various 
neurodegenerative disorders.  Further, genetic polymorphisms in many RBPs with LC 
domains, including TDP-43, fused in sarcoma (FUS), and heterogeneous 
ribonucleoprotein (hnRNP) A1, cause ALS and/or FTD (Bentmann et al., 2013; 
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Couthouis et al., 2012; Gitler & Shorter, 2011; Neumann et al., 2006).  The disease-
linked mutations predominantly occur in the LC domain of each of these proteins and are 
gain-of-function mutations that increase their propensity to aggregate (Johnson et al., 
2009; Kwiatkowski et al., 2009).  More recently, disease-linked mutations in FUS and 
hnRNP A1 have been shown to promote the phase transition of SGs from normally 
reversible liquid droplets to irreversible fibrils capable of sequestering additional RBPs 
out of solution (Huang, Lempicki, & Sherman, 2009; Molliex et al., 2015; Murakami et 
al., 2015; Nott et al., 2015; Ramaswami et al., 2013).  Thus, dysfunction of RBPs has 
emerged as a crucial contributor to neuronal dysfunction in a variety of 
neurodegenerative conditions (Fig. 9).   
 
 
Figure 9: Low complexity domains of stress granules regulate phase transition between 
soluble, liquid-droplet, and amyloid-like states  
Cytoplasmic RNA granules such as stress granules (SGs) assemble due to the presence of prion-like, low-
complexity (LC) domains in RNA binding proteins (RBPs). In physiological conditions, RNA granules 
behave like liquid droplets, allowing them to reversibly assemble and disassemble; granules can also be 
cleared by autophagy. In disease, stable amyloid-like assemblies form stochastically from persistent SGs, 
and disease-linked mutations affecting the LC domains accelerate this phase transition. Over time, these 
stable, persistent assemblies might evolve into the pathological inclusions characteristic of 
neurodegenerative disease. Adapted from (Ramaswami et al., 2013). 
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Our lab has discovered that SG pathology is a heretofore undescribed clinical 
feature of tauopathies.  SGs are abnormally large in AD and FTDP-17 cortex, and co-
localize with phosphorylated tau pathology (Fig. 10) (Vanderweyde et al., 2012).  
Further, SGs progressively accumulate over the course of disease in various mouse 
models of tauopathy (i.e. rTg4510, PS19, JNPL3) (Vanderweyde et al., 2012).  Many 
studies have reported that activation of stress-sensing eIF2α kinases, which induce SG 
formation, is elevated in AD brain tissue (Bell, Meier, Ingram, & Abisambra, 2016; 
Ohno, 2014), while emerging evidence suggests that Aβ oligomers promote the 
translational stress response via phosphorylation of eIF2α (Lourenco et al., 2013; Ma et 
al., 2013).  Together, these studies raise the possibility that the aggregation of tau in 
disease occurs via its interaction with SGs.  This possibility is particularly plausible due 
to the physiological role of SG proteins such as TIA1 in regulating the aggregation of 
natively unstructured proteins such as tau.  However, the effect of SGs on the progression 
of tau aggregation and neuronal loss in tauopathies has not been investigated.   
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Figure 10: Stress granules associate with tau pathology in human tauopathies 
A. Frontal cortex from a human subject with AD immunolabeled with antibodies to phospho- (CP-13, PHF-
1) or total (Tau-5) tau (green) and TIA-1 (red). Nuclei were identified with DAPI (blue). Note that TIA-1 
colocalized with both phosphorylated and total tau aggregates. Adapted from (Vanderweyde et al., 2012). 
 
Summary 
 Abnormal aggregation of tau is the defining pathological hallmark of tauopathies 
such as AD.  However, the cellular mechanisms precipitating tau pathogenesis in disease 
remain unknown.  Emerging evidence suggests that the neuropathology in various 
neurodegenerative diseases, including tau aggregates in AD, is associated with SGs.  
Here, we propose that the interaction of tau with SGs promotes tau misfolding and 
aggregation.  Further, the chronic stress associated with disease produces SGs that are no 
longer transient, but persistent, which serves to sequester additional RBPs out of the 
nucleus.  The resulting nuclear depletion of RBPs leads to deregulated splicing of nascent 
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mRNA transcripts, many of which encode synaptic proteins required for proper 
neurotransmission.  Thus, SGs may induce neurotoxicity by either a gain-of-function (i.e. 
accelerating tau aggregation) or a loss-of-function (i.e. disruption of RBP mediated 
mRNA splicing) mechanism.  However, the role of SGs in the progression of tau 
pathology and toxicity in AD is unknown.   
 
Hypothesis 
The interaction of tau with RNA binding proteins in stress granules 
promotes tau aggregation and toxicity. 
 
Specific Aims 
Aim 1: To determine whether tau regulates stress granule formation in neurons 
Aim 2: To determine whether the interaction of tau with stress granules promotes tau 
pathophysiology in neurons 
Aim 3: To determine whether reducing endogenous TIA1 protects against the progression 
of tauopathy in vivo 
Aim 4: To determine if TIA1 reduction protects against tau mediated mRNA splicing 
deficits in vivo 
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MATERIALS AND METHODS 
 
Cell Culture:  Mouse immortalized hippocampal neuronal (HT22) cells were maintained 
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine 
serum, 1% non-essential amino acids, 1% penicillin/streptomycin, and 4.5 g/L glucose.  
Cells were transfected using 2 µL Lipofectamine (Invitrogen) per µg DNA plasmids, 
incubated for 24 hours, and treated for 24 h (25 µM salubrinal, 5 g/ml puromycin, 10 
g/ml cycloheximide).  At 48 hours post-transfection, the cells were either lysed in 
radioassay immunoprecipitation (RIPA) buffer (50 mM Tris-HCl, 150 mM NaCl, 1% 
Triton X-100, 0.1% SDS) for analysis by immunoblotting or fixed for 15 min in 4% 
PFA/PBS for analysis by immunocytochemistry (see below).  For primary mouse 
hippocampal cultures, neonatal (P0) pups were deeply aneasthetized and their brains 
dissected.  P0 hippocampi were incubated in 0.25% trypsin supplemented with DNase for  
15 min, gently triturated and filtered, and grown on 12 or 18 mm glass coverslips for 21 
days in vitro (DIV) in Neurobasal medium supplemented with B-27 (Invitrogen). 
 
Tau kinase Inhibitors: HT22 cells were plated on 18 mm glass coverslips pre-coated with 
Poly-D Lysine and transfected 24 h later using Lipofectamine 2000 transfection reagent 
according to manufacturer’s instructions (Life Technologies).  24 h after transfection, 
cells were treated with 10 μM Salubrinal (Santa Cruz Biotech, Cat#202332) or DMSO 
plus one of the following small molecule tau kinase inhibitors for 24 h: 5 μM GSK3β 
Inhibitor XXVI (EMD Millipore, Cat#361569), 5 μM Cdk 2/5 (EMD Millipore, 
  
26 
Cat#219448), 250 nM p38 MAPK (Invitrogen, SB203580), 20 μM MARK/Par-1 (EMD 
Millipore, 39621), or 20 nM Fyn (Invitrogen, PP2, Cat#PHZ1223).  
 
AAV Transduction:  At DIV2, primary hippocampal neurons were transduced with 
AAV9 vectors at a multiplicity of infection (MOI) of (mRFP, mRFP-TIA1, shTIA1-GFP, 
or shControl-GFP).  On DIV5, neurons were transduced with AAV9-WT or P301L tau 
virus (MOI 20).  
 
Immunocytochemistry: Fixed cells were rinsed 3x in phosphate buffered saline (PBS) 
followed by permeablization for 15 min in PBS/0.1% Triton X-100 (PBS-T).  Triton X-
100 was used in all blocking, washing, and incubation steps for all antibodies except for 
MC1, which recognizes a conformational epitope sensitive to detergent.  After 
permeablizing the cell membranes, cells were blocked in PBS-T supplemented with 10% 
normal donkey serum for 1 h, followed by incubation with primary antibodies diluted in 
PBS-T/5% normal donkey serum overnight at 4°C.  Primary antibodies used were: CP13 
(1:150), PHF1 (1:150), MC1 (1:150), and Tau13 (1:5,000) anti-tau antibodies 
(generously provided by Drs. Peter Davies and Nicholas Kanaan); TIA1 (1:300, Santa 
Cruz); MAP2 (1:1000, Aves).  The next day, cells were washed 3x in PBS-T followed by 
incubation with Alexa-conjugated secondary antibodies (Jackson ImmunoResearch) 
diluted 1:700 in PBS-T/5% normal donkey serum.  After secondary incubation, cells 
were washed 3x in PBS-T and mounted onto microscope slides using ProLong Gold 
antifade reagent.   
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Live-Cell Microscopy: Live-cell imaging was performed using an Olympus DSU 
spinning disk confocal capable carrying lasers at 405, 488, 543, and 633 nm, or a Zeiss 
Axio Observer Z1.  Time course images were captured using a 63x oil objective, at 30s 
intervals up to 6 hours.  
 
Photo-Conversion: Photo-convertible WT human tau (PC-Tau) was generated by 
subcloning human 0N4R tau into the pPS-CFP2-C mammalian expression vector 
(Evrogen cat# FP801).  This expression vector encodes a cyan-to-green fluorescent 
protein under control of the CMV promoter, and has been optimized for high expression 
in mammalian cells.  Primary neurons were cultured on MatTek glass-bottom dishes 
suitable for live-cell imaging.  Neurons were transfected at DIV5 with PC-WT ± RFP 
TIA1 or mCherry, using Lipofectamine-2000 transfection reagent (Invitrogen) and aged 
to DIV18-23 prior to photoconversion.  Activation was optimized and performed using a 
diode 405nm laser on a Zeiss LSM-710 Duo Scan at 63X magnification, for efficient 
photo-conversion of tau with minimal photo-bleaching.  Photo-conversion was performed 
using the 405nm laser powered at 20%.  The samples were scanned first to make sure that 
no photo-conversion had occurred prior to laser treatment.  To prevent photo-conversion 
during preliminary imaging, the laser was set with the 405nm laser powered at 9%, and 
imaged using a gain of 7-800.  Next, the photo-conversion was accomplished with the 
405nm laser powered at 20%, and samples scanned with 20 iterations of treatment, after 
which the samples were imaged again to confirm photoconversion.  Following laser 
activation, neurons were imaged on a Zeiss Axio Observer Z1, at 63X magnification, at 
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20 min intervals over 6 hours.  Quantification of tau fluorescence at the neuron soma was 
performed using ImageJ by manually outlining the neuronal soma at Time=0 and 
analyzing fluorescence intensity within that ROI at each subsequent timepoint.  All 
values are expressed as the percentage of initial fluorescence intensity for a given neuron 
(ie: Time=0 was set to 100% independently, for each neuron).  
 
Immunoprecipitation for cell culture studies:  Lysates (100-300 µg) were pre-cleared with 
rec-Protein G-Sepharose 4B Conjugate beads (Invitrogen), then immunoprecipitated (IP-
ed) overnight at 4°C with either 0.5 µl PHF1, 1 µl Tau5 (Abcam), 1µL MC1, or 0.5 µL 
TIA1 (Santa Cruz) antibody, followed by addition of 50 µl rec-Protein G-Sepharose 4B 
Conjugate beads for 2 hour at 4°C.  The beads were then centrifuged and washed 3x in 
PBS, followed by elution in 1x SDS-sample buffer at 95°C for 5 min.  IP eluates were 
collected and analyzed by immunoblot (see below).   
 
Cell Death studies:  Caspase 3/7 cleavage and apoptotic DNA fragmentation were 
quantified according to manufacturer’s instruction using the Caspase-Glo 3/7 Assay kit 
(Promega) and TiterTACS Colorimetric Apoptosis Detection kit (Trevigen).  
 
Animals:  Tau-/- (Mapt-/-) mice were generated as described by Dawson and colleagues 
(Dawson et al., 2001).  TIA1-/- (Tia1-/-) mice (B6.129S2(C)-Tia1
tm1Andp
/J) were 
generated by Anderson and colleagues and obtained from Harvard University, Dana 
Farber Cancer Institute (Phillips et al., 2004); these mice have been backcrossed for 10+ 
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generations to a 100% C57BL/6J genetic background.  PS19 (B6;C3-Tg(Prnp-
MAPT*P301S)PS19Vle/J, stock #008169) and C57BL/6J (stock #000664) mice were 
purchased from Jackson Laboratories (Yoshiyama et al., 2007).  All animals were housed 
in IACUC-approved vivariums at Boston University School of Medicine.  To generate 
colonies of P301S TIA1+/+ and P301S TIA1+/- mice, PS19 mice were bred with Tia1-/- 
and C57BL/6J mice to produce pups with one or two copies of the endogenous mouse 
Tia1 allele, respectively, on the same mixed genetic background.  P301S Tau mice on 
homozygous Tia1-/- background were not used in this study due to low breeding 
efficiency, as previously reported, and to control for the mixed genetic background of our 
P301S TIA1+/+ and P301S TIA1+/- colonies.  Mice were aged to 3, 6, and 9 months for 
analysis by the behavioral, biochemical, and histological approaches described below.  
Sample sizes were chosen based on prior publications using these mice (Yoshiyama et 
al., 2007). 
 
Behavioral analysis of PS19 mice:  All behavioral analyses utilized roughly equal 
numbers of male and female mice, and were performed at 6 months of age prior to the 
onset of the neuromuscular symptoms of disease (i.e. ataxia, hind limb 
weakness/paralysis).  For the Open Field (OF) assay, mice were placed in a light- and 
sound-proof chamber (22 cm wide x 42 cm long) and recorded for 30 min using infrared 
cameras (Swann Security, Victoria, Australia).  Total locomotor activity, center time, 
mean speed, and freezing behaviors, amongst other parameters, were automatically 
measured using ANY-maze behavioral tracking software (Stoelting, Wood Dale, IL).  For 
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the Y maze spontaneous alternation task, animals were placed in an opaque, Y shaped 
maze with 3 arms of equal length (15 inches each) that diverged at equal angles, and 
recorded for 10 min.  The total number and sequence of arm entries over the test period 
was scored by 2 blinded observers.  A successful alternation was defined as consecutive 
entries into all three arms without returning to a previously visited arm.  Thus, the 
maximum number of alternations was the total number of arm entries minus two, and the 
correct alternation percentage was calculated as (actual alternations/maximum 
alternations)×100.  For the novel object recognition (NOR) test, animals were habituated 
to the testing chambers for 2 days prior to testing day, 30 min each.  The testing 
chambers were rectangular (22 cm wide x 42 cm long) apparatuses completely covered 
on the outside in 4 different patterns of construction paper to make the environment 
opaque and to allow the mice to spatially orient themselves in the apparatus.  The 4 
patterns used for the wall cues were blank (white), polka dots, horizontal bars, and 
vertical bars (all black and white).  On testing day, animals were placed in the chamber 
and allowed to explore 2 identical objects for 5 min (exploration phase).  90 min later, the 
animals were returned to the testing chamber with one of the two objects replaced with a 
novel object.  The exploratory behavior of the animals was recorded for 5 min using 
infrared cameras (Swann Security, Victoria, Australia).  The objects used in the study 
were T-25 cell culture flasks filled with sand and multi-colored rectangular lego stacks, 
as described previously (Leger et al., 2013).  All experimental factors, including the type 
and location of the novel object, were counterbalanced throughout the experiment.  The 
amount of time spent exploring the familiar and novel objects, determined by head 
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placement within 0.5 cm of each object, was automatically measured using ANY-maze 
behavioral tracking software (Stoelting, Wood Dale, IL).  Animals that did not meet a 
minimum exploration time (5 s) over the course of the 5 min test session were excluded 
from downstream analysis.  For the survival study, animals were assessed daily starting at 
7 months of age by the veterinary staff of the Boston University Animal Science Center.  
Endpoint criterion was determined to be at least one of the following: dragging or 
paralysis of 2 or more limbs, postural instability/inability to feed, or greater than 10% 
loss in body weight.  For statistical analysis of animal studies, we behaviorally assessed 
(on average) 16 mice per group in order to achieve sufficient power to detect moderate 
differences between groups (based on the expected effect size of approximately 0.5).  
Post-hoc power analysis confirmed an achieved statistical power of 80%. 
 
Tissue Processing:  Animals were deeply anesthetized and perfused with ice cold 
phosphate buffered saline (PBS), followed by brain dissection.  The left hemisphere was 
fixed in 4% paraformaldehyde/PBS for 24 h, and then transferred to 30% sucrose/PBS 
solution for 48 h prior to freezing in OCT media for cryosectioning.  Brains were cut into 
40 µm coronal sections and stored at -20°C in 30% glycerol/30% ethylene glycol/PBS 
solution until day of staining.  From the right hemisphere, the cerebellum, hippocampus, 
striatum, and cerebral cortex tissues were separately dissected and flash frozen on dry ice 
prior to biochemical analysis as described below.   
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Histology:  Nissl and Gallyas Silver staining were performed on 40 µm free-floating 
sections using the FD Cresyl Violet™ (cat#PS102-01) and FD NeuroSilver™ Kit II 
(cat#PK301A) kits from FD NeuroTechnologies according to manufacturer’s 
instructions.  For neuron number studies, the number of Nissl-positive neurons per field 
was counted by three blinded observers, and the average was determined.  Neuronal loss 
was also determined by a secondary method, NeuN immunohistochemistry (see below), 
and quantified using Imaris Bitplane automated imaging software.  For Layer II/III 
cortical thickness studies, Nissl stained sections were imaged at 10x magnification using 
a brightfield microscope.  The length between the most superficial point of Layer II and 
the deepest point of Layer III was measured using Zen Blue microscope and image 
analysis software.  At least 5 measurements were taken per image, 3 images per mouse 
(n=5 mice/group).  For thioflavin S (ThioS) staining, 40 µm sections were mounted onto 
glass microscope slides and allowed to completely dry.  Slides were washed sequentially 
in 70% and 80% ethanol, 1 min each, prior to incubating in 1% ThioS/80% ethanol 
solution for 15 min.  Sections were then sequentially washed in 80% and 70% ethanol, 1 
min each, followed by two rinses in distilled water.  Slides were mounted in Prolong 
Gold antifade reagent and stored in the dark until imaging.   
 
Immunohistochemistry:  For immunohistochemistry (IHC), 40 µm sections prepared as 
described above were immunostained free-floating in 12-well plates.  Sections were 
washed in Tris buffered saline (TBS), followed by permeabilization in TBS 
supplemented with 0.05% Triton X-100 (TBS-T), 3 washes 10 min each.  Sections were 
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then incubated in citric acid based antigen unmasking solution (Vector Laboratories, 
cat#H-3300) for 1 h at 70°C.  Following antigen retrieval, sections were cooled to room 
temperature (RT), washed 3 times in TBS-T, and incubated in blocking buffer (TBS-T 
supplemented with 5% normal donkey serum and 1% bovine serum albumin) at RT for 2 
h.  Sections were then incubated in primary antibody solutions diluted in blocking buffer 
for 48 h at 4°C.  The primary antibodies used were as follows: AT8 (1:100, 
ThermoFisher Scientific, cat#MN1020), CP13 and PHF1 (1:100, generously provided by 
P. Davies), TIA1 (1:300, abcam ab40693), NeuN (1:1000, EMD Millipore cat#ABN78), 
and Synaptophysin (1:300, SantaCruz Biotechnology sc-17750).  After 48 h, sections 
were washed 4 times in TBS-T and incubated in donkey Alexa Fluor488/594-conjugated 
secondary antibodies (Jackson ImmunoResearch) diluted 1:500 in blocking buffer for 2 h 
at RT.  After incubation in secondary antibodies, the sections were washed 2 times in 
TBS-T, followed by a 20 min incubation in DAPI nuclear stain (1:20,000 in TBS-T), and 
2 final washes in TBS-T.  Sections were then mounted on microscope slides in Prolong 
Gold antifade reagent for imaging using epifluorescence and/or confocal microscopes.  
All staining steps were performed with gentle agitation.  Plates were covered in 
aluminum foil for all steps following addition of secondary antibodies to prevent 
photobleaching of fluorophores.   
 
Fluorescence microscopy:  Confocal microscopy was performed using a Carl Zeiss LSM 
510. Super-resolution images were recorded with a Vutara 200 super-resolution 
microscope (Bruker Nano Surfaces., Salt Lake City, UT) with single molecule 
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localization (SML) using biplane FPALM technology (Juette et al., 2008).  
 
Biochemical fractionation:  Hippocampus and cortex tissues were homogenated in 10x 
v/w (L:mg) Hsaio TBS buffer (50 mM Tris, pH 8.0, 274 mM NaCl, 5 mM KCl) 
supplemented with protease and phosphatase inhibitor cocktails (Roche, 
cat#05892791001 and cat#04906837001), as described previously.  100 mg cortical and 
50 mg hippocampal homogenates were ultracentrifuged at 28,000 rpm at 4°C for 20 min.  
The supernatant (S1) fractions were ultracentrifuged a second time at 55,000 rpm at 4°C 
for 20 min to separate the TBS-extractable supernatant (S1c) and pellet (S1p) fractions.  
S1p pellets were resuspended in 4x volume of TE buffer relative to the starting weight of 
the tissue homogenate.  Next, the pellet from the first spin (P1) was homogenized in 5x 
v/w Buffer B (10 mM Tris, pH 7.4, 800 mM NaCl, 10% sucrose, 1 mM EGTA, 1 mM 
PMSF) using a microcentrifuge pestle, and then ultracentrifuged at 22,000 rpm at 4°C for 
30 min.  Detergent was then added to the supernatant (S2) fraction to yield a final 
concentration of 1% sarkosyl, followed by incubation at 37°C on a thermomixer for 1 h.  
The samples were then ultracentrifuged at 55,000 rpm at 4°C for 1 h to yield the 
sarkosyl-soluble (S3, supernatant) and sarkosyl-insoluble (P3, pellet) fractions.  Finally, 
RIPA buffer was added to the remaining unused brain homogenates to a final 
concentration of 50 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, and 
5mM EDTA.  S1p, S3, P3, and total (RIPA-soluble) fractions from the same starting 
tissues were then analyzed by SDS-PAGE as described below.   
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Immunoblot:  Reducing and non-reducing protein samples were separated by gel 
electrophoresis and transferred to nitrocellulose membranes using the Bolt SDS-PAGE 
system (Life Technologies).  Membranes were blocked in 5% nonfat dry milk (NFDM) in 
TBS supplemented with 0.025% Tween-20 (TBS-T) for 1 h at RT, followed by 
incubation overnight at 4°C in primary antibody diluted in 5% bovine serum 
albumin/TBS-T.  Primary antibodies used were as follows: Tau5 (1:1000), Tau13 
(1:25,000), TOC1 (1:500), and TNT1 (1:500) anti-tau antibodies (Combs et al., 2016); 
PHF1 (1:500) and CP13 (1:500) anti-tau antibodies (generously provided by P. Davies); 
TIA1 (1:500, Santa Cruz Biotechnology, sc-1751), acetylated-α-tubulin (1:1000, Cell 
Signaling Technologies, cat#5335S), total α-tubulin (1:5000), synaptophysin (1:1000, 
Santa Cruz), PSD-95 (1:1000, NeuroMab), total and cleaved caspase 3 (1:10,000, Cell 
Signaling), actin (1:10,000, Millipore), PABP (1:1000, abcam ab21060), and DDX6 
(1:500, Bethyl Labs cat#A300-460A).  Membranes were then washed 3 times with TBS-
T and incubated in HRP-conjugated secondary antibodies (Jackson ImmunoResearch) 
diluted in 1% non-fat dry milk (NFDM)/TBS-T at RT for 1 h.  After incubation in 
secondary antibody, membranes were washed 3 times in TBS-T and developed using 
SuperSignal West Pico Chemilluminescent ECL substrate (ThermoFisher Scientific, 
cat#34080).   
 
ELISAs:  Capture antibodies (Tau5, TNT1, and TOC1) were diluted to a final 
concentration of 2 ng/µl in phosphate buffered saline (PBS) and adsorbed to Nunc 
Maxisorp 96-well plates (Cole Palmer, cat#EW-01928-08) for 1 h.  Plates were washed 
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4x in PBS, blocked for 1 h with 5% NFDM/PBS, and washed again 4x in PBS.  For non-
denaturing analysis of S1 fractions from 9 month PS19 cortex, 20 µg/well samples were 
diluted in PBS and added to each well in triplicate.  Known concentrations of 
recombinant human tau (WT 0N4R) were used to generate a standard curve.  Samples 
were incubated for 1.5 h at RT, washed 4x in PBS, and then incubated for 1 h with 
detection antibody (rabbit anti-R1 total tau) diluted 1:10,000 in 5% NFDM/PBS(Combs 
et al., 2016).  Plates were washed 4x in PBS followed by incubation with HRP-
conjugated donkey anti-rabbit IgG (Jackson ImmunoResearch) diluted 1:5,000 in 5% 
NFDM/PBS for 1 h.  Plates were washed 4x in PBS and incubated in OPB solution (1 
mg/ml OPB in 0.05 sodium phosphate, pH 5.0, 0.05 M citric acid, and 1% hydrogen 
peroxide) for 15 min at RT.  Reactions were stopped using 2.5 M sulfuric acid, and the 
absorbance was measured at 490 nm.   
 
Microtubule binding assay:  Frozen cortex tissue was homogenized in 10x v/w (L:mg) 
RAB buffer (0.1 M MES, pH 6.8, 0.5 mM MgSO4, 1 mM EGTA, 2 mM DTT, 4 M 
Glycerol, 2 mM GTP, 0.1% Triton X-100).  50 mg homogenate was ultracentrifuged at 
50,000 rpm at 30°C for 40 min.  Supernantant (S, unbound) fraction was removed to a 
new microcentrifuge tube and stored at -80°C.  Pellet (P, microtubule-bound) fractions 
were re-suspended in urea buffer (30 mM Tris-HCl, pH 8.4, 8 M urea, 1% CHAPS).  10 
µL of each the supernatant and pellet fractions were analyzed by SDS-PAGE.   
  
37 
Image analysis:  Images were analyzed for total fluorescence, co-localization, puncta, and 
cell numbers, as appropriate, using Imaris Bitplane and ImageJ image analysis software.  
For Sholl analysis and quantification of total dendritic length, neurite tracing was 
performed by tracing MAP2-positive processes in the Fiji plugin for ImageJ.  Live-cell 
tracking of granule movements and velocity was performed using Imaris Bitplane 
software.  All statistical analyses were performed using GraphPad Prism data analysis 
software. 
 
Immunoprecipitation for Proteomics: For TIA1 IP, 10 month Tia1-/-, Mapt-/-, and WT 
C57BL/6J (the genetic background) male mice were anesthetized in an isoflurane 
chamber and perfused with ice cold PBS.  The brains were then dissected to separate the 
hindbrain, hippocampus, and cerebral cortex.  Tissues were slowly frozen by submersion 
in methanol on dry ice and homogenized in RIPA lysis buffer (50 mM Tris-HCl, 150 mM 
NaCl, 1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, pH 6.8) supplemented 
with protease (Roche Cat#04693159001) and phosphatase inhibitor (Roche 
Cat#04906837001) cocktails.  TIA1 was immunoprecipitated from 2 mg cortex lysate 
using 10 μg goat anti-TIA1 polyclonal antibody (Santa Cruz Biotech, Cat#sc-1751) 
immobilized on Pierce Direct IP columns according to manufacturer’s instructions 
(Thermo Scientific, Cat#26148).  The TIA1 IP eluates were then separated on a Novex 4-
12% Bis-Tris polyacrylamide gel (Life Technologies, Cat#NP0323) and stained with 
Simply Blue Coomassie G-250 SafeStain (Life Technologies, Cat#LC6060).  Whole gel 
lanes were then excised and shipped to the UMass Mass Spectrometry and Proteomics 
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facility for analysis by LC-MS/MS.  For Tau IPs, total tau was immunoprecipitated from 
1 mg brain lysate of 6 month old Mapt-/- (negative control), non-transgenic (WT Tau 
TIA1+/+, the background strain for PS19 studies), and PS19 cortex tissues using 10 µg 
Tau5 or Tau13 mouse monoclonal antibody.  All procedures regarding column 
preparation, IP, elution, and sample preparation for LC-MS/MS were performed exactly 
as described for the TIA1 IP above.   
 
Proteomics, In Gel Digestion: Gel slices were cut into 1x1 mm pieces and placed in 
1.5ml eppendorf tubes with 1ml of water for 30 min.  The water was removed and 50 ul 
of 250 mM ammonium bicarbonate was added.  For reduction 20 μl of a 45 mM solution 
of 1, 4 dithiothreitol (DTT) was added and the samples were incubated at 50 C for 30 
min.  The samples were cooled to room temperature and then for alkylation 20 μl of a 
100 mM iodoacetamide solution was added and allowed to react for 30 min.  The gel 
slices were washed 2 X with 1 ml water aliquots.  The water was removed and 1ml of 
50:50 (50mM Ammonium Bicarbonate: Acetonitrile) was placed in each tube and 
samples were incubated at room temperature for 1 h.  The solution was then removed and 
200 ul of acetonitrile was added to each tube at which point the gels slices turned opaque 
white.  The acetonitrile was removed and gel slices were further dried in a Speed Vac.  
Gel slices were rehydrated in 75 μl of 2 ng/μl trypsin (Sigma) in 0.01% ProteaseMAX 
Surfactant (Promega): 50mM Ammonium Bicarbonate.  Additional bicarbonate buffer 
was added to ensure complete submersion of the gel slices. Samples were incubated at 
37C for 21 h.  The supernatant of each sample was then removed and placed in a separate 
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1.5 ml eppendorf tube.  Gel slices were further dehydrated with 100 ul of 80:20 
(Acetonitrile: 1% formic acid).  The extract was combined with the supernatants of each 
sample.  The samples were then dried down in a Speed Vac.  Samples were dissolved in 
25 μl of 5% Acetonitrile in 0.1% trifluroacetic acid prior to injection on LC/MS/MS. 
 
LC-MS/MS on Q Exactive: A 3.0 μl aliquot was directly injected onto a custom packed 2 
cm x 100 μm C18 Magic 5 μm particle trap column.  Labeled peptides were then eluted 
and sprayed from a custom packed emitter (75μm x 25cm C18 Magic 3μm particle) with 
a linear gradient from 95% solvent A (0.1% formic acid in water) to 35% solvent B 
(0.1% formic acid in Acetonitrile) in 90 minutes at a flow rate of 300 nanoliters per 
minute on a Waters Nano Acquity UPLC system.  Data dependent acquisitions were 
performed on a Q Exactive mass spectrometer (Thermo Scientific) according to an 
experiment where full MS scans from 300-1750 m/z were acquired at a resolution of 
70,000 followed by 10 MS/MS scans acquired under HCD fragmentation at a resolution 
of 17,500 with an isolation width of 1.6 Da.  Raw data files were processed with 
Proteome Discoverer (version 1.4) prior to searching with Mascot Server (version 2.5) 
against the Uniprot database.  Search parameters utilized were fully tryptic with 2 missed 
cleavages, parent mass tolerances of 10 ppm and fragment mass tolerances of 0.05 Da.  A 
fixed modification of carbamidomethyl cysteine and variable modifications of acetyl 
(protein N-term), pyro glutamic for N-term glutamine, oxidation of methionine were 
considered.  Search results were loaded into the Scaffold Viewer (Proteome Software, 
Inc.). 
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Proteomic Analysis and Quantitation: Quantitative proteomic analysis was performed 
using the iBAQ quantitative ion currents for proteins identified by LC-MS/MS 
normalized to the quantitative values of the target antigen (i.e. TIA1, tau) detected in 
each sample.  Proteins identified in the TIA1-/- samples were considered to be 
nonspecific binding proteins to the IP antibody and excluded from all subsequent 
analyses.  Gene lists of detected proteins were then uploaded into the Database for 
Annotation, Visualization and Integrated Discovery (DAVID) resource available via the 
NIH website.  3 different gene lists were uploaded: 1) the complete list of proteins 
detected to bind TIA1 in the WT mouse cortex; 2) the list of proteins whose association 
with TIA1 decreased by ≥ 2-fold in Tau-/- compared to WT samples; and 3) the list of 
proteins whose association increased by ≥ 2-fold in Tau-/- compared to WT samples.  
Functional annotation terms with False Discovery Ratio (FDR) values < 0.05 were 
considered to be statistically significant. 
 
Network Visualization Analysis: The 163 proteins identified in the TIA1 binding 
proteome in WT C57BL/6J cortex were uploaded as a gene list and analyzed by the 
DAVID Functional Annotation Clustering tool (Huang et al, 2008; Huang et al, 2009). 12 
resulting clusters with enrichment FDR < 0.05 were identified, and each of the 163 
proteins was associated to the cluster(s) based on its membership in the clustered gene 
sets.  A network was created by adding a connection between protein pairs sharing 
annotation clusters.  Edge weights were determined as the number of shared annotation 
clusters between protein pairs with thicker edges representing stronger functional 
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associations between proteins (the smallest number of clusters shared between any two 
proteins was 1, and the largest was 8).  The resulting network was visualized using the 
software Gephi 0.8.2 and arranged using the Force Atlas 2 layout algorithm.  The 
network was generated using the python programming language (Python Software 
Foundation), and the networkx (Hagberg, 2008), numpy, and pandas python packages 
(Jones, 2001). 
 
RNA-sequencing and analysis:  Total brain (cortex) RNA extracts were purified 
according to manufacturer’s instruction using the Qiagen Qiazol Lysis Reagent (Cat# 
79306) and RNeasy Mini kit (Cat# 73404).  The quality of the RNA preparations was 
confirmed using an Agilent bioanalyzer instrument (RIN scores > 9.0).  A total of 100 ng 
of RNA in a 5 μl volume was used for library preparation and RNA-Seq (n=3/genotype).  
Paired-end sequencing libraries were prepared by the Mayo Clinic sequencing core 
facilities (Rochester, MN) with the TruSeq Stranded Total Sample Preparation kit 
(Illumina), after which samples were subjected to quality control, cluster generation, and 
sequencing at a read depth of 60 million reads per sample on the Illumina HiSeq 2000 
platform.  The reads were de-multiplexed and converted to FASTQ format using 
CASAVA software from Illumina (by the Mayo Clinic core).  All RNA-Seq data for each 
individual RNA sample are available at the NCBI Gene Expression Omnibus under 
accession number GSExxxxx.   
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Sequence Alignment:  Sequence alignment was performed using TopHat v2.0.12 against 
the UCSC mm10 Assembly.  Expression values were calculated with featureCounts 
v1.4.6-p2, and differential expression analysis was done using DESeq2 (Love, Huber, & 
Anders, 2014) and the volcano plots were made in R (v3.1.1; http://www.r-project.org/).  
Gene Set Enrichment Analysis (GSEA) was performed as described previously 
(Subramanian et al., 2005). 
 
Splicing analysis:  Quantification of alternative splicing (AS) events were done 
separately using OLego, a seed-and-extend aligner that has high sensitivity for splice-
junction mapping of very small seeds (14-nt seed size) (Wu, Anczuków, Krainer, Zhang, 
& Zhang, 2013).  After alignment using OLego, we determined and quantified 
differential cassette exon events using the Quantas module, as described in OLego, and 
used Fisher's exact test to evaluate the statistical significance of splicing changes.     
 
Quantitative RT-PCR:  Total brain (cortex) RNA extracts purified as described above 
were reverse-transcribed using the Applied Biosystems High-Capacity cDNA Reverse 
Transcription Kit according to manufacturer’s instruction (Cat# 4368814).  RT-PCR 
reactions were performed in quadruplicate in a 384-well plate using 1 ng cDNA template, 
200 nM forward and reverse primers, and 2x iQ SYBR Green Supermix (BioRad, Cat# 
#1708880) per well.  Primer pairs for splice isoforms were designed to span exon-
junctions of alternative splicing events.  RT-PCR reactions were performed on a 7900HT 
Fast Real-Time PCR System (Applied Biosystems).  The primers used were the 
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following: Gria2_total_forward, GTATCCTTCATCACACCAAG; Gria2_total_reverse, 
CTCAATCAAGCTAAGGAGTG; Gria2_Ex14_Flip_forward, 
TAAGAAATGCGGTTAACCTC; Gria2_Ex14_Flip_reverse, 
GTCGTACCACCATTTGTTT; Gria2_Ex15_Flop_forward, 
GTCCACAATGAATGAGTACA; Gria2_Ex15_Flop_reverse, 
GCACTGGTCTTTTCCTTAAT; Snap25_total_forward, 
TTGCATTGAAGAAGAAACCT; Snap25_total_reverse, AGAACCTTGTCTTCTCCG; 
Snap25_Ex5_Incl_forward, AAGAAGGCATGAACCATATC; 
Snap25_Ex5_Incl_reverse, ACAAGGACATATGAAAAGGC, 
Snap25_Ex6_Incl_forward, TTTGGTTATGTTGGATGAGC; 
Snap25_Ex6_Incl_reverse, ATCCTGATTATTGCCCCAG; Camk2b_total_forward, 
GTATGCAGCCAAGATCATTA; Camk2b_total_reverse, 
AGCTTCTCTCTCCAGTTTC; Camk2b_Ex13_Skip_forward, 
TGGAATGTCTGAAGAAGTTC; Camk2b_Ex13_Skip_reverse, 
TCTGGGGCTGAGAAATTC; Camk2b_Ex13_Incl_forward, 
GAAAGCAGATGGAGTCAAG; Camk2b_Ex13_Incl_reverse, 
CTCTATGGTTGTGTTGGTG; Gapdh_total_forward, TGGTCTACATGTTCCAGTAT; 
and Gapdh_total_reverse, GATGACAAGCTTCCCATTC.  The relative amounts of each 
transcript, including splice isoforms, were calculated by normalizing the Ct scores to a 
reference transcript (∆CtGapdh).  Alternative splice isoforms were then further normalized 
to the total transcript level detected in the sample.  The ratio of exon inclusion was then 
determined to be [(Isoform 1 ∆CtGapdh) / (Total ∆CtGapdh)] / [(Isoform 2 ∆CtGapdh) / (Total 
  
44 
∆CtGapdh)].  Since the raw Ct counts better reflect the amplification efficiency of each 
primer pair than the true expression levels of each splice isoform, we normalized the 
relative exon inclusion ratios in each genotype to WT level = 1.  Thus, the values 
reported in the alternative splicing figures accurately reflect the relative changes in exon 
inclusion between groups, but not necessarily their true physiological levels in each 
genotype.  RT-PCR reactions were performed using 3 male and 3 female tissues per 
genotype (n=6/group) to control for sex differences in alternative splicing events and 
transcript expression.   
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CHAPTER ONE 
Interaction of tau with the RNA binding protein TIA1 regulates tau 
pathophysiology and toxicity 
 
Adapted from Vanderweyde et al. Cell Reports 2016 
 
 
Introduction 
 
 RNA binding proteins (RBPs) are a class of about 800 proteins that function in 
the nucleus to regulate mRNA maturation, including splicing, RNA helicase activity, 
RNA polymerase elongation, and nuclear export (Anderson & Kedersha, 2008).  RBPs 
also function in the cytoplasm where they regulate RNA translation, trafficking, 
sequestration, and degradation.  RBP function is strongly regulated by the multiple 
signaling cascades integrated with RNA translation/protein synthesis, which will be 
referred to in this dissertation as “translational signaling.”  The cytoplasmic actions of 
RBPs play a particularly crucial role in neurobiology because the large distance between 
the soma and synapse demands a proportionately large role of RBPs in the trafficking of 
mRNA transcripts (L. Liu-Yesucevitz et al., 2011). 
Increasing evidence links neurological disease processes to dysfunction of 
neuronal RBPs, RNA granules, and stress granules (SGs) (Ramaswami et al., 2013; 
Wolozin, 2012).  SGs are a particular type of RNA granule that accumulates during the 
translational response to stress.  RBPs, such as T cell intracellular antigen 1 (TIA1), 
contain prion-like, low-complexity domains, which promote their physiological 
reversible aggregation (Anderson & Kedersha, 2008; Buchan & Parker, 2009; Gilkes et 
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al., 2004).  Nucleation by core RBPs, such as TIA1, is followed by recruitment of 
secondary RBPs to form a mature SG, which is a key component of stress-induced 
translational suppression.  SGs play a dynamic role in mRNA triage by sorting 
sequestered mRNAs for re-initiation, storage, or degradation. 
Mutations in multiple RBPs cause motor neuron diseases, including Amyotrophic 
Lateral Sclerosis (ALS) (Y. R. Li, King, Shorter, & Gitler, 2013).  Many of the mutations 
in RBPs that are linked to disease appear to increase the tendency of these proteins to 
aggregate (Johnson et al., 2009; Kwiatkowski et al., 2009).  Studies from our lab and 
others show that the mutations also increase RNA granule formation, leading to SGs that 
are larger and more abundant, as well as larger and slower transport granules (Alami et 
al., 2014, Colombrita et al., 2009, Liu-Yesucevitz et al., 2010 and Liu-Yesucevitz et al., 
2014).  Studies with recombinant FUS and hnRNP A1 indicate that these proteins exhibit 
a normal ability to cycle between solution and gel phases, forming liquid droplets.  
However, disease-linked mutations in either protein impair the phase transition, leading 
to formation of stable amyloid-like fibrils (Lin, Protter, Rosen, & Parker, 2015; Molliex 
et al., 2015; Nott et al., 2015). 
Formation of pathological RNA granules is associated with neuropathology.  For 
instance, TIA1 co-localizes with neuropathology in brain tissue of subjects with 
Alzheimer’s disease (AD), frontotemporal dementia with parkinsonism (FTDP-17), 
frontotemporal lobar degeneration (FTLD-U), ALS, Huntington’s disease, Creutzfeld-
Jakob disease, and spinomuscular atrophy, as well as in animal models of these diseases 
(Liqun Liu-Yesucevitz et al., 2010; Vanderweyde et al., 2012; Wolozin, 2012).  Our 
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previous work suggests that the biology of tau is intimately linked to TIA1, with the 
proteins accumulating concomitantly with each other over the disease course in brain 
tissue from subjects with human tauopathies, as well as animal models (Vanderweyde et 
al., 2012). 
We now report that tau promotes SG formation and modulates the patterns of 
protein interactions of TIA1, a core SG component.  The interaction between tau and 
TIA1 promotes tau misfolding and assembly at the site of SGs, and results in the 
degeneration of processes and stimulation of apoptotic markers in primary neurons.  
Reducing TIA1 inhibits tau misfolding and degeneration in neuronal cultures.  These 
results indicate that tau plays an important role in neuronal RBP biology and suggest that 
RBPs and SGs contribute to the misfolding of tau.  These results also raise the possibility 
that the pathophysiology of tauopathies, such as AD, is associated with dysfunction of 
RBP biology. 
 
Results 
Tau increases the somatodendritic localization of TIA1 
 
 The distribution of TIA1 was examined in primary cultures of hippocampal 
neurons from wildtype (WT) and Mapt-/- (tau-/-) mice to investigate whether tau 
regulates the distribution of TIA1 (Fig. 12A).  Primary hippocampal neurons from tau-/- 
mice were transduced with TIA1-GFP ± AAV1 WT Tau-V5 or P301L Tau-V5.  TIA1 
exhibited strong nuclear localization in neurons from tau-/- mice, with few TIA1 granules 
(Fig. 12A).  Co-overexpressing TIA1 with tau dramatically increased the amount of 
  
48 
somatodendritic TIA1, with the TIA1 fluorescence exhibiting a strong granular character 
(Fig. 12A); little or no TIA1 was observed in axons (Fig. 11A).  Quantification shows 
that P301L tau significantly increased the size of TIA1 SGs compared to WT tau but 
produced fewer SGs than WT tau (Fig. 12A-C), which is strikingly similar to effects 
produced in neurons by disease-linked mutations in RBPs, such as TDP-43 (Liqun Liu-
Yesucevitz et al., 2014).   
 
Figure 11: TIA1 is excluded from axons 
Hippocampal neurons labeled for MAP2 (blue, a dendritic marker), MC1 (green, detecting misfolded tau) 
or TIA1 (red).  MC1 reactivity (green) can be seen in axons and dendrites.  Axons are denoted by white 
arrows, and labeled with MC1 but not with MAP2. Note that little or no TIA1 is apparent in the axons.  
Scale bar = 20 μm. 
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Figure 12: Tau increases the somatodendritic localization of TIA1 
A. Imaging for V5 (tau), GFP (TIA1), and MAP2 in primary hippocampal tau knockout neurons transduced 
with TIA1-GFP lentivirus ± AAV1-WT tau-V5 or AAV1-P301L tau-V5. Images indicate tau increases 
TIA1 movement into processes and SG formation (n = 100/condition, three independent experiments).  B-
C. WT or P301L tau increases TIA1 granules in tau-/- neurons. Granule density (B) and area (C) were 
determined using ImageJ to quantify TIA1 puncta per neuron for both endogenous TIA1 staining and 
exogenous TIA1-GFP fluorescence (n = 100/condition).  D. Live-cell imaging was done on tau-/- primary 
hippocampal neurons transduced with AAV1-TIA1-mRFP ± AAV9-WT or P301L tau. The number of 
moving particles per neuron was determined with BitPlane (Imaris) (n = 20/condition, three independent 
experiments).  E-G. Scatterplots of TIA1+ granule area versus distance from soma in tau-/- neurons. TIA1 
average granule velocity versus granule area for neurons transduced with: (E) TIA1-RFP, (F) WT 
tau/TIA1-RFP, and (G) P301L tau/TIA1-RFP (n = 20/condition).  H. Quantification of the net displacement 
of TIA1-positive granules in both anterograde (+) and retrograde (–) directions (n = 20/condition, three 
independent experiments).  Scale bars = 10 μm. ∗∗p < 0.01, and ∗∗∗p < 0.001. [ Fig. 12A-H provided by T 
Vanderweyde] 
 
The ability of tau to regulate TIA1 RNA granule formation suggests a biological 
role for tau in RNA granule trafficking, which was investigated using live-cell imaging.  
Tau-/- neurons (3 days in vitro [DIV], DIV 3) were transduced with AAV1-TIA1-mRFP 
(a monomeric form of RFP) ± AAV9-WT or P301L tau, and at DIV 21, the neurons were 
imaged.  Compiled traces showing particle localization and tracks of TIA1 granules show 
decreased granule movement with tau expression (Fig. 12D–G).  Tau inhibited net 
displacement and velocity of TIA1 granules, with retrograde (–) movement inhibited 
more than anterograde (+) movement (Figure 12H).  Granule size was inversely 
correlated with granule velocity (Fig. 12D–G), with the trend particularly pronounced 
with P301L tau where the granule area versus velocity graph shows a distinct inflection at 
about 1.2 μm2 (Fig. 12G).  As with SG formation, this effect is strikingly similar to the 
relationship between size and granule movement among TDP-43 granules (Alami et al., 
2014; Liqun Liu-Yesucevitz et al., 2014). 
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Tau increases stress granule number and size 
Next, we investigated the effects of tau on SG formation using mouse 
hippocampal HT22 cells.  Stress induces TIA1 to exit the nucleus, aggregate, and bind 
transcripts to form SGs (Fig. 13A); SG formation can be prevented by concurrent 
treatment with protein synthesis inhibitors, such as cycloheximide, that stabilize 
ribosomes on the mRNA.  Expressing human tau (4R0N WT and P301L) increased SG 
formation in the HT22 cells (Fig. 13B).  HT22 cells were transfected with human tau 
(4R0N WT and P301L) and then examined ± arsenite (0.5 mM, 30 min) to induce SGs.  
Tau overexpression strongly increased RNA granule formation under basal and stressed 
conditions (Fig. 13B).  Double labeling of these granules demonstrated that they are 
bona-fide SGs because they are positive for two SG markers: TIA1 and poly(A) binding 
protein (PABP); in addition, co-treatment with 10 μg/ml cycloheximide prevented 
formation of the tau/SG complexes (Fig. 13B). 
Immunoprecipitations (IPs) were performed to test whether TIA1 associates with 
tau biochemically. HT22 cells were transfected with WT tau (4R0N) and TIA1, and the 
human specific Tau13 antibody was used to IP the complex, followed by immunoblotting 
for TIA1; IP with anti-TIA1 antibody followed by immunoblotting with Tau13 was also 
performed, which produced compelling evidence indicating robust associations (Fig. 
13C). 
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Figure 13: Tau promotes stress granule formation 
A. TIA1 translocates to the cytoplasm with stress, where it nucleates SGs and inhibit synthesis of non-
essential proteins.  B. HT22 cells overexpressing WT tau, P301L tau, or β-gal followed by arsenite 
treatment (0.5 mM, 30 min) to induce formation of SGs positive for TIA1, PABP, and tau (identified with 
the Tau13 antibody). Formation of tau+ SGs is reversed with cycloheximide treatment (10 μg/ml, CHX). 
Quantification is presented in Figure S2B, based on three independent experiments.  C. Immunoblots and 
IPs showing levels of Tau13, TIA1, and actin in lysates and immunoprecipitates from HT22 cells 
transfected with EGFP, WT tau, or P301L ± TIA1-RFP.  D. Live-cell imaging of TIA1-RFP was done in 
HT22 cells 24 hr after transfection with EGFP, WT tau-EGFP, or P301L tau-EGFP and co-transfection 
with TIA1-mRFP. 500 μM arsenite was added to the cells to stimulate SG formation and images were taken 
every 15 s for 30 min. Representative images shown for 0, 6, and 12 min, with arrows at 6 min indicating 
the SG formation. High-magnification insets are shown.  E. Upper panel: Graph of the average number of 
SGs per cell over time per condition (n = 12 per condition), Lower panel: Graph of the average area of SG 
formation over time (n = 12).  F. Graph depicting the mean time to reach 50% maximal SG formation 
(based on SG numbers per cell) (n = 12/condition).  G. Overexpressing tau (4R0N, P301L) in HEK293 
cells inhibits protein synthesis detected using the SUnSET method and the anti-puromycin antibody, 
12D10.  Scale bars = 10 μm. ∗∗∗p < 0.001. [Fig. 13C-F provided by T Vanderweyde; Fig. 13G provided by 
J Abisambra] 
 
Next, we applied a live-cell imaging approach to examine the effects of tau on SG 
dynamics.  Expressing tau with TIA1-RFP strongly increased the rate of SG formation 
(Fig. 13D–F).  P301L tau accelerated the rate of SGs formation more than WT tau, with 
increased consolidation into larger SGs (Fig. 13D–F).  Taken together, these studies point 
to an important role of tau in regulating the trafficking and assembly of RNA granules, 
including SGs.  
SGs are thought to reflect adaptation of protein synthesis to stress; typically the 
stress-induced changes are associated with an overall reduction in protein synthesis.  
Analysis of Tet-inducible HEK293 cells overexpressing 0N4R tau showed a decrease in 
total protein synthesis (measured by SUnSET assay) in response to tau overexpression 
following addition of doxycycline, which is consistent with the data above suggesting 
that tau promotes SGs and the translational stress response (Fig. 13G). 
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Tau regulates the interaction of TIA1 with its proteome 
Proteomic studies revealed a surprising role for tau in regulating the proteins that 
interact with TIA1.  To investigate whether tau exerts control over TIA1 protein 
interactions, TIA1 was immunoprecipitated from cortical brain tissue of 10 month old 
WT (C57BL/6J), tau-/-, and TIA1-/- mice.  The specificity of the TIA1 IP was verified by 
immunoblotting with anti-TIA1 antibody (Fig. 14A), and the resulting TIA1 proteome 
was examined by OrbiTrap liquid-chromatography tandem mass spectrometry (LC-
MS/MS).  163 proteins were identified that were present in TIA1 immunoprecipitates 
from WT or tau-/- brains and absent in the TIA1 immunoprecipitates from TIA1-/- 
brains, indicating that these proteins specifically associate with endogenous TIA1 (Fig. 
14C; Appendix I).  Protein associations identified by LC-MS/MS were validated by 
repeat analysis of fresh samples, as well as by immunoblot for tau and four proteins that 
gave strong signals by mass spectrometry: RPL7, EWSR1, HNRNPR, and DDX5 (Fig. 
14A-B).  As expected, endogenous mouse tau (MAPT) was abundantly detected in the 
TIA1 immunoprecipitates (Appendix I).  Figure 14C summarizes the average protein 
level for each TIA1-binding protein detected in the WT versus tau-/- LC-MS/MS samples 
by a hierarchically clustered heatmap. 
Next, we analyzed the TIA1-binding proteome using the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) bioinformatics resource available via 
the National Institute of Health (Huang et al., 2007, 2009).  As expected, 
immunoprecipitating TIA1 from WT mouse brain tissue identified proteins exhibiting 
statistically significant enrichment (false discovery rate [FDR] <0.05) for annotation 
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terms related to RNA metabolism (Appendix II), including ribonucleoprotein (FDR = 
6.30e-06), RNA-binding (FDR = 2.09e-05), and RNA recognition motif RNP-1 (FDR = 
2.15e-03); proteins involved in mitochondrial and vesicular/synaptic function also 
exhibited significant enrichment (Appendix II).  We also constructed a network diagram 
to understand the functional connectivity of TIA1-binding proteins in the brain (Fig. 
14D).  In the network, lines connecting nodes indicate shared functional annotations with 
other proteins in the TIA1 network; the size of each node corresponds to the degree of 
replication in the WT samples (n=3).  Note that some proteins listed in the hierarchical 
table (Fig. 14C) are absent from the network (Fig. 14D) because they lack known shared 
functional annotations with the other TIA1-binding proteins.  The network of TIA1-
binding proteins in WT mouse cortex includes multiple proteins linked to RNA 
metabolism, including ribosomal proteins (e.g., RPL6, 7, 10A, 13 and 13A, MRPL46, 
RPS3, and 4X), translational regulatory proteins (EIF4A1, PABPC1, and NACA), small 
nuclear ribonucleoproteins (SNRNP70 and SNRPB), heterogeneous nuclear 
ribonucleoproteins (HNRNPF, HNRNPR and HNRNPUL2, EWSR1, and SYNCRIP), 
and helicases (DDX5 and DDX17) (Fig. 14D).  Importantly, deletion of tau eliminated 
the interaction of TIA1 with many proteins in the network, particularly those associated 
with RNA metabolism and RNA translation (Fig. 14D, red circles).  This network 
analysis of the TIA1-binding proteomes from the WT and tau-/- mouse brain highlights 
the important role that tau plays in regulating proteins that interact with TIA1, with loss 
of tau abrogating interactions with multiple core TIA1-binding proteins, including 
EWSR1, RPL6, RPL7, MRPL46, RBM17, and SNRNP70 (Figures 14C–F).  To further 
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validate this finding, we separately analyzed the proteins decreasing (Fig. 14E) or 
increasing (Fig. 14F) their association with TIA1 in tau-/- mice compared to WT mice in 
order to understand how tau expression affects the protein interactions of TIA1.  Proteins 
decreasing their association with TIA1 were enriched for various functional annotation 
terms related to RNA metabolism, including ribosomal, ribonucleoprotein, and RNA-
binding (Fig. 14E).  Taken together, these results suggest that the presence of tau protein 
is required for normal interaction of TIA1 with the RNA metabolism machinery. 
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Figure 14: Tau regulates the TIA1-binding proteome in the brain 
A-B. IP of TIA1 from the TIA1-/-, C57BL/6 and tau-/- mouse cortical lysates used for the proteomic studies 
(A), with quantification in (B) (n = 3). TIA1 was evident in the C57BL/6 and tau-/- lysates but absent from 
the TIA1−/− lysates. Excluding from the proteomic analysis any proteins that were present in the TIA1-/- 
IP eliminates proteins immunoprecipitated non-specifically. Binding of RPL7 and EWSR1 to TIA1 was 
greatly reduced in the tau-/- cortices, as suggested by the mass spectrometry studies. In contrast, binding of 
DDX5 to TIA1 was not affected by the absence of tau.  C. Hierarchical clustering of proteins associated 
with TIA1 upon IP from WT and tau-/- mice, using the MS1 current channel for semiquantitative 
measurements.  D. Network diagram depicting the TIA1-binding proteome in the WT mouse cortex. Edges 
connecting nodes denote shared functional annotation terms (greater than three) between the connected 
proteins, as determined by DAVID functional clustering analysis. Proteins highlighted in red were not 
detected in any of the three tau-/- samples analyzed, indicating that their interaction with TIA1 is tau 
dependent. Node size is proportional to the degree of replication in the WT samples (n = 3 mice per group). 
Only edges containing more than three shared annotation clusters are shown. Background circles indicate 
protein clusters in the TIA1 network including RNA metabolism (orange), cytoskeleton (yellow), 
vesicles/synaptic function (gray), and mitochondrial (green).  E-F. Keyword functional annotation terms 
exhibiting statistically significant enrichment (FDR <0.05) in the genes lists of proteins decreasing (E) or 
increasing (F) their association with TIA1 by at least 2-fold in tau-/- compared to WT cortex, as determined 
using the DAVID bioinformatics resource (Huang et al., 2009). ∗p < 0.05; #p < 0.1 (trend level). [Fig.14C-
D provided by E Lummertz da Rocha] 
 
RNA binding proteins in the TIA1-binding proteome co-localize with tau pathology in 
vivo 
The strong role of tau in the TIA1-binding proteome raised the possibility that 
TIA1-associated RBPs might co-localize with tau pathology in vivo.  Brain tissue (frontal 
cortex) from 11 month old rTg4510 mice were labeled with antibodies for TIA1, 
EWSR1, DDX5, RPL7, TDP-43, and FUS (Fig. 15A); all samples were co-labeled with 
the anti-phospho (S396/S404)-tau antibody, PHF1.  Proteins present in the TIA1 network 
(TIA1, EWSR1, DDX5, and RPL7) all co-localized with PHF1-positive tau pathology.  
The RPL7 reactivity was notable because it tended to localize to the outer rim of tau 
pathology (Fig. 15A).  The co-localization between PHF1 and RBPs was generally 
associated with depletion of nuclear RBP immunofluorescence, particularly for TIA1 and 
EWSR1 (Fig. 15A).  No co-localization with PHF1-positive tau pathology was observed 
for RBPs that were not detected in the TIA1-binding network (i.e. TDP-43 or FUS), 
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indicating that inclusion in disease pathology is specific for TIA1-binding proteins and 
not a general effect of RBP promiscuity (Fig. 14-15). 
 
 
Figure 15: TIA1 network RNA binding proteins co-localize with tau pathology in rTg4510 
mice 
A. Immunohistochemistry for TIA1, EWSR1, DDX5, RPL7, and TDP-43 and FUS (green), PHF1 (red), 
and DAPI (blue) in frontal cortex of 11-month-old rTg4510 mice.  B-C. Quantification of co-localization 
demonstrates strong localization of TIA1 network members with PHF1 reactivity (n = 5 mice).  Scale bars 
= 10 μm. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 by One-way ANOVA with Tukey’s post-hoc 
comparisons.  
 
TIA1 and tau interact biochemically 
Studies using primary neuronal cultures confirmed the presence of functional 
interactions between tau and TIA1.  Hippocampal neurons from tau-/- mice were grown 
in culture and transduced with AAV9-WT or P301L tau ± AAV1-TIA1-mRFP (or 
mRFP) (Fig. 16A).  Immunoblotting demonstrated that TIA1 regulates tau levels.  TIA1 
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overexpression reduced levels of total tau, while TIA1 knockout increased levels of total 
tau (Fig. 16A-B).  The mechanism of regulation appeared to have limited dependence on 
the proteasomal or autophagic systems, because neither MG132 nor chloroquine 
treatment fully prevented TIA1-induced tau reduction (Fig. 16C).  Immunoblot analysis 
of TIA1 IPs indicated that both total (Tau13) and phospho-tau (PHF1) bound exogenous 
and endogenous TIA1 (Fig. 16A).  Pre-treating the lysate with RNase A, or use of a TIA1 
construct lacking the three RNA recognition motifs abolished the association, indicating 
that tau associated with TIA1 through an RNA intermediate (Fig. 16D, data for RNase A 
treatment shown).  The role of RNA intermediates supports the hypothesis that tau 
participates in RNA granule biology.  Tau could also interact with RNA directly as 
suggested by prior studies (Kampers et al., 1996; X. Wang et al., 2006). 
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Figure 16: Tau associates with TIA1 via an RNA intermediate  
A. Tau immunoprecipitates with TIA1, and TIA1 is found bound to MC1+ misfolded tau in primary 
hippocampal Tau knockout neurons. Left panel: Immunoblots showing levels of total tau (Tau13), 
phosphorylated tau (PHF1), TIA1, and actin in lysates from primary hippocampal tau-/- neurons transduced 
AAV1-TIA1-RFP ± AAV9-WT or P301L Tau. Middle panel: Immunoprecipitation of TIA1, followed by 
immunoblotting with Tau13, PHF1, and TIA1. Right panel: Immunoprecipitation of MC1 tau, followed by 
immunoblotting with Tau13, PHF1, and TIA1.  B. Immunoblots showing higher levels of total tau (Tau5 
antibody) in primary cortical neurons from TIA1-/- vs C57Bl/6J (control) mice.  C. Immunoblots showing 
levels of total tau (Tau13), phosphorylated tau (PHF1), TIA1- RFP, endogenous TIA1 (eTIA1) and actin in 
lysates  from HT22 cells transfected with β-gal, P301L Tau, P301L Tau-PMIM, or P301L Tau-NULL, then 
treated overnight with 5 μM MG132 or 50 μM chloroquine.  D. Immunoprecipitation with HA-antibody in 
lysates from HEK293 cells transfected with TIA1-HA ± WT tau, showing loss of binding after treatment 
with RNase A. [Fig. 16A-C provided by T Vanderweyde; Fig. 16D provided by P Ash] 
 
TIA1 promotes the misfolding and stability of tau in granules 
The association of tau with TIA1 complexes raised the possibility that TIA1 
might also modulate tau misfolding.  TIA1 forms RNA granules, which provide a local 
environment concentrated with intrinsically disordered proteins and RNA, a known 
promoter of tau aggregation.  To test this hypothesis, the relationship between TIA1 
levels and tau misfolding was examined.  The response of tau misfolding to knockdown 
of endogenous TIA1 was examined first.  TIA1 knockdown was validated by 
immunoblot (Fig. 17A).  Next, primary hippocampal neurons (DIV 2) were transduced 
with AAV1 WT human tau, then transduced with AAV9 expressing shRNAs targeting 
TIA1 (shTIA1) or a scrambled sequence (shScr) on DIV 4 to knockdown TIA1 
expression, and aged to DIV 21.  Analysis of MC1 reactivity at DIV 21 demonstrated that 
TIA1 knockdown elicited a robust decrease in MC1 levels (Fig. 17B-C). 
Overexpressing TIA1 exhibited a robust reciprocal response, increasing levels of 
MC1 reactivity.  Tau-/- hippocampal neurons were transduced with WT or P301L tau 
AAV9 and TIA1-GFP or GFP lentivirus, and immunolabeled for MC1 tau and MAP2.  
Imaging demonstrated that neurons co-expressing tau and TIA1 displayed abundant 
  
63 
MC1-positive granules in processes that were not apparent in neurons expressing tau 
alone, and that co-expressing TIA1 increased the size of the granules (Fig. 17D-F). 
 
Figure 17: TIA1 regulates tau misfolding and stimulates consolidation of misfolded tau into 
granules 
A. Validation of TIA1 knockdown by shTIA1. Immunoblots showing high levels of total tau (Tau13 
antibody) in lysates from HT22 cells transfected with EGFP, WT tau, P301L tau co-transfected with 
shControl (shCtrl) or shTIA1.  B. Immunocytochemistry of hippocampal neurons transduced with TIA1 or 
control short hairpin RNA (shRNA) (using co-transduction with AAV-GFP to identify transduced neurons) 
and stained for misfolded tau (MC1, red) and MAP2 (blue). Neurons transfected with TIA1 shRNA show 
reduced MC1 reactivity.  C. Quantification of MC1 levels in neurons transfected with TIA1 or control 
shRNA (n=50 neurons per condition, three independent experiments). ∗∗p<0.01 by unpaired Student’s t-
test. Scale bar = 10 μm.  D. Immunocytochemistry for MC1 tau and MAP2 in primary tau−/− hippocampal 
neurons transduced with AAV9-WT or P301L tau co-transduced with EGFP or TIA1-GFP lentivirus. Scale 
bar = 10 μm. High-magnification inset of dendritic processes show MC1 staining; scale bar = 4 μm.  E-F. 
Quantification of MC1 granule count and average MC1 granule area per neuron (n=100 neurons/condition, 
three independent experiments). G. Live-cell imaging of photo-convertible tau (PC-Tau). Following photo-
conversion, PC-Tau expressing neurons were imaged for 6 hr. Representative images are shown for the 0- 
and 6-hr time points showing stabilization of tau in granules in cells co-expressing TIA1.  H. Quantification 
of PC-Tau from neurons at varying time points after photo-conversion (n=20 per condition, three 
  
64 
independent experiments). Scale bar = 10 μm. ∗p < 0.05 ∗∗∗p < 0.001. [Fig. 17D-F provided by T 
Vanderweyde; Fig. 17G-H provided by K Youmans-Kidder] 
 
The ability of TIA1 to promote tau granules led us to hypothesize that TIA1 
increased the stability of tau in granules.  To test this hypothesis, we generated a photo-
convertible tau (PC-Tau, WT 0N4R) construct that stably converts from cyan to green, 
transfected cortical neurons (DIV 5) with the PC-Tau ± TIA1, performed the photo-
activation at DIV 21, and then imaged over 6 h.  Neurons transfected with PC-Tau plus 
mCherry control exhibited green tau fluorescence present both diffusely and in granules.  
The tau fluorescence decreased steadily over 6 h down to a level of approximately 40% 
of the original fluorescence levels, indicating normal turnover of tau (Fig. 17G-H).  In 
contrast, cortical neurons co-transfected with PC-Tau and TIA1 exhibited greatly reduced 
tau turnover, with PC-Tau fluorescence remaining above 80% at 6 h (Fig. 17G-H).  
Expressing TIA1 with tau also caused a higher proportion of the tau to localize to 
granules, consistent with figure 17D-F.  Biochemical analysis of TIA1 
immunoprecipitates revealed that the association of tau with TIA1 increased the ratio of 
sarkosyl-insoluble to sarkosyl-soluble tau (not shown, please refer to (Vanderweyde et 
al., 2016)).  These data indicate that TIA1 stabilizes tau in granules, which promotes the 
accumulation of insoluble tau.  
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Translational inhibitors and kinase inhibitors modulate SGs and tau granules in 
neuronal dendrites 
The interaction between tau and TIA1 points to compelling approaches for 
modulating formation of tau granules in neurons.  SGs are regulated by translational 
inhibition.  Cycloheximide prevents elongation, which leaves ribosomes stalled on 
mRNA and inhibits SG formation, while puromycin causes premature translational 
termination leading to release of the 60S ribosomal subunit from the mRNA, promoting 
SG formation.  Analysis of tau granules in neuronal cell lines demonstrated that 
cycloheximide prevented formation of tau granules (Fig. 13A), while puromycin 
stimulated formation of tau granules (data not shown).  We hypothesized that tau 
granules might be regulated in a similar manner in neuronal dendrites. 
Primary cultures of tau-/- hippocampal neurons were transduced with AAV9-WT 
tau or P301L tau ± AAV1-mRFP or TIA1-mRFP (Fig. 18).  Neurons co-expressing WT 
or P301L tau with mRFP exhibited tau that was localized diffusely along processes, with 
only weak granules evident (Fig. 18A).  However, co-transducing WT or P301L tau with 
TIA1 resulted in processes with large granules positive for tau and TIA1, and little to no 
diffuse tau (Fig. 18A, arrows).  Comparison of the effects of the two different 
translational inhibitors, puromycin and cycloheximide, highlighted the role of 
translational signaling in mediating the formation of tau granules.  Neurons were treated 
at DIV 21, immunolabeled for Tau13 and MAP2 (microtubule associated protein 2, a 
dendritic marker), and imaged (Fig. 18B-C).  Treatment with puromycin yielded larger 
and more abundant tau granules that were particularly accentuated by TIA1/tau 
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overexpression (Fig. 18B).  Conversely, treatment with cycloheximide (10 μg/ml) yielded 
dendritic tau (and TIA1) that was spread diffusely with only small, less defined granules 
apparent (Fig. 18C).  Thus, the localization and granule formation of tau and TIA1 are 
both modulated by translational signaling. 
The role of tau in SG biology in neurons also suggests that kinases that regulate 
tau dynamics might also regulate tau-mediated SG formation in neurons.  For instance, 
proline-directed kinases are known to phosphorylate tau, which leads to dissociation of 
tau from microtubules and increases the propensity of tau to aggregate (Lee, Brunden, 
Hutton, & Trojanowski, 2011; Matenia & Mandelkow, 2009).  Chemical inhibitors of 
GSK3β, CDK5, p38 MAPK, MARK, and Fyn all significantly inhibited formation of 
granules positive for TIA1 and PHF1-positive phospho-tau (Fig. 18D-E).  The strongest 
SG inhibition was observed with the p38 MAPK inhibitor, which is known to act 
downstream of each of these kinases (Roux & Blenis, 2004). 
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Figure 18: Tau granules are regulated by translational inhibitors 
A-C. Immunocytochemistry for tau13 antibody and MAP2 in primary cultures of tau-/- hippocampal 
neurons transduced with AAV1-RFP or AAV1-TIA1-mRFP ± AAV9-WT or P301L tau and treated with 
vehicle (basal, A), puromycin (B), or cycloheximide (C). The columns on the right show images at high 
magnification (arrows identify tau granules).  D. In HT22 cells following transfection with TIA1 and WT 
tau and treatment with the p38 kinase inhibitor (SB203580, 20 μM).  E. Quantification of inhibition of SGs 
and tau granules in HT22 cells following treatment for 24 hr with one of five different kinase inhibitors: 
GSK3β (XXVI, 20 μM), CDK2/5 (alkylbenzyldimethyammonium chloride, 5 μM), p38 MAPK 
(SB203580, 20 μM), MARK/Par-1 (39621, 20 μM), and Fyn (PP2, 20 nM). F. Inhibition of tau-induced 
TIA1+ SGs in HT22 cells following transfection with TIA1 and WT tau and treatment for 24 hr with the 
PKR inhibitor (C16, 1 μM) or PERK inhibitor (GSK2606414, 50 nM).  G. Quantification of granule count 
in cells treated with kinase inhibitors. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 by One-Way ANOVA with 
Tukey’s post-hoc comparisons; 100 cells per condition, based on three independent experiments (D-G). 
Scale bars = 10 μm (low-magnification), 2 μm (inset). [Fig. 18A-C provided by T Vanderweyde] 
 
Use of phospho-mimetic tau constructs demonstrated a direct role for proline-
directed tau phosphorylation in modulating SG formation.  Transfections were performed 
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using phospho-mimetic (PMIM) or phospho-null (PNULL) tau constructs in which all 14 
proline-directed S/T residues were replaced with either aspartate or alanine (Hoover et 
al., 2010).  HT22 cells were transfected with P301L, P301L PMIM, or P301L PNULL 
tau ± TIA1-RFP.  Cells were treated ± 25 μM salubrinal, and SGs were imaged for 
endogenous TIA1 (Fig. 19A-B) or transfected TIA1-RFP (Fig. 19B-C).  Imaging showed 
more SGs in the presence of PMIM tau, and fewer SGs in the presence of PNULL tau 
(Fig. 19A-C).  Salubrinal treatment increased the number of SGs in all conditions; 
salubrinal inhibits the PP2A adaptor protein, GADD34, thereby increasing eIF2α 
phosphorylation and reducing mRNA translation (Boyce et al., 2005).  These data point 
to direct phosphorylation of tau as a modulator of SG and tau granule formation in 
neurons. 
 
Figure 19: Tau induced stress granule formation requires tau phosphorylation 
A-C. Phosphorylation of tau increases TIA1+ granules endogenously (A, images; C, quantification) and 
with over-expressed TIA1 (B, images; C, quantification) (N=50). Immunocytochemistry for endogenous 
TIA1 in HT22 cells transfected with EGFP, or Tau (P301L, P301L PMIM or P301L NULL) treated with 
vehicle (DMSO) or 25 μM salubrinal. The WT Tau-NULL construct has had 14 sites exhibiting increased 
phosphorylation in AD replaced with alanine (Hoover et al., 2010). The Tau NULL construct exhibited 
fewer cells with granules. Scale bar 10 μm. Insert = high magnification image. Scale bar = 2 μm. * p<0.05, 
**p<0.01, ***p<0.001. [Fig. 19A-C performed in two independent experiments by D Apicco and T 
Vanderweyde; representative images in Fig. 19A provided by T Vanderweyde] 
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The eukaryotic translation initiation factor eIF2α is regulated by phosphorylation.  
We investigated whether inhibiting PKR or PERK, two kinases that phosphorylate eIF2α, 
might also inhibit tau mediated SG formation.  SGs were induced by transfection with 
TIA1 ± WT tau.  After 24 h, the cells were treated with inhibitors of PKR (C16, 1 μM, 
Sigma) or PERK (GSK2606414, 50 nM, EMD/Millipore), and then the number of SGs 
was quantified after 24 h.  PKR or PERK antagonists strongly inhibited tau-mediated SG 
formation (Fig. 18F-G).  Thus, inhibiting translationally directed kinases also decreases 
tau-mediated SG formation. 
 
TIA1 modulates tau pathophysiology and toxicity 
The results above identify a functional interaction between TIA1 and tau, with tau 
promoting formation of TIA1-positive SGs, and TIA enhancing both tau catabolism and 
tau consolidation.  Further studies suggest that the functional interactions between TIA1 
and tau also extend to neurodegeneration, where our results show that TIA1 knockout 
inhibits tau-mediated degeneration, while TIA1 overexpression increases tau-mediated 
degeneration.  Effects on degeneration were investigated by transducing hippocampal 
neurons (DIV 3) from WT or tau-/- mice with AAV9-WT or P301L tau ± AAV1-TIA1-
mRFP or mRFP, and imaging for MAP2 at DIV 21 (Figures 20A-B).  Next, hippocampal 
neurons (DIV 3) from TIA1-/- mice were transduced with AAV9-WT or P301L tau ± 
AAV1-TIA1-mRFP or mRFP, and imaged for MAP2 at DIV 21 (Fig. 20A-C).  Co-
expressing TIA1 with tau significantly decreased dendritic length but had no effect 
independent of tau (Fig. 20B).  P301L tau also caused toxicity on its own; neurons 
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transduced with P301L tau exhibited significant dendritic shortening compared to 
neurons transduced with WT tau.  However, TIA1 knockout prevented this toxicity (Fig. 
20C).  Hippocampal neurons (DIV 3) from TIA1-/- mice transduced with AAV9-P301L 
tau exhibited neurite lengths similar to WT neurons and neurons transduced with AAV9-
WT tau (Fig. 20C).  These data indicate that TIA1 expression is necessary for dendrite 
shortening associated with expression of P301L tau (Fig. 20B, right panel). 
Additional studies suggest that the modulation of dendritic length by TIA1 and 
tau is sensitive to translational signaling.  Tau-/- and TIA1-/- hippocampal neurons were 
transduced with AAV9-WT tau or P301L tau ± AAV1-TIA1-mRFP or mRFP, and at 
DIV 21 treated with the translation inhibitors puromycin (5 μg/ml) or cycloheximide (10 
μg/ml).  Translational inhibition with cycloheximide did not affect dendrite length, while 
treatment with puromycin, which induces SGs, potentiated the decrease in dendritic 
length associated with TIA1/tau overexpression (Fig. 21A-B). 
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Figure 20: TIA1 modulates tau pathophysiology and toxicity 
A-C. Images (A) and quantification (B and C) of dendrite traces of hippocampal neurons (primary culture, 
DIV 21) using MAP2 labeling of WT and tau-/- mice (B) or TIA1-/- mice (C), transduced with AAV1-
TIA1-mRFP or mRFP ± AAV9-WT or P301L tau (n = 30/condition, four independent experiments).  D. 
Immunoblots showing levels of synaptophysin, PSD-95, caspase-3, and cleaved caspase-3 in WT primary 
cortical neurons transduced with AAV1-TIA1-mRFP or mRFP ± AAV9-WT or P301L tau.  E. 
Luminescent quantification of caspase cleavage (Caspase-Glo 3/7 Assay kit, Promega). Comparison of the 
amount of caspase cleavage in tau-/- primary hippocampal neurons (DIV 21) transduced with AAV1-TIA1-
mRFP or mRFP ± AAV9-WT or P301L treated with 25 μM salubrinal (n = 3 wells/condition, four 
independent experiments).  F. Colorimetric quantification of DNA fragmentation to measure apoptosis 
(TiterTACS Colorimetric Apoptosis Detection kit, Trevigen). Tau-/- primary hippocampal neurons (DIV 
21) transduced with AAV1-TIA1-mRFP or mRFP ± AAV9-WT or P301L tau under basal conditions and 
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treatments with 25 μM salubrinal (n = 3 wells/condition, four independent experiments).  Scale bar = 10 
μm. ∗∗p < 0.01, and ∗∗∗p < 0.001. [Fig. 20A-F provided by T Vanderweyde] 
 
Induction of toxicity was also apparent using biochemical assays.  We examined 
levels of synaptic and apoptotic markers by immunoblot in WT primary cortical neurons 
transduced with AAV1-mRFP or TIA1-mRFP ± AAV9-WT tau or P301L tau.  Markers 
examined included synaptophysin, PSD-95, caspase-3, and cleaved caspase-3.  The data 
indicate a striking loss in the pre-synaptic marker synaptophysin in neurons co-
transduced with tau and TIA1, indicating a corresponding loss of axonal terminals (Fig. 
20D).  Levels of cleaved caspase-3 were also elevated in TIA1 and tau co-transduced 
neurons indicating enhanced toxicity (Fig. 20E), which was potentiated by concurrent 
treatment with 25 μM salubrinal (Fig. 20E).  Interestingly, changes in the post-synaptic 
marker PSD-95 levels were not prominent (Fig. 20D), consistent with results from animal 
models indicating that pre-synaptic degeneration precedes neuron loss in tauopathies 
(Yoshiyama et al., 2007).  Analysis of DNA fragmentation showed that TIA1 also 
increased apoptosis in tau expressing neurons (Fig. 20F).  These data suggest that the 
interaction of TIA1 with tau can promote neurodegeneration under conditions where SG 
formation is enhanced, such as occurs with TIA1 overexpression or exposure to SG 
inducers. 
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Figure 21: Translational inhibitors modulate tau toxicity 
A. Quantification of the % change in dendrite lengths in hippocampal neurons (primary culture, DIV21) 
from tau-/- mice transduced with AAV1-TIA1-mRFP or mRFP ± AAV9-WT or P301L tau and treated with 
translation inhibitors puromycin (SG-promoting) or cycloheximide (SG inhibiting). Comparison is to 
neurons from C57Bl/6J (control) mice. (N=30/condition).  B. The same experiment as in D, but done in 
TIA-/- neurons (N=30/condition).  Scale bar = 10 μm. ***p<0.001. [Fig. 2-A-B provided by T 
Vanderweyde] 
 
Discussion 
Tau is classically considered to function as a microtubule binding protein that 
plays an important role in axonal stabilization and vesicular trafficking; however, in 
tauopathies tau accumulates in the somatodendritic compartment where it forms protein 
aggregates.  The cellular logic behind somatodendritic accumulation of tau is poorly 
understood.  Our results suggest that the shift in tau localization to the somatodendritic 
compartment occurs to facilitate formation of SGs, which are RNA/protein complexes 
that are part of the translational response to stress.  SGs normally accumulate in the soma 
and dendrites in response to stress as small insoluble macromolecular complexes.  In 
neurodegenerative diseases, SGs become very large, and associate with pathological 
proteins, such as tau (in AD and FTDP-17) and TDP-43 (in ALS) (Liqun Liu-Yesucevitz 
et al., 2010; Vanderweyde et al., 2012).  In moderation, this stress response is beneficial, 
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but an over-active SG response causes a deleterious, degenerative response, such as that 
caused by overexpressing tau and either co-expressing with TIA1 or treating with 
puromycin. 
TIA1 is known to be a protein involved in nuclear splicing, but recent studies also 
show that it is one of the core proteins that nucleates cytoplasmic SGs (Anderson & 
Kedersha, 2008).  The network of proteins that associate with TIA1 in the brain includes 
14 proteins that are very strongly linked from a functional perspective.  This group of 
proteins includes RBPs typically associated with the spliceosome (SNRPB, SNRNP70, 
DDX5, and RBM17), RBPs associated with mRNA transport (HNRNPR and EWSR1), 
and multiple ribosomal proteins (RPL6, 7 10A, 13, 13A; RPS3, 4X).  The prominence of 
ribosomal proteins highlights the important role of RNA translation in this network.  Loss 
of tau abrogates the binding of TIA1 to five out of 14 proteins in this core network 
(RPL6, RPL7, EWSR1, SNRNP70, and RBM17), which points to a role for tau in this 
translational and transport machinery (Fig. 14D).  TIA1 shows reduced dendritic 
localization in tau-/- neurons (Fig. 12A-B), which suggests altered interactions with 
trafficking proteins, but the mechanism for this altered localization remains to be 
determined.  The interaction between tau and TIA1 parallels a recent study demonstrating 
that TIA1 interacts with tubulin to regulate microtubules in yeast (X. Li, Rayman, 
Kandel, & Derkatch, 2014).  In addition, the interaction of TIA1 with proteins, such as 
SIRT2 and clathrin (CLTB), have not been reported previously and might point to 
regulatory interactions unique to the brain.  The prominence of members of the U1 
SNRNP family (SNRNP70, SNRPB, and RBM17) in the TIA1 network is striking (Fig. 
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14C-D).  Previous work identified strong accumulation of cytoplasmic SNRNP70 
aggregates in the AD brain (Bai et al., 2013).  The presence of these TIA1-binding 
proteins whose binding is tau dependent points to interactions that might be more 
prominent in neurons or glia than in somatic cells. 
The TIA1-binding proteome might differ between neurons and most peripheral 
cells because neurons must manage RNA biology in dendrites and synapses.  RNA must 
be transported to the synapse, where RNA translation is tightly linked to synaptic activity 
through activity-dependent translation.  This means that RBPs exert a much larger 
footprint on cellular activity outside of the nucleus in neurons (and possibly glia) than in 
somatic cells.  The prominence of ribosomal proteins in the brain TIA1 network 
combined with the presence of RBPs important for RNA transport, such as HNRNPR, 
SYNCRIP, and EWSR1, emphasizes an important role for tau in regulating RNA 
transport and translation during stress.  Under basal conditions, tau is present in dendrites 
only at low levels but localizes to the somatodendritic compartment during stress 
(Frandemiche et al., 2014; Hoover et al., 2010; Zempel et al., 2013; Zempel & 
Mandelkow, 2014).  Tau might function in this context to slow RNA granule transport 
and regulate the interaction of TIA1 with other SG proteins, which would facilitate SG 
formation and the translational stress response. 
The immunohistochemical studies of the TIA1 proteome complement existing 
studies to highlight an important role for the TIA1-binding network in the 
pathophysiology of AD and other tauopathies.  Each of the four RBPs examined that 
were part of the TIA1 interactome co-localized with tau pathology.  One of these 
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proteins, RPL7, is a tau-dependent TIA1-binding protein that has also been observed to 
be associated with tau in human pathological samples (Minjarez et al., 2013).  Another 
tau-dependent TIA1-binding protein is EWSR1, which is genetically linked to ALS 
(Couthouis et al., 2012).  These intersecting pieces of evidence suggest a model in which 
the accumulation of aggregated RBPs in tauopathies might result from shared hyperactive 
SG pathways that also leads to the accumulation of aggregated tau. 
The intersection of SGs with tau biology becomes particularly important when 
considering therapeutic implications.  Protein aggregation in neurodegenerative disease 
has been classically considered to result from dysfunctional protein misfolding.  
However, SGs and other RNA granules exhibit protein aggregation that occurs as part of 
a normal physiological pathway, exhibiting inherent abilities to cycle between liquid and 
solid states (Lin et al., 2015; Molliex et al., 2015; Nott et al., 2015; Vanderweyde et al., 
2012).  In the cell, TIA1 functions as a core component of SGs, promoting their 
nucleation.  The studies above take advantage of the importance of TIA1 for nucleation 
of tau granules and SGs.  We show that deletion or knockdown of TIA1 in cultured 
neurons reduces the ability of cells to form SGs, inhibits pathological tau misfolding, and 
prevents tau-mediated degeneration.  Thus, our work identifies TIA1 knockdown as a 
potentially important approach to inhibit tau misfolding and tau-mediated degeneration. 
A large number of biochemical pathways also have the ability to disperse SGs and 
RNA granules.  Each of these pathways is a potential target for drug discovery.  We show 
that proline-directed tau kinases, which are known to regulate the association of tau with 
microtubules, also regulate the tau-mediated SG pathway.  Attention to the SG pathway 
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highlights compelling approaches to regulation.  For instance, drug discovery efforts built 
around inhibiting SG formation have been successfully used to identify novel agents that 
prevent aggregation of TDP-43, which might be an effective treatment for ALS (Boyd et 
al., 2013; Kim, Zhan, Hanson, & Tibbetts, 2012).  Translational inhibitors provide an 
additional mechanism for regulation.  The translational inhibitors puromycin and 
cycloheximide reciprocally induce or prevent tau-mediated SG formation, respectively, 
and also modulate the tau-mediated degeneration associated with TIA1 overexpression.  
Long-term puromycin or cycloheximide treatment is admittedly toxic, but we show that 
kinases regulating eIF2α phosphorylation, including PKR and PERK, regulate tau-
mediated SG formation.  These kinases might be particularly effective for tauopathies, 
such as AD, because they appear to inhibit disease processes at multiple levels, including 
preventing toxicity associated with β-amyloid (Devi & Ohno, 2014).  Thus, the role of 
tau in RNA granule biology highlights the potential role of reversible protein aggregation 
in the pathophysiology of tauopathies and presents a corresponding wide range of 
therapeutic avenues for pharmacotherapy of AD.  
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CHAPTER TWO 
Reducing TIA1 inhibits the accumulation of stress granules and protects 
against tau-mediated neurodegeneration in vivo 
 
Adapted from Apicco et al. Nature Neuroscience 2017 [Submitted] 
 
 
Introduction  
 Misfolding and aggregation of microtubule associated protein tau (MAPT, tau) is 
a defining pathological hallmark of tauopathies such as Alzheimer’s disease (AD) and 
frontotemporal lobar degeneration (FTLD-tau).  Tau is normally located in axons where 
it functions to bind and stabilize microtubules.  In tauopathies, tau is mis-sorted to the 
somatodendritic compartment where it misfolds and aggregates, forming insoluble 
neurofibrillary tangles (NFTs) (Yipeng Wang & Mandelkow, 2015).  Tau aggregation is 
classically thought to proceed in a linear fashion, with misfolded tau followed by an 
oligomeric intermediate that assembles into insoluble fibrils.  However, the cellular 
mechanisms that regulate tau aggregation in disease remain unknown.   
RNA binding proteins (RBPs) are gaining increasing attention in the field of 
neurodegenerative disease due to their frequent involvement in disease pathology and 
genetics (Ash et al., 2014; Bentmann et al., 2013; King, Gitler, & Shorter, 2012; Y. R. Li 
et al., 2013; Nussbacher et al., 2015; Ramaswami et al., 2013).  The structure of RBPs is 
particularly striking because these proteins contain glycine-rich, low-complexity (LC) 
domains that mediate reversible phase transition between soluble and liquid droplet 
states.  Self-aggregation of these LC domains promotes prion-like aggregation of RBPs 
and client mRNA transcripts to form RNA granules (Anderson & Kedersha, 2008).  
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RBPs predominantly function in the nucleus to mediate RNA transcription, splicing, and 
maturation.  However, their regulated aggregation to generate RNA granules also allows 
them to mediate diverse cytoplasmic functions, which includes nuclear-cytoplasmic 
shuttling, mRNA transport, and translational initiation/repression.  Cytoplasmic RNA 
granules are especially critical and abundant in neurons, which require extensive 
transport and local regulation of specialized mRNA in dendritic spines and axon 
terminals (L. Liu-Yesucevitz et al., 2011; Nussbacher et al., 2015).  RNA granules also 
mediate the translational response to stress, forming stress granules (SGs), which 
function in part to transiently sequester transcripts that are not necessary for the stress 
response (Anderson & Kedersha, 2008; Buchan & Parker, 2009; N Kedersha & 
Anderson, 2002; Protter & Parker, 2016).  SGs are thought to contribute to 
neurodegenerative diseases since they co-localize with neuropathology, and these 
diseases present a chronic stress for cells.  
Aggregation mediated by LC domains in RBPs regulates formation of RNA 
granules, such as SGs, and appears to be critical for the involvement of RBPs in disease.  
Mutations in TDP-43, FUS, hnRNP A1, hnRNP A2/B1, TAF15, EWSR1, ATXN2, and 
many other RBPs cause Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Lobar 
Degeneration (FTLD-U), or Spinocerebellar Ataxia, while mutations in TIA1 and VCP (a 
protein that disaggregates SGs) cause myopathies (Ash et al., 2014; Couthouis et al., 
2012; Gitler & Shorter, 2011; Hackman et al., 2013; Johnson et al., 2009; King et al., 
2012; Kwiatkowski et al., 2009).  Many of these disease-linked RBPs also represent the 
primary pathological aggregates in each of these diseases (i.e. TDP-43, FUS, TIA1).  The 
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aggregation process can be directly linked to the biochemical behavior of these RBPs 
because disease-linked mutations in FUS and hnRNP A1 are able to accelerate the phase 
transition of recombinant RBPs from soluble to liquid droplet states, and can directly 
promote the irreversible transition from liquid droplet to amyloid-like fibrils (Lin et al., 
2015; Molliex et al., 2015; Nott et al., 2015).  Thus, dysfunctional RBP aggregation 
appears to greatly influence the development of neurodegenerative disease.   
 Recent results from multiple groups suggest that aggregation of RBPs is also a 
pathological feature in tauopathies (Ash et al., 2014; Bentmann et al., 2013; Brunello, 
Yan, & Huttunen, 2016; Vanderweyde et al., 2012).  Various RBPs, including the SG 
nucleating protein TIA1, co-localize with phosphorylated tau inclusions in patient tissues 
and progressively accumulate with tau aggregates in mouse models of disease (i.e. 
Tg4510, JNPL3, and PS19) (Vanderweyde et al., 2012).  This observation was surprising 
because tau was not previously known to interact with RBPs or regulate RNA 
metabolism.  Importantly, the association of tau with RNA granules containing TIA1 
promotes tau-mediated neurodegeneration in primary cultures of hippocampal neurons, 
while TIA1 knockdown or knockout inhibits tau misfolding and toxicity (Vanderweyde 
et al., 2016).  The interaction between tau and TIA1 increased the stability of tau, 
promoted its misfolding, and increased the tendency of tau to form sarkosyl-insoluble 
aggregates.  Taken together, these data raised the possibility that the interaction between 
tau and TIA1 might drive part of the neurodegenerative process in tauopathies.  
The interaction of tau with RBPs regulates the translational stress response, 
promoting formation of SGs.  However, whether RBPs also impact the process of tau 
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aggregation in vivo, as well as whether this interaction affects tau-mediated 
neurodegeneration in the brain is unknown.  The results presented below demonstrate that 
reducing TIA1 protects against neurodegeneration and prolongs survival in PS19 
transgenic tau mice.  This protection is evident through multiple independent lines of 
evidence including increased binding of tau to microtubules, stabilization of the synaptic 
arbor, improved memory performance, and reduced neuronal loss.  This work also adds 
to a growing body of evidence suggesting that tau oligomers exert a stronger influence on 
neurodegeneration than NFTs.  
 
Results 
Heterozygous knockout of Tia1 reduces cytoplasmic translocation of TIA1 and SG 
formation in PS19 mice 
PS19 transgenic tau mice, which overexpresses the human P301S tau mutation 
(1N4R) linked to FTLD-tau under the control of the mouse prion promoter, were utilized 
to investigate whether reduction in endogenous TIA1 protects against the progression of 
tauopathy in vivo (Yoshiyama et al., 2007).  These mice exhibit an age-dependent 
progressive tauopathy characterized by NFTs, neuronal loss, and premature mortality 
(Yoshiyama et al., 2007).  We bred PS19 mice with Tia1-/- (Phillips, Kedersha, Shen, 
Blackshear, & Anderson, 2004) or background strain (C57BL/6J) mice to generate 
tauopathy mice that express either 1 or 2 copies of the Tia1 allele, which we will refer to 
as P301S TIA1+/- and P301S TIA1+/+ mice, respectively.  Analysis of endogenous TIA1 
protein levels by immunoblot confirmed that TIA1 protein expression in the brain was 
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reduced by >50% in 3 month old P301S TIA1+/- compared to P301S TIA1+/+ mice (Fig. 
22A-B).   
We next investigated whether Tia1 heterozygosity reduced the number of 
cytoplasmic TIA1 granules.  Immunohistochemistry (IHC) of neurons in the 
hippocampus of 6 month old PS19 mice revealed a greater than 50% reduction in the 
number of cytoplasmic TIA1 granules (Fig. 22C-D), as well as a similar reduction in 
cytoplasmic TIA1 granules co-localizing with poly(A) binding protein (PABP), a marker 
of SGs (Fig. 23A-B).  The P301S TIA1+/+ mice also exhibited considerable depletion of 
nuclear TIA1, consistent with the disease process producing chronic stress (Fig. 23A).  In 
contrast, P301S TIA1+/- mice were protected against loss of nuclear TIA1 (Fig. 23C).  
Taken together, these data show that Tia1 heterozygosity inhibits the formation of 
cytoplasmic TIA1 granules and rescues nuclear localization of TIA1 in vivo. 
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Figure 22: TIA1 expression level and granules are reduced in P301S TIA1+/- brain   
A. Immunoblot of TIA1 from total brain lysates of 3 month old P301S TIA1+/+ and P301S TIA1+/- mice.  
B. Quantification of relative TIA1 protein level normalized to β-actin from A. **p<0.0095 by Student’s t-
test (n=5/group).  C. IHC of cytoplasmic TIA1 granules (green, arrows) and DAPI (blue) in 6 month P301S 
TIA1+/+ and P301S TIA1+/- hippocampus (CA3). Scale bar = 5 m. note that TIA1 granules in P301S 
TIA1+/+ mice are enlarged compared to non-transgenic mice.  D. Quantification of number of TIA1 
granules per cell in C. **p<0.01 by 2-way ANOVA with Tukey’s post-hoc comparisons (n=4 mice/group, 
at least 20 cells imaged per mouse). Error bars represent means ± SEM. 
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Figure 23: TIA1 reduction decreases cytoplasmic stress granules in PS19 mice while 
increasing nuclear TIA1 
A. IHC of DAPI (blue), TIA1 (green), and PABP (red) in 9 month Layer II LEnt. Arrows denote lack of 
nuclear TIA1 staining in P301S TIA1+/+ mice.  B. Quantification of the number of cytoplasmic granules 
co-positive for TIA1 and PABP from A. **p<0.01 by 1-way ANOVA with Tukey’s post-hoc tests (n=4 
mice/group, at least 20 cells imaged per mouse).  C. Quantification of nuclear TIA1 immunofluorescence in 
A. ***p<0.001 by unpaired Student’s t-test (n=4 mice/group, at least 20 cells imaged per mouse). Error 
bars represent means ± SEM. 
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TIA1 reduction rescues synaptic and neuronal loss in PS19 mice 
 Our previous studies indicated that reducing TIA1 (by either knockdown or 
knockout) protects against tau toxicity in primary cultured hippocampal neurons 
(Vanderweyde et al., 2016).  Since these studies reflect relatively short duration 
experiments, we proceeded to investigate whether TIA1 reduction also reduces synaptic 
and neuronal degeneration in vivo.  P301S TIA1+/+ mice exhibit progressive neuronal 
loss between 6 and 12 months of age that is preceded by presynaptic degeneration 
(Yoshiyama et al., 2007).  We focused quantification studies on the CA3 region of the 
hippocampus due to the high density of both axon terminals and neuronal cell bodies, and 
because synaptic and neuronal loss in P301S TIA1+/+ mice are well characterized in this 
region.  Compared to non-transgenic (WT Tau) mice, 6 month old P301S TIA1+/+ mice 
exhibited reduced immunofluorescence of synaptophysin (SYP), a presynaptic terminal 
protein (Fig. 24A-B).  In contrast, SYP immunofluorescence was increased in P301S 
TIA1+/- compared to P301S TIA1+/+ mice (Fig. 24A-B), indicating reduced presynaptic 
degeneration.  Levels of post-synaptic markers, including PSD-95, were unchanged at 6 
months in P301S TIA1+/+ mice (not shown).   
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Figure 24: TIA1 reduction rescues synaptic and axonal loss in PS19 mice 
A. IHC of NeuN (green) and synaptophysin (SYP, red) in the CA3 region of 6 month non-transgenic (WT 
Tau) and PS19 (P301S Tau) hippocampus. Scale bar = 20 µm.  B. Quantification of relative SYP 
expression from A. *p<0.0135 **p<0.0067 by 2-way ANOVA with Tukey’s post-hoc test (n=6/group).  C. 
Immunoblot of total tau detected in microtubule (MT)-bound (pellet, P) and unbound (supernatant, S) 
fractions in 6 and 9 month WT and PS19 cortex.  D. Quantification of ratio of MT-bound to MT-unbound 
tau in A. *p=0.0138 by Student’s t-test (n=4/group).  E. Immunoblot of acetylated (Lys40) and total α-
tubulin in the hippocampus of 6 month old P301S TIA1+/+ and P301S TIA1+/- mice.  F. Quantification of 
the ratio of acetylated to total α-tubulin in 6 month PS19 cortex. *p=0.0138 by Student’s t-test (n=4/group). 
Error bars denote means ± SEM. 
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Tau binds and stabilizes microtubules (MTs), which promotes axonal outgrowth 
and fast axonal transport.  Because previous studies indicate that neurodegeneration in 
P301S TIA1+/+ mice is associated with reduced association of tau with MTs (Yoshiyama 
et al., 2007), we investigated whether TIA1 reduction might protect binding of tau to 
MTs in these mice.  MT-bound (pellet, P) and unbound (supernatant, S) fractions were 
separated by centrifugation in RAB buffer, as described previously (Yoshiyama et al., 
2007).  As expected, tau progressively accumulated in the MT-unbound (S) fraction of 
P301S TIA1+/+ mice between 6 and 9 months of age, indicating dissociation of tau from 
MTs (Fig. 24C).  In contrast, significantly less tau was detected in the MT-unbound (S) 
fraction of P301S TIA1+/- mice, resulting in a 3-fold increase in the ratio of MT-bound 
(P) to unbound (S) tau at 9 months of age (Fig. 24C-D).  We also tested the microtubule 
system by examining tubulin acetylation, which is known to increase with microtubule 
stability (Conde & Cáceres, 2009; Matsuyama et al., 2002; Penazzi, Bakota, & Brandt, 
2016).  P301S TIA1+/- mice exhibited an increase in the ratio of acetylated to total α-
tubulin in hippocampal lysates (Fig. 24E).  These data indicate that TIA1 reduction 
protects the synaptic arbor against tau-mediated degeneration while providing an 
associated stabilization of MTs.  
We proceeded to quantify total neuron numbers in the hippocampus (CA3) and 
lateral entorhinal cortex (LEnt) of P301S TIA1+/+ and P301S TIA1+/- mice.  The 
number of Nissl-positive neurons and NeuN (neuron specific nuclear protein)-positive 
nuclei were increased in P301S TIA1+/- mice compared to P301S TIA1+/+ mice in both 
CA3 and LEnt at 9 months of age (Fig. 25A-C, 26A).  We also assessed the effect of 
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TIA1 reduction on gross cortical atrophy by measuring the distance between the most 
superficial part of Layer II and the deepest part of Layer III in the LEnt (Fig. 26A) and 
primary somatosensory (S1) cortex (Fig. 25D) of 9 month P301S TIA1+/+ and P301S 
TIA1+/- mice.  P301S TIA1+/+ mice exhibited a 54 and 21 percent reduction in Layer 
II/III thickness in LEnt and S1 cortex, respectively, while P301S TIA1+/- mice were not 
significantly different from non-transgenic mice (Fig. 25E, 26B).  Taken together, our 
data suggests that TIA1 reduction protects against tau-mediated neurodegeneration in 
vivo.  
 
Figure 25: TIA1 reduction protects against neurodegeneration in PS19 mice 
A. Representative Nissl stain of CA3 in 9 month non-transgenic and PS19 mice.  Scale bar = 20 m.  B-C. 
Quantification of number of Nissl+ (B) and NeuN+ (C) neurons per field in C. *p<0.05 **p<0.01 by 2-way 
ANOVA with Tukey’s post-hoc tests (n=5/group).  D. Representative images of cortical layers I through VI 
in 9 month non-transgenic and PS19 cerebral cortex (primary somatosensory cortex, S1). Scale bar = 100 
m. Red asterisks and arrowheads denote the start of Layer II and end of Layer III, respectively.  E. 
Quantification of average Layer II/III cortical thickness in S1 from D. **p<0.01 by 2-way ANOVA with 
Tukey’s post-hoc tests (n=5/group). Error bars denote means ± SEM. 
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Figure 26: TIA1 reduction protects against tau-mediated neurodegeneration in the lateral 
entorhinal cortex   
A. Quantification of the number of Nissl-positive neuronal cell bodies per field in Layer II/III LEnt of 9 
month non-transgenic (WT Tau) and PS19 (P301S Tau) mice. *p<0.05 by 2-way ANOVA with Tukey’s 
post-hoc tests (n=5/group).  B. Quantification of average Layer II/III cortical thickness in 9 month LEnt. 
**p=0.0095 ***p<0.001 by 2-way ANOVA with Tukey’s post-hoc tests (n=5/group). Error bars represent 
means ± SEM. 
 
TIA1 reduction improves memory and extends lifespan in PS19 mice 
 We next sought to determine whether TIA1 reduction alleviated the behavioral 
phenotype of PS19 mice.  Previous studies found that PS19 mice exhibit cognitive 
impairment in the Y maze spontaneous alternation task and hyperactivity/anxiolysis in 
the Open Field (OF) task (Takeuchi et al., 2011).  In the Y maze, 6 month P301S 
TIA1+/+ mice exhibited reduced spontaneous alternation compared to non-transgenic 
mice (Fig. 27A-B), indicating an impairment in spatial working memory.  Remarkably, 
TIA1 reduction rescued the performance of P301S TIA1+/- mice to normal working 
memory levels (Fig. 27B); TIA1 reduction had no effect in non-transgenic mice (Fig. 
27B).  We next applied the novel object recognition (NOR) task to a separate cohort of 
mice in order to independently confirm the effect of TIA1 reduction on cognitive 
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function using a second memory task.  As expected, 6 month old P301S TIA1+/+ mice 
were not able to distinguish between the novel and familiar objects, indicating an 
impairment in recognition memory (Fig. 27E).  In contrast, non-transgenic (WT Tau 
TIA1+/+ and WT Tau TIA1+/-) and P301S TIA1+/- mice exhibited greater than 65% 
preference indices (PIs) for the novel object, confirming that their recognition memory 
was highly functional (Fig. 27E).  Importantly, P301S TIA1+/+ and P301S TIA1+/- mice 
did not differ in their locomotor activity in the Y maze, OF, or NOR tasks, indicating that 
their improved memory performance could not be attributed to differences in locomotor 
or anxiety behaviors (Fig. 27C-D, Fig. 28A-D).  Thus, TIA1 reduction improves spatial 
working and recognition memory in PS19 mice, but does not alter the locomotor or 
anxiety phenotypes.  These results suggest that RBPs exert an especially important 
influence on tau-mediated perturbations related to cognition, which is the primary clinical 
feature of tauopathies.    
 PS19 mice die prematurely due to motor ataxia and hindlimb paralysis, with a 
previously reported median survival of 9 months and 80% mortality by 12 months of age 
(Yoshiyama et al., 2007).  Our cohort of PS19 mice crossed to a C57BL/6J background 
(P301S TIA1+/+) recapitulated this lifespan phenotype (Fig. 27F-G).  The P301S 
TIA1+/- mice exhibited a striking increase in lifespan, living 3.1 months longer on 
average (mean lifespan = 12.4 months, n=14; compared to 9.3 months for P301S 
TIA1+/+, n=20), with 50% surviving to 12 months of age without overt symptoms of 
disease (e.g., ataxia, hind limb weakness, hunched posture, etc.) (Fig. 27F-G).  All of the 
non-transgenic mice in this study (WT Tau TIA1+/+, n=12; WT Tau TIA1+/-, n=16) 
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survived to 12 months of age without evidence of motor or neurological symptoms (not 
shown).  Thus, TIA1 reduction extends lifespan by 33.3% in PS19 mice.  These findings 
indicate that TIA1 reduction confers robust behavioral protection against tau-mediated 
neurodegeneration and premature mortality in PS19 mice.    
 
Figure 27: TIA1 reduction improves memory and prolongs lifespan in PS19 mice   
A. Schematic of Y maze.  B. Percent correct alternations in the Y maze spontaneous alternation task for 6 
month old non-transgenic and PS19 mice. *p=0.0213 **p=0.0072 by 2-way ANOVA with Tukey’s post-
hoc comparisons (n=16-20 mice/group).  C. Total number of arm entries over 10 min testing period in Y 
maze spontaneous alternation task. **p<0.01 by 2-Way ANOVA with Tukey’s post-hoc comparisons.  D. 
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Total distance traveled over time in the Open Field exploratory activity task. Main effect of P301S tau 
transgene (***p<0.001) by 2-way ANOVA; P301S TIA1+/+ and P301S TIA1+/- curves are not statistically 
different by Tukey’s post-hoc comparisons.  E. The novel object recognition (NOR) task was used to assess 
recognition memory in non-transgenic (WT Tau) and PS19 (P301S Tau) mice. Mice were habituated to the 
testing chambers for 2 days (30 min/d) prior to testing. On testing day, mice were allowed to explore 2 of 
the same objects (familiar object) for 5 min. 90 min later, the mice were returned to the testing chamber, 
which now contained one of the familiar objects plus a novel object. Preference index (PI) for each mouse 
was determined by dividing the amount of time spent exploring the novel object by the total amount of time 
spent exploring both objects (PI = 100 * (Tnovel/Tnovel + Tfamiliar). *p<0.05 by 2-Way ANOVA with Tukey’s 
post-hoc comparisons (n=14-15 mice/group).  F. Mean age until meeting endpoint criteria for P301S 
TIA1+/+ compared to P301S TIA1+/- mice. ***p=0.0009 by unpaired Student’s t-test.  G. Kaplan-Meier 
survival plot of P301S TIA1+/+ (n=14) compared to P301S TIA1+/- (n=20) mice. ***p= 0.0005 by the 
Gehan-Breslow-Wilcoxon test. Error bars denote means ± SEM. 
 
 
Figure 28: PS19 mice exhibit hyperactive locomotor activity and reduced anxiety behaviors 
independent of Tia1 genotype 
A-D. P301S transgene expression increased distance traveled (A), mean speed (B), and center time (C) in 
the OF task, while decreasing freezing time (D). Main effect of P301S Tau transgene by 2-way ANOVA 
(p<0.05) for total distance traveled, mean speed, center time, and freezing time. Bars represent means ± 
SEM. 
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TIA1 reduction regulates tau phosphorylation in an age-dependent manner 
 Aggregated tau in AD and FTLD-tau is hyper-phosphorylated at a variety of 
disease-specific phospho-epitopes.  We compared the age-dependent accumulation of 
phosphorylated tau pathology in P301S TIA1+/+ and P301S TIA1+/- mice by IHC.  As 
expected, P301S TIA1+/+ mice accumulated detectable levels of CP13 (S202)- and AT8 
(S202/T205)-phosphorylated tau in the hippocampus by 3 months of age (Fig. 29A).  
Little to no phosphorylated tau was observed in the cortex or cerebellum of P301S 
TIA1+/+ mice at 3 months of age (not shown), consistent with the expected progression 
of disease in PS19 mice.  In contrast, P301S TIA1+/- mice exhibited reduced levels of 
CP13- and AT8-phosphorylated tau in the hippocampus (CA1, CA3) compared to P301S 
TIA1+/+ mice (Fig. 29B-C), suggesting that TIA1 reduction delays the onset of 
pathology in PS19 mice.  This reduction of tau pathology in young P301S TIA1+/- mice 
is consistent with our prior short-term studies using cultured neurons (Vanderweyde et 
al., 2016).   
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Figure 29: TIA1 reduction elicits a biphasic change in tau phosphorylation in PS19 mice 
A. IHC of DAPI (blue), NeuN (green), and CP13 phospho (S202)-tau in 3 (top panels) and 6 (bottom) 
month CA3 in non-transgenic and PS19 mice.  B-C. Quantification of CP13 and AT8 (S202/T205) 
phospho-tau immunofluorescence at 3 months in CA1 and CA3 from A. *p<0.05 **p<0.01 by unpaired 
Student’s t-test (n=6/group).  D. Quantification of CP13 phospho-tau immunofluorescence at 6 months in 
CA3 from A. **p=0.0044 by unpaired Student’s t-test (n=6/group). Error bars represent means ± SEM. 
 
We proceeded to determine how TIA1 reduction affected tau phosphorylation at 
later stages of disease by measuring the levels of CP13- and PHF1-phosphorylated tau at 
6 and 9 months of age.  PHF1-positive tau selectively labels tau phosphorylated at a 
phospho-epitope (S396/S404) that is highly correlated with fibrillar tau aggregates.  
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Surprisingly, TIA1 reduction led to increased immunofluorescence for AT8- and CP13-
phosphorylated tau at 6 and 9 months (Fig. 29D, CP13 data shown).  TIA1 reduction also 
increased the number of PHF1-positive neurons in LEnt and CA3 at 9 months of age 
(Fig. 31A-B).  While almost 20% of PHF1-positive inclusions co-localized with 
cytoplasmic TIA1 in P301S TIA1+/+ mice, less than 5% of PHF1 inclusions contained 
TIA1 in P301S TIA1+/- mice (Fig. 31C-D).  The P301S TIA1+/- mice also showed a 
striking rescue of TIA1 nuclear localization, with TIA1 being largely restricted to the 
nucleus even in PHF1-positive neurons (Fig. 31C).  Immunoblot analysis of total brain 
lysates confirmed that levels of CP13- and PHF1-phosphorylated tau were increased in 
aged P301S TIA1+/- compared to P301S TIA1+/+ mice (Fig. 30A-C); total tau levels 
were also slightly elevated (Fig. 30D).  Thus, TIA1 reduction initially decreased the level 
of phosphorylated tau pathology in PS19 mice, but then induced an age-dependent 
increase in phosphorylated tau at later stages of disease.  This suggests that reducing 
TIA1 delays the onset of disease pathology, and then modifies tau phosphorylation and 
aggregation once the disease process has been initiated.  
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Figure 30: TIA1 reduction increases levels of phosphorylated tau in PS19 mice 
A. Immunoblot analysis of PHF1, CP13, Tau13 (total tau), and α-tubulin levels in total brain lysates of 6 
month P301S TIA1+/+ and P301S TIA1+/- mice.  B-D. Quantification of PHF1+ (B), CP13+ (C), and total 
(D) tau in A. PHF1 and CP13 phospho-tau levels were normalized to total tau levels (Tau13) detected in 
each sample. #p= 0.0981 *p=0.0276 **p=0.0079 by unpaired Student’s t-test (n=4/group). Error bars 
represent means ± SEM. 
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Figure 31: TIA1 reduction leads to an age-dependent increase in tau phosphorylation 
A. IHC of DAPI (blue) and PHF1 (S396/S404) phospho-tau in the lateral entorhinal cortex (LEnt) of 9 
month old P301S TIA1+/+ and P301S TIA1+/- mice. Scale bar = 10 m.  B. Quantification of number of 
PHF1+ cells in A. *p=0.0483 **p=0.0028 by 3-way ANOVA with Bonferroni post-hoc tests (n=5/group).  
C. Confocal images of PHF1+ cells in P301S TIA1+/+ and P301S TIA1+/- LEnt. Scale bar = 2 m.  D. 
Quantification of percent of PHF1+ cells with TIA1 co-localization in C. **p=0.0074 by Student’s t-test 
(n=5/group). Error bars denote means ± SEM. 
 
TIA1 reduction accelerates neurofibrillary tangle formation 
 The age-dependent increase in tau pathology in P301S TIA1+/- mice was also 
apparent when analyzing NFTs.  As expected, 9 month P301S TIA1+/+ mice developed 
widespread Gallyas-positive and thioflavin S (ThioS)-positive tangles throughout the 
hippocampus and temporal cortex (Fig. 32A-D).  P301S TIA1+/- mice exhibited 
increased numbers of Gallyas silver-positive neurons in both the frontal (primary motor 
area, M1) and temporal (LEnt) cortices (Fig. 32B); TIA1 reduction also increased the 
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level of ThioS fluorescence in these brain areas (Fig. 32C-D).  The number of Gallyas 
Silver-positive tangles did not differ between the two cohorts in the CA3 region of the 
hippocampus, perhaps resulting from a “ceiling effect” caused by the advanced level of 
pathology in the hippocampus relative to other brain areas in this model (Fig. 32B).  
However, despite equal number of tangles in CA3 at 9 months of age, there was no 
relationship between tangle burden and neuronal loss in either P301S TIA1+/+ or P301S 
TIA1+/- mice (r
2
 = 0.07; Fig. 33).  Thus, the neuroprotection associated with TIA1 
reduction in PS19 mice occurred independent of NFTs, consistent with previous studies 
which suggest that NFTs are not the primary cause of neuronal loss in tauopathies (de 
Calignon et al., 2010; Kuchibhotla et al., 2014; Rocher et al., 2010; Santacruz et al., 
2005).  These results are the first to our knowledge to demonstrate behavioral 
improvement and neuronal protection in a mouse model of tauopathy despite the 
increased presence of NFTs.  
  
99 
 
Figure 32: TIA1 reduction increases neurofibrillary tangles in PS19 mice 
A. Representative images of Gallyas Silver stained neurofibrillary tangles in 9 month P301S TIA1+/+ and 
P301S TIA1+/- mice. Scale bar = 40 m.  B. Quantification of number of Gallyas Silver+ tangles in the 
frontal cortex (primary motor area, M1), lateral entorhinal cortex (LEnt), and CA3. *p<0.05 by 3-way 
ANOVA with Bonferroni post-hoc tests (n=5/group).  C. Representative images of LEnt from 9 month non-
transgenic and PS19 mice stained with Thioflavin S (ThioS). Scale bar = 20 m. Red inserts denote high 
magnification images of ThioS+ tangles in P301S TIA1+/+ and P301S TIA1+/- LEnt.  D. Quantification of 
ThioS fluorescence in C. *p=0.0213 by Student’s t-test (n=5/group). Error bars denote means ± SEM. 
 
  
100 
 
Figure 33: The number of Gallyas Silver neurofibrillary tangles does not correlate with 
neuronal loss in 9 month PS19 mice 
Number of Gallyas Silver+ tangles plotted against the number of Nissl+ neurons in CA3 of the same 
animals for 9 month P301S TIA1+/+ and P301S TIA1+/- mice (r
2
 = 0.07). 
 
TIA1 reduction selectively decreases soluble tau oligomers 
The improved phenotype in P301S TIA1+/- mice concurrent with the increased 
presence of various classical markers of disease pathology (i.e. tau phosphorylation, 
NFTs) led us to hypothesize that TIA1 reduction alters the structural or biochemical 
properties of tau aggregates, producing tau species that are less toxic.  This possibility 
seemed particularly plausible given the recent findings that neurons containing NFT-like 
inclusions remain functional and that different strains of tau aggregates exhibit distinct 
patterns of propagation and pathophysiology when injected into tauopathy mice (Hyman, 
2014; Kfoury et al., 2012; Mirbaha et al., 2015; Sanders et al., 2014).  Biochemical 
fractionation studies identify tau species with distinct structural properties that are 
apparent upon separation of TBS-extractable (S1), sarkosyl-soluble (S3), and sarkosyl-
insoluble (P3) fractions (Sahara et al., 2013).  The aggregate material from the soluble 
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fraction (S1p fraction, separated by a sequential high-speed spin of the S1 TBS-
extractable fraction) contains oligomeric tau species that correlate with 
neurodegeneration in rTg4510 mice, while the P3 fraction contains mostly fibrillar, 
hyper-phosphorylated (CP13-/PHF1-positive) tau (Berger et al., 2007).  Therefore, we 
applied these same approaches to biochemically fractionate brain tissue from P301S 
TIA1+/+ and P301S TIA1+/- mice.  Immunoblot analysis of 6 and 9 month old cortex 
tissue showed that tau progressively accumulated in both the S1p and P3 (sarkosyl-
insoluble) fractions of P301S TIA1+/+ mice (Fig. 34A-B).  Under non-reducing 
conditions, immunoblot analysis of the S1p fraction with a total tau antibody (Tau13) 
identified predominant bands at 64, 140 and 170 kD, corresponding to tau monomers and 
oligomers (Fig. 34A), as described previously (Berger et al., 2007; Sahara et al., 2013).  
TIA1 reduction greatly decreased the level of all tau isoforms detected in the S1p 
fraction, while concomitantly increasing the level of tau in the P3 fraction (Fig. 34A-C).  
ELISAs performed under non-denaturing conditions with antibodies that recognize 
pathological conformations of misfolded (TNT1, recognizing exposure of the 
phosphatase-activating domain [PAD]) and oligomeric tau (TOC1) (Combs et al., 2016) 
confirmed that TIA1 reduction decreased the accumulation of misfolded tau oligomers in 
the soluble fraction (Fig. 35A-B).  This result suggests that TIA1 reduction shifts the 
pathway of tau aggregation, preventing the accumulation of oligomeric tau while 
accelerating the accumulation of insoluble tau fibrils.   
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Figure 34: TIA1 reduction shifts the biochemical and structural properties of tau 
aggregation 
A. Immunoblot for total tau (Tau13) in the S1p (top) and P3 (bottom) fractions of 6 and 9 month P301S 
TIA1+/+ and P301S TIA1+/- cortex.  B-C. Quantification of tau accumulation in the S1p (B) and P3 (C) 
fractions from A. #p<0.10 **p<0.01 ***p<0.001 by 2-way ANOVA with Tukey’s post-hoc comparisons 
(n=4/group). Error bars denote means ± SEM. 
 
 
Figure 35: TIA1 reduction decreases soluble tau oligomers in PS19 mice 
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A-B. Quantification of tau oligomers in the soluble (S1) fraction of 9 month P301S TIA1+/+ and P301S 
TIA1+/- cortex detected by non-denaturing ELISA using TNT1 (A) and TOC1 (B) antibodies. The results 
were normalized to levels of total tau in the same fractions detected by ELISA using Tau5. TNT1 and 
TOC1 concentrations were estimated based on Tau5 immunoreactivity to a standard curve of increasing 
concentrations of recombinant tau protein.  #p<0.10 **p= 0.0073 by unpaired Student’s t-test (n=3/group).  
Error bars represent means ± SEM. 
 
RNA binding proteins co-aggregate with tau oligomers in vivo 
Since aggregation of tau oligomers in the S1p fraction was sensitive to TIA1 
reduction, we next investigated whether TIA1 also accumulated in the S1p fraction.  
Immunblot analysis of TIA1 revealed an age-dependent accumulation of TIA1 in both the 
S1p and P3 fractions of PS19 mice (Fig. 36A).  Surprisingly, TIA1 reduction selectively 
decreased TIA1 levels in the S1p, but not the P3, fraction (Fig. 36A).  Further 
immunoblot analysis showed that this phenomenon also occurred for other RBPs 
associated with SGs, including PABP and DDX6 (Fig. 36A).  We next analyzed the S1p 
(‘tau oligomer fraction’) of PS19 cortex by OrbiTrap liquid chromatography tandem 
mass spectrometry (LC-MS/MS) in order to determine if this biochemical fraction is 
enriched for other RBPs.  As expected, the level of tau protein detected in the S1p 
fraction was significantly elevated in P301S TIA1+/+ compared to non-transgenic (WT 
Tau TIA1+/+) cortex (Appendix II).  Bioinformatic analysis of the proteins identified in 
the S1p fraction of P301S TIA1+/+ cortex revealed statistically significant enrichment 
(FDR < 0.05) for various annotations related to RNA metabolism, including poly(A) 
RNA binding (FDR = 1.33e-106), RNA binding (FDR = 4.02e-42), and RNA recognition 
motif domain (FDR = 9.95e-17) (Fig. 36B).  Further, poly(A) RNA binding is the top 
most significant gene ontology (GO) annotation enriched in the list of proteins increasing 
their accumulation in the S1p fraction of P301S TIA1+/+ compared to non-transgenic 
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(WT Tau TIA1+/+) mice (Fig. 36B), which was prevented in P301S TIA1+/- mice 
(Appendix II).  Taken together, these results suggest that RBPs co-accumulate with tau 
oligomers in the S1p fraction.  These studies also identify the biochemical properties of 
pathological RBP aggregates in vivo.   
 
Figure 36: TIA1 reduction decreases RNA binding protein aggregation in the S1p fraction 
A. Immunblot analysis of the RNA binding proteins TIA1, PABP, and DDX6 in P301S TIA1+/+ and 
P301S TIA1+/- cortex in the S1p (top panels) and P3 (bottom panels) of 6 and 9 month PS19 mice.  B. 
Molecular function gene ontology (GO) annotation terms significantly enriched in the S1p fraction of 
P301S TIA1+/+ cortex. Note that poly(A) RNA binding and RNA binding are the top two most significant 
annotation terms.  
 
Discussion 
Dysfunction of RBPs is implicated in multiple neurodegenerative diseases 
(Bentmann et al., 2013; Gitler & Shorter, 2011; Y. R. Li et al., 2013; Nussbacher et al., 
2015; Wolozin, 2012).  Here, we demonstrate an essential role for RBPs in the 
pathogenesis and progression of tauopathies.  Our results show that reducing TIA1, a 
core nucleating SG protein, leads to a robust decrease in RBP aggregation in cytoplasmic 
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SGs, which is associated with decreased neurodegeneration, improved memory, and 
prolonged survival.  Surprisingly, this neuroprotection occurred despite the increased 
presence of various classical markers of disease pathology, including insoluble tau fibrils.  
This finding adds to a growing body of literature indicating that NFTs are not the primary 
cause of neuronal loss in tauopathies (Kuchibhotla et al., 2014; Rocher et al., 2010; 
Santacruz et al., 2005).  Further, our results raise the possibility that NFTs may function 
as a protective mechanism against soluble tau oligomers, which are more toxic.   
The ability of TIA1 reduction to impact on the pathophysiology of tau raises the 
possibility that the biology of tauopathies shares features in common with 
neurodegenerative diseases caused by RBP aggregation (i.e. ALS, FTLD-U) and begins 
to unify two seemingly disparate pathological mechanisms previously linked mainly by 
similar neuroanatomical losses.  We previously demonstrated that tau interacts with TIA1 
and many other RBPs in the brain (Vanderweyde et al., 2012, 2016).  TIA1 complexes in 
particular contain multiple hnRNPs, ribosomal proteins (RPSs and RPLs), elongation 
initiation factors, and RNA helicases.  Several of these proteins (e.g., EWSR1, RPL7, and 
DDX5) bind to TIA1 through tau, and were previously shown to associate with tau 
pathology in vivo (Vanderweyde et al., 2016).  The association of tau with these RBPs 
provides a mechanistic basis for the linkage between tau and diseases associated with 
RBPs. 
Since TIA1 is a core, SG-nucleating RBP, reducing TIA1 dramatically decreased 
formation of SGs containing not only TIA1, but many other RBPs.  This effect is 
strikingly evident in our results in which we used PABP as a general marker for SGs.  
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PABP binds to most cytoplasmic mRNA and identifies SGs independently of TIA1 
(Anderson & Kedersha, 2008).  The strong reduction of cytoplasmic PABP granules 
indicates a general reduction in RBP aggregation.  A surprising observation was the 
normalization of the cellular distribution of TIA1 in P301S TIA1+/- mice; these mice 
exhibited predominantly nuclear TIA1 and few cytoplasmic TIA1 granules, much like the 
non-transgenic mice.  This may result from a mass action effect whereby reducing the 
cellular pool of TIA1 decreases the availability of TIA1 to achieve sufficiently high local 
concentrations for self-templated assembly of its LC domains, which results in fewer 
TIA1 granules but greater availability of diffuse, soluble TIA1 monomers.  The increased 
nuclear localization of TIA1 in P301S TIA1+/- mice raises the possibility that nuclear 
functions of TIA1, such as splicing, are also improved.  The benefits of TIA1 reduction 
might also extend to other RBPs that bind TIA1 and/or tau, or are recruited to SGs.   
An increasing number of studies point to tau oligomers as the crucial toxic species 
in tauopathies.  Tau multimers are known to accumulate in the brains of tau mice as 
pathology develops, and tau oligomers impair memory (Berger et al., 2007; Lasagna-
Reeves et al., 2011).  Tau misfolding, resulting in PAD exposure, is a pathological 
conformational change that can disrupt axonal transport and occurs in several tauopathies 
(Combs et al., 2016).  The current study provides an example where the distribution of 
large and small tau aggregates is shifted by reducing TIA1.  The ability of TIA1 
reduction to shift the pattern of tau aggregation suggests that oligomerization of tau can 
be controlled by RBPs, and that reducing RBPs inhibits the accumulation of soluble 
oligomers.  Our results suggest that RBPs, such as TIA1, bind and stabilize tau in its 
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oligomeric state, preventing its further aggregation into NFTs.  Thus, by reducing TIA1, 
tau oligomers are free to assemble into PHFs, accelerating NFT accumulation at the 
expense of oligomeric tau.  Importantly, the accelerated transition from oligomers to 
fibrils following TIA1 reduction improves the behavioral phenotype of PS19 mice, 
raising the possibility that in disease NFTs arise as a neuroprotective response to the 
elevated tau oligomer burden.  However, our results do not exclude the possibility that 
some contribution to survival results from neuroprotective effects of TIA1 reduction 
independent of its effects on tau.  In this regard, it is notable that TIA1 heterozygosity has 
not been reported to affect lifespan in non-transgenic mice (Phillips et al., 2004).   
The PS19 mouse model used in this study is a well-accepted disease model that 
exhibits many features of human tauopathy, including synaptic loss, neuronal loss, and 
formation of characteristic tau pathology.  However, mouse models that are based on tau 
overexpression necessarily differ from the human disease.  Mouse models are subject to a 
constant proteostatic stress from overexpressed tau that is not present in human disease, 
where tau is expressed at endogenous levels.  Our results indicate that TIA1 reduction 
does not decrease levels of tau nor the proteostatic stress caused by its overexpression.  
Thus, the overexpressed transgenic tau still experiences an ongoing pressure to aggregate 
in P301S TIA1+/- mice.  With the TIA1-mediated tau aggregation pathway inhibited, tau 
is forced to aggregate via alternative pathways that favor fibril formation over oligomers.  
Importantly, the resulting shift in oligomeric versus fibrillar tau aggregates confers robust 
neuroprotection despite the persistent aggregation of tau.   
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The current study presents a strong example in which the appearance of NFTs 
does not correlate with neuronal death, and is the first study demonstrating 
neuroprotection and enhanced survival despite increased NFTs.  These data suggest that 
while the accumulation of fibrillar tau is required for diagnosis of AD and other 
tauopathies, it might not necessarily predict important functional outcomes of disease, 
including cognition and survival.  This is highlighted by the repeated clinical failures of 
therapeutics that target insoluble protein aggregates in AD and other neurodegenerative 
disorders (Rachelle S Doody et al., 2014; Herrup, 2015; Karran et al., 2011; 
Vandenberghe et al., 2016).  More importantly, our findings identify a biological 
context—the stress-induced aggregation of RNA granules—whereby oligomeric tau 
aggregates can be modulated, suggesting new therapeutic strategies for tauopathies.  In 
this light, our findings complement the work of other groups who have reported 
phenotypic benefits of compounds that inhibit the translational stress and unfolded 
protein responses in animal models of neurodegenerative diseases (Ma et al., 2013; 
Moreno et al., 2012; Radford, Moreno, Verity, Halliday, & Mallucci, 2015).  Taken 
together, the work presented here supports a model of tauopathy whereby stress-induced 
aggregation of RBPs and misfolded proteins (i.e. tau) promotes neuronal dysfunction and 
neurodegeneration.  Targeting this pathway may represent a novel therapeutic 
opportunity for the treatment of a spectrum of neurodegenerative diseases, including AD.   
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CHAPTER THREE 
Combined transcriptomic and proteomic analyses in a mouse model of tauopathy 
identify dysfunctional RNA metabolism as a central driver of tau pathogenesis 
 
Adapted from Apicco et al. Neuron 2017 [In Preparation] 
 
 
Introduction 
 Emerging evidence links neurodegenerative disease processes to dysfunction of 
RNA metabolism and RNA binding proteins (RBPs) (Ash et al., 2014; Y. R. Li et al., 
2013; Nussbacher et al., 2015; Vanderweyde et al., 2016).  RBPs control all aspects of 
intracellular mRNA splicing, transport, and utilization, and exert a particularly influential 
role in neurons due to the long distance between the soma and synapse (L. Liu-
Yesucevitz et al., 2011; Nussbacher et al., 2015).  The unique biology and morphology of 
neurons requires them to express many neuron-specific proteins whose isoforms are 
subject to extensive pre-mRNA processing and alternative splicing (Q. Li, Lee, & Black, 
2007; Liqun Liu-Yesucevitz et al., 2014; Yap & Makeyev, 2013; Zheng & Black, 2013).  
Many of these splice isoforms encode synaptic proteins that are critical not only for 
maintaining neuron survival, but also for dynamically regulating the balance between 
excitatory and inhibitory neurotransmission in the brain.  These processes are particularly 
critical in the context of neurodegenerative diseases where the homeostatic mechanisms 
mediating synaptic function and neuronal survival are already challenged by the chronic 
stress of disease.   
RBPs possess two conserved protein domains: RNA recognition motifs (RRMs) 
that allow them to bind single stranded RNA molecules and low-complexity (LC) 
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domains that allow them to reversibly self-aggregate.  LC domains (also known as ‘prion-
related’ domains [PRDs] or intrinsically disorder regions [IDRs]) are defined by their 
inclusion of glycine- and uncharged polar amino acid (asparagine, glutamine and 
tyrosine)-rich repeats, which allows for templated assembly of RBPs into RNA granules, 
including stress granules (SGs) (Anderson & Kedersha, 2008; Buchan & Parker, 2009; Y. 
R. Li et al., 2013; Protter & Parker, 2016).  These LC domains allow for the reversible 
phase transition between soluble, liquid droplet, and amyloid-like states.  Recently, 
mutations in several RBPs have been demonstrated to cause motor neuron diseases, 
frontotemporal dementias (FTDs), and myopathies (Ash et al., 2014; Bentmann et al., 
2013; Couthouis et al., 2012; Hackman et al., 2013; King et al., 2012; Wolozin, 2012).  
These disease-linked mutations overwhelmingly occur in the LC domains of RBPs, and 
are gain-of-function mutations that promote RBP phase transition (Johnson et al., 2009; 
Kwiatkowski et al., 2009).  Studies using fused in sarcoma (FUS) and heterogeneous 
nuclear ribonucleoprotein (hnRNP) A1 have demonstrated that disease-linked mutations 
accelerate the phase transition from normally reversible liquid droplet to irreversible 
amyloid-like fibrils (Lin et al., 2015; Molliex et al., 2015; Nott et al., 2015).  These 
amyloid-like fibrils are strikingly reminiscent of the insoluble protein inclusions 
characteristic of many neurodegenerative diseases, and have been shown to sequester 
additional RBPs out of solution in vitro (Molliex et al., 2015).  In fact, in multiple 
neurodegenerative diseases, the primary pathological protein aggregate is an LC domain-
containing RBP known to undergo phase transitions (i.e. for TDP-43 and FUS in 
  
111 
Amyotrophic Lateral Sclerosis).  Thus, the biology of RBPs greatly influences the 
pathophysiology of neurodegenerative diseases.   
Recently, our group discovered an essential role for the RBP T cell intracellular 
antigen 1 (TIA1) in the progression of tauopathies such as Alzheimer’s disease (AD) and 
FTLD-tau.  In tauopathies, microtubule associated protein tau (MAPT, or tau), which 
normally binds microtubules to stabilize the axonal cytoskeleton, becomes mislocalized 
to the somatodendritic compartment where it misfolds and aggregates into insoluble 
neurofibrillary tangles (NFTs).  Despite being the defining pathological hallmark of 
disease, the cellular logic behind mis-sorting and aggregation of tau is unknown.  Our 
group has recently demonstrated a novel role for somatodendritic tau in regulating the 
formation of stress granules (SGs) in dendrites (Vanderweyde et al., 2016).  SGs are non-
membrane bound macromolecular complexes composed of protein and mRNA that 
accumulate in the cytoplasm in response to stress (Anderson & Kedersha, 2008; Nancy 
Kedersha et al., 2013; Protter & Parker, 2016; Wolozin, 2012).  SGs are nucleated by 
self-assembly of TIA1, which involves formation of an insoluble core and the secondary 
recruitment of other RBPs via interaction of their LC domains (Anderson & Kedersha, 
2008; Protter & Parker, 2016).  SGs progressively aggregate in multiple mouse models of 
tauopathy and co-localize with phosphorylated tau inclusions in human AD and FTLD-
tau tissues (Vanderweyde et al., 2012).  These tau/SG aggregates sequester additional 
proteins, including various RBPs, into pathological aggregates (Vanderweyde et al., 
2016), raising the possibility that loss of RBP function may be a novel component of 
tauopathies such as AD.  Prior results from our lab have demonstrated that reducing 
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levels of endogenous TIA1 in PS19 transgenic tau mice protects against virtually all 
aspects of disease progression, including presynaptic degeneration, memory impairment, 
neuronal loss, and premature mortality (Apicco et al. 2017).  Immunohistochemical and 
biochemical studies revealed that the mechanism of neuroprotection associated with 
TIA1 reduction involved the dispersion of cytoplasmic SGs, which rescued TIA1 
localization to the nucleus (Apicco et al. 2017).  These results suggest that the abnormal 
sequestration of RBPs in SGs contributes to the progression of disease.  However, the 
consequences of pathological SG formation on RNA metabolism in the context of 
tauopathy are unknown.   
Here, we present the mRNA transcriptome associated with tau-mediated toxicity 
in PS19 mice.  Using RNA-sequencing, we analyzed the brain mRNA transcriptome of 
PS19 compared to non-transgenic mice, and discovered both a dramatic downregulation 
of RBP functions and a corresponding deregulation of synaptic mRNA splicing.  
Importantly, these tau-induced changes were largely corrected in PS19 mice 
heterozygous for TIA1, suggesting that the vast majority of dysfunctional RNA 
regulation in tauopathies requires sequestration of RBPs in SGs.  Our results point to 
dysregulation of RBPs as a major pathogenic driver in tauopathies such as AD.   
 
Results 
RNA binding proteins are dysregulated in PS19 mice 
 Our lab previously used PS19 transgenic tau mice, which overexpress the human 
P301S tau mutation that causes FTLD-tau, to show that inhibiting SG formation by 
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heterozygous knockout of Tia1 protects against the progression of tauopathy in vivo.  
PS19 mice heterozygous for Tia1 (P301S TIA1+/-) exhibited reduced nuclear-to-
cytoplasmic translocation of RBPs, reduced formation of cytoplasmic SGs, stabilized 
microtubules, improved memory, decreased presynaptic and neuronal degeneration, and 
prolonged lifespan (Apicco et al. 2017).  These results suggested that rescue of tau-
induced changes in RNA metabolism might be a significant contributor to the 
neuroprotection associated with TIA1 reduction. 
   In order to determine how RNA metabolism is altered in PS19 mice, we isolated 
total RNA extracts from 9 month old non-transgenic (WT Tau TIA1+/+) and PS19 
(P301S TIA1+/+) cortex tissue.  RNA from P301S TIA1+/- and WT Tau TIA1+/- 
littermates was also purified in order to compare the effects of TIA1 reduction in the 
presence and absence of the tau transgene, respectively.  We chose to analyze the 
transcriptome at the 9 month time point because this corresponds to an age where P301S 
TIA1+/+ mice are severely affected by tauopathy, while P301S TIA1+/- mice are largely 
unaffected (Apicco et al. 2017); non-transgenic mice exhibit no symptoms of disease or 
abnormal aging at 9 months regardless of Tia1 genotype.  After confirming the quality of 
our RNA extracts (RIN scores > 9.0), we prepared cDNA libraries for next-generation 
sequencing (RNA-seq) using the Illumina TruSeq Stranded Total RNA Library Prep Kit 
(n=3/genotype).  Samples were read at a depth of 60 million reads per sample on an 
Illumina Hiseq 2000 machine, and aligned to the mouse genome using the Bowtie and 
Tophat programs, as described previously (Trapnell et al., 2012; Trapnell, Pachter, & 
Salzberg, 2009).   
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 We first analyzed the differential expression of mRNA transcript levels.  339 
transcripts were discovered to be significantly up- or down-regulated (FDR < 0.05) in 
PS19 compared to non-transgenic cortex (Appendix III).  We separately analyzed the up- 
and down-regulated transcripts using the DAVD bioinformatics tool (Huang et al., 2007, 
2009) in order to determine the functional annotation terms enriched in each gene list.  43 
BioCarta pathway annotations were enriched in the gene list of down-regulated 
transcripts (Appendix IV), including pre-mRNA splicing (FDR = 2.7e-4), processing of 
capped intron-containing pre-mRNA (FDR = 5.4e-4), and mRNA-splicing (FDR = 6.6e-
4).  Further, the top most significant downregulated gene ontology (GO) biological 
process and cellular component terms were RNA-splicing (FDR = 0.01102) and 
spliceosomal complex (FDR = 0.00109), respectively (Appendix IV).  In contrast, no 
BioCarta pathway annotations were enriched in the up-regulated transcripts, suggesting 
that there is not a strong biological trend in the transcripts that become upregulated in 
tauopathy.  Figure 37 summarizes the down-regulated pathways in the PS19 compared to 
non-transgenic mice.  These results suggest that abnormal processing of mRNA, 
especially in regards to RNA splicing, is one of the predominant features of tauopathy, 
which is consistent with RNA-seq studies from human AD parietal lobe (James D. Mills 
et al., 2013).     
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Figure 37: mRNA transcripts downregulated in PS19 mice are enriched for Pathway 
annotations involving RNA splicing 
Top 10 most significant KEGG Pathway annotation terms enriched in the list of transcripts significantly 
downregulated (FDR < 0.05) in PS19 (P301S TIA1+/+) compared to non-transgenic (WT Tau TIA1+/+) 
cortex. Note that the top 4 most significant annotation terms all concern mRNA splicing/processing or gene 
regulation.   
 
We next examined whether the down-regulation of pathways related to RNA 
metabolism reflected an underlying reduction in RBPs levels.  Expression level analysis 
was performed for transcripts in the RNA-seq data that were encompassed by the GO 
molecular function annotation ‘RNA-binding’ (Fig. 38).  Of the 37 RBPs identified, 30 
were decreased in the PS19 compared to the non-transgenic samples (Fig. 38), including 
Snrnp70, Rbm 11/17, Hnrnpa3, Snrp b/c/f, and U2af1.  These results suggest that 
expression of various proteins critical for RNA splicing, including RBPs, are reduced in 
PS19 cortex.     
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Figure 38: RNA binding protein transcript levels are reduced in PS19 cortex 
Heatmap of differential expression of mRNA transcripts encoding RNA binding proteins, as determined by 
their inclusion in the annotation term category ‘RNA-binding’ (as determined by the GO Molecular 
Function database). Blue and red represent decreased and increased transcript expression, respectively, 
relative to average transcript level (z-transformed) in the gene set.  [Fig. 38 provided by C Zheng, Mayo 
Clinic] 
 
Transcripts encoding synaptic proteins are alternatively spliced in PS19 mice 
 The observation that RNA splicing pathways are down-regulated in PS19 mice 
led us to investigate the specific transcripts that were subject to alternative splicing.  
Thus, we further analyzed our RNA-seq data using the OLego and Quantas programs to 
identify significant alternative splicing events in the PS19 compared to non-transgenic 
brain (Wu et al., 2013).  OLego detects 6 different types of alternative splicing events: 
cassette exons (skipped exon), tandem cassettes (exon duplication), mutually exclusive 
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exons (mutually exclusive inclusion of one of two alternative exons), alternative 5’ splice 
site selection, alternative 3’ splice site selection, and intron retention (Wu et al., 2013).  
Cassette exons were by far the most frequently observed event in our RNA-seq data, 
constituting 58.6% of detected events, followed by tandem cassettes (13.9%), intron 
retention (13.0%), alternative 3’ or 5’ splice site selection (8.6%), and mutually exclusive 
exons (4.9%).  
 We first analyzed the list of alternatively spliced mRNA transcripts using the 
DAVID bioinformatics tool in order to describe the biological functions of alternatively 
spliced genes, and to gain insight into the cellular functions affected by abnormal splicing 
in tauopathies.  GO biological process annotations related to neurotransmission and 
synaptic function were strongly enriched in the gene list of alternatively spliced 
transcripts (Fig. 39).  The top 10 most significant GO terms included synapse (FDR = 
4.55e-12), presynaptic membrane (FDR = 3.84e-9), postsynaptic density (FDR = 5.61e-
8), and dendrite (FDR = 3.29e-6) (Appendix V).  These data suggest that aberrant 
splicing induced by tauopathy primarily affects proteins involved in neurotransmission 
and synaptic structure/function.    
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Figure 39: mRNA transcripts encoding synaptic proteins are alternatively spliced in PS19 
mice 
Gene ontology (GO) Biological Process annotation terms significantly enriched (top 10, False Discovery 
Ratio [FDR] < 0.05) in genes alternatively spliced (FDR < 0.05) in PS19 (P301S TIA1+/+) compared to 
non-transgenic (WT Tau TIA1+/+) cortex.  
 
 We next investigated the specific splice isoforms and exons most significantly 
affected in PS19 mice.  Table 2 summarizes the top 20 most significant alternative 
splicing events detected in PS19 compared to non-transgenic cortex.  Notably, 10 of these 
20 transcripts encode proteins with known roles at the synapse (Table 2).  Further, several 
of the affected exons have known functional effects on the resulting protein isoforms.  
For example, Gria2 encodes the GluR2 subunit of the α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptor, which is the primary ionotropic 
transmembrane glutamate receptor present at postsynaptic dendritic spines that mediates 
fast synaptic transmission in the brain (Kittler & Moss, 2006).  AMPA receptors are 
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heterotetrameric complexes consisting of 2 dimers of GluR1, GluR2, GluR3, or GluR4 
(Kittler & Moss, 2006).  Notably, AMPA receptors containing GluR2 subunits are 
impermeable to calcium ions, which distinguish them from other glutamate receptor 
types, such as GluR2-lacking AMPA receptors and NMDA receptors (Bassani, Valnegri, 
Beretta, & Passafaro, 2009; Isaac, Ashby, & McBain, 2007; Wollmuth & Sobolevsky, 
2004).  Importantly, alternative splicing of the GluR2 subunit determines the 
desensitization kinetics of the receptor (Koike, Tsukada, Tsuzuki, Kijima, & Ozawa, 
2000; Pei et al., 2009).  GluR2 undergoes mutually exclusive alternative splicing to 
contain either exon 14 (“Flip” isoform) or exon 15 (“Flop” isoform).  While Flop-
containing AMPA receptors desensitize rapidly after opening of the channel in response 
to glutamate, Flip-containing receptors desensitize more slowly, rendering the cell more 
susceptible to excitotoxicity (Koike et al., 2000; Pei et al., 2009).  Interestingly, while 
GluR1 and GluR3 are subject to the same mutually exclusive alternative splicing of 
exons 14 and 15 as GluR2, the channel opening and closing kinetics are identical for both 
the Flip and Flop isoforms (Pei et al., 2009).  Thus, the correct ratio of exons 14 and 15 
specifically in GluR2 transcripts is not only required for the maintenance of proper fast 
excitatory synaptic transmission, but is also disproportionately critical for guarding 
against excitotoxic cell stress (Fig. 40).   
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Table 2: Top 20 genes alternatively spliced in PS19 cortex 
List of the top 20 most significant (FDR < 0.05) alternative splicing events in PS19 (P301S TIA1+/+) 
compared to non-transgenic (WT Tau TIA1+/+) cortex. Note that some genes appear on the list multiple 
times because a change in mutually exclusive exons will also be recorded as a significant cassette (exon 
skipping) event, etc. Please refer to Appendix V for complete list of alternative splicing results.  
 
 Our RNA-seq data show that the ratio of exon 14 to exon 15 inclusion in Gria2 is 
elevated almost 2-fold in PS19 compared to non-transgenic cortex (Table 2; Appendix 
VI), producing an increase in Flip GluR2-containing AMPA receptors.  This finding 
suggests a mechanism for the excitotoxic neuron death characteristic of human 
tauopathies, and perhaps explains why pharmacological agents that inhibit excessive 
glutamatergic neurotransmission, such as memantine, confer moderate symptomatic 
efficacy in patients with Alzheimer’s disease (Lipton, 2005).  Our RNA-seq data also 
identify Snap25 and Camk2b as critical synaptic transcripts that are alternatively spliced 
in PS19 cortex (Table 2; Appendix VI).  Snap25 (Synaptosomal-associated protein 25) is 
a t-SNARE protein that regulates vesicle docking and membrane fusion at pre-synaptic 
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terminals, facilitating neurotransmitter release (Ya Wang & Tang, 2009).  Splicing of 
Snap25 controls the membrane fusion properties of alternative splice isoforms.  For 
example, exon 5 versus 6 inclusion is developmentally regulated in the brain for Snap25, 
and deficits in this regulation have been reported to impair synaptic plasticity (G Nagy et 
al., 2005; Gábor Nagy et al., 2004; Sørensen et al., 2003).  Camk2b is a 
calcium/calmodulin-dependent serine/threonine kinase that functions as a molecular 
switch in post-synaptic dendritic spines to phosphorylate heterotetrameric GluR1/GluR2-
containing AMPA receptors, targeting them for membrane insertion in response to 
synaptic activity (Kittler & Moss, 2006).  Thus, Camk2b activity in conjunction with 
AMPA receptor trafficking is known to regulate long term potentiation (LTP), which is 
commonly thought to be the cellular mechanism underlying memory (Bliss & 
Collingridge, 1993).  Taken together, the high prevalence in PS19 mice of dysfunctional 
RNA splicing in transcripts encoding proteins involved in glutamatergic synaptic 
transmission strongly implicates dysregulation of this system as a key contributor to 
memory deficits in tauopathies.   
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Figure 40: Alternative splicing of AMPA receptor subunits determines glutamatergic 
desensitization kinetics 
Schematic of GluR2 receptor domain structure. GluR2 is a transmembrane receptor with four 
transmembrane domains (red, I-IV). Alternative splicing of exon 14 and 15 in the extracellular domain 
(Flip/Flop domain, yellow) determines desensitization kinetics in response to glutamate, which binds in the 
ligand binding domain (box inset). Exon 15 containing GluR2 transcripts (Flop variant) produce receptors 
with an energetically unfavorable conformation in the open (glutamate bound) state, which causes the 
receptor to rapidly desensitize to glutamate. That is, the receptor undergoes a conformational change that 
closes the cation pore in order to reestablish an energetically favorable conformation. Exon 14 containing 
GluR2 receptors (Flip variant) are also unstable in their open conformation, but are less so compared to 
Flop variants, causing them to desensitize at a slower rate. As a result, Flip GluR2 isoforms prolong the 
intracellular influx of cations following glutamate binding, leading to a greater depolarization of the post-
synaptic cell relative to Flop isoforms. The relative ratio of Flip versus Flop GluR2 isoforms is critical to 
ensuring the proper balance between inhibitory and excitatory neurotransmission.   
 
TIA1 reduction rescues dysfunctional synaptic splicing in PS19 mice 
 Our transcriptomic analysis of alternative splicing in PS19 mice suggested 
significant dysregulation in excitatory neurotransmission.  However, whether TIA1 
reduction rescues these splicing alterations is unknown.  We therefore compared the 
relative levels of alternative splice isoforms of synaptic mRNA transcripts in P301S 
TIA1+/- mice with those in P301S TIA1+/+ mice.  GO analysis of alternatively spliced 
transcripts in P301S TIA1+/- compared to P301S TIA1+/+ cortex revealed that the top 3 
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most significant annotation terms are synapse (FDR = 6.22e-13), postsynaptic density 
(FDR = 4.03e-12), and presynaptic membrane (FDR = 1.09e-10) (Appendix VII).  This 
result suggests that TIA1 reduction either returns transgenic tau-induced changes in 
mRNA splicing to baseline or produces a further dysregulation of alternatively spliced 
synaptic transcripts.  We therefore examined the inclusion indices for all cassette exon 
splicing events detected between all 4 genotypes to determine whether TIA1 reduction in 
PS19 mice increased (exacerbation effect) or decreased (rescue effect) the change in exon 
inclusion relative to non-transgenic mice.  Surprisingly, TIA1 reduction decreased the 
transgenic tau-induced change in exon inclusion index in 198 out of 284 (69.7%) total 
cassette exons, indicating an overwhelming net “rescue” effect (Appendix VI).  Figure 41 
summarizes the effect of TIA1 reduction on exon inclusion in non-transgenic and PS19 
mice in a hierarchically clustered heatmap.  Normalization of wildtype exon inclusion 
levels were especially prominent for transcripts encoding proteins with GO annotations 
related to nervous system development and synaptic transmission (Fig. 41).  Interestingly, 
in many cases, TIA1 reduction in non-transgenic mice (WT Tau TIA1+/-) altered exon 
inclusion similarly to transgenic tau in P301S TIA1+/+ mice (Fig. 41), suggesting that 
loss of TIA1 function induces splicing alterations reminiscent of tauopathy.  This result 
also suggests an interaction between the TIA1 and tau genotypes, with TIA1 reduction 
producing different effects in the non-transgenic compared to tauopathy animals.   
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Figure 41: TIA1 reduction normalizes splicing of cassette exons in PS19 mice 
Inclusion indices for statistically significant (FDR < 0.1) cassette exon alternative splicing (AS) events 
detected in the RNA-seq data were calculated by dividing the number of reads including a given exon 
where an inclusion/skip occurs by the total number of reads for that transcript. Z-transformed inclusion 
indices were then plotted in a heatmap to visualize changes in exon inclusion between genotypes. Genes 
were hierarchically clustered according to gene ontology (GO) terms (box inset). Note that TIA1 reduction 
in PS19 mice (P301S Tau TIA1+/-, green) returns the majority of transgenic tau-induced changes in PS19 
mice (P301S Tau TIA1+/+, red) towards non-transgenic (WT Tau TIA1+/+) levels, particularly in the 
nervous system development (light green), presynaptic process (dark red), and synaptic signaling (orange) 
GO clusters. [Fig. 41 provided by C Zhang] 
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We next investigated whether TIA1 reduction corrected the splicing alterations in 
the specific excitatory synaptic transcripts most significantly changed in PS19 compared 
to non-transgenic cortex (Table 2), including Gria2, Snap25, and Camk2b.  We designed 
primer pairs that spanned exon junctions of transcripts including/excluding the affected 
exons, as well as primers to amplify total transcript levels (spanning constitutive exons) 
for normalization of each splice isoform (Fig. 42).  RT-PCR analysis confirmed that the 
ratios of exon inclusion were statistically different in PS19 compared to non-transgenic 
cortex for all three transcripts (Fig. 42A-C).  More importantly, TIA1 reduction restored 
the ratio of exon inclusion versus exclusion to the levels detected in non-transgenic (WT 
Tau TIA1+/+) mice (Fig. 42A-C).  For example, the ratio of exon 14 (Flip)-containing 
Gria2 transcripts was significantly elevated in P301S TIA1+/+ mice, but not different 
from wildtype levels in P301S TIA1+/- mice (Fig. 42A).  For Snap25, the relative ratio of 
exon 5- to exon 6-containing transcripts was reduced in P301S TIA1+/+ mice, while 
P301S TIA1+/- mice were not significantly different from non-transgenic mice (Fig. 
42B).  Finally, skipping of exon 13 in Camk2b transcripts was decreased in P301S 
TIA1+/+ mice, which was then reversed in P301S TIA1+/- mice (Fig. 42C).  
Interestingly, while TIA1 reduction had no effect in non-transgenic (WT Tau) mice for 
all 3 transcripts, TIA1 reduction over-corrected the rate of exon 13 inclusion in PS19 
mice for Camk2b (Fig. 42C).  These results confirm that the alternative splicing events 
detected in our RNA-seq data represent true mRNA splicing deficits intrinsic to 
tauopathy in PS19 mice.  More importantly, the aberrant mRNA splicing of excitatory 
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synaptic transcripts induced by transgenic tau overexpression was corrected by TIA1 
reduction.   
 
Figure 42: TIA1 reduction rescues P301S tau-induced alternative splicing in PS19 cortex 
A-C. Relative exon inclusion for statistically significant (FDR < 0.05) alternative splicing events in PS19 
(P301S TIA1+/+) compared to non-transgenic (WT Tau TIA1+/+) cortex was confirmed for Gria2 (A), 
Snap25 (B), and Camk2b (C) by RT-PCR. Left panels depict exon structure and forward (F) and reverse 
(R) primer design for each transcript. Ratios of exon inclusion were quantified by calculating the relative 
expression of each splice isoform compared to a housekeeping transcript (∆Ct Gapdh), normalizing each 
splice isoform to the total transcript level for each gene, and dividing the relative expression of isoform 1 to 
isoform 2. All ratios were then normalized to WT Tau TIA1+/+ ratio = 1; thus, the quantification in the 
graphs to the right represent relative (and not absolute) changes in the ratio of splice isoforms. *p<0.05 
**p<0.01 ***p<0.001 by 2-Way ANOVA with Tukey’s post-hoc comparisons. Error bars denote means ± 
SEM (n=6 mice/group; 3 males and 3 females per genotype).  
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TIA1 reduction restores functional interaction of tau with the cytoskeleton 
 Our transcriptomic studies revealed a surprising role for TIA1 in mediating 
dysfunctional RNA splicing of synaptic transcripts in tauopathy, with TIA1 reduction 
rescuing many of the transgenic tau-induced alternative splicing events.  We next sought 
to determine how TIA1 reduction affected tau interactions on the protein level.  Thus, we 
immunprecipitated tau from cortex tissue of 6 month old non-transgenic, P301S 
TIA1+/+, and P301S TIA1+/- mice to understand how the proteins that bind tau (i.e. the 
tau ‘interactome’) evolve during disease.  Mapt-/- cortex was used as a negative control 
to identify non-specific binding proteins to our total tau antibodies (Tau5 and Tau13).  
Immunoprecipitations (IPs) were performed in biological triplicate, and the co-
immunoprecipitating proteins were analyzed by OrbiTrap liquid chromatography tandem 
mass spectrometry (LC-MS/MS), as described previously (Vanderweyde et al., 2016).   
 Tau IPs from non-transgenic cortex identified proteins consistent with the known 
functional roles of tau (Appendix VIII).  Tau-binding proteins included cytoskeletal 
proteins such as multiple tubulin (TUBB3, A4, B2, B5, B4, A8, B6) and F-actin 
(ACTN1, 2, 4) subunits, kinases (CSNK2 A1, A2, B, CAMKK1, MAPK10, STK32C, 
PRKCD), and phosphatases (PPP6C, PTPN11, DUSP3).  We also identified various 
synaptic proteins (GRIA1, PSD3, SYT7, SLC17A6, SLC30A3), ribosomal subunits 
(RPL11, 13A, 22, 23A, 27, 38 and RPS7, 15), and RBPs (DDX17, SNRPA, B, D3, E, 
FUS, FMR1, and hnRNP U, Q) (Appendix VIII).  Bioinformatic analysis confirmed that 
the normal tau interactome was enriched for proteins encompassed by the annotation 
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terms ribonucleoprotein (FDR = 3.54e-11), cytoskeleton (FDR = 1.34e-5), and 
microtubule (FDR = 3.57e-4) (Appendix VIII).   
 Tau IPs from 6 month P301S TIA1+/+ cortex identified a tau interactome that 
was largely distinct from the tau-binding proteome in non-transgenic mice.  Proteins 
binding tau in 6 month P301S TIA1+/+ cortex were enriched for various annotation terms 
not detected in the normal tau interactome, including mitochondrion (FDR = 5.48e-9), 
hydrolase (FDR = 1.763-6), and oxidoreductase (FDR = 5.94e-4); annotations related to 
the cytoskeleton were still enriched, but were not one of the top 5 most significant 
annotation terms (Appendix IX).  Further, many of the most predominant binding 
proteins in the non-transgenic cortex were completely lost in P301S TA1+/+ mice, 
including TUBB3, TUBA4, and TUBB2 (Appendices VIII & IX).  This result suggests 
that a significant component of tau dysfunction in PS19 mice arises from the loss of 
functional tau interaction with the cytoskeleton.   
We next investigated how TIA1 reduction affected the tau interactome in PS19 
mice.  Bioinformatic analysis using DAVID revealed that proteins increasing their 
association with tau in P301S TIA1+/- compared to P301S TIA1+/+ cortex were enriched 
for functional annotation terms related to the actin and microtubule cytoskeleton, 
including cytoskeleton (FDR = 1.21e-6) and actin-binding (FDR = 2.08e-5) (Fig. 43; 
Appendix X); interaction of tau with synaptic proteins was also enhanced.  To confirm 
this finding, we performed an in vivo microtubule binding assay to validate that TIA1 
reduction in PS19 mice increases the association of tau with the microtubule system.  
P301S TIA1+/+ and P301S TIA1+/- cortex tissues were homogenized in RAB buffer, 
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and ultracentrifuged to separate the microtubule (MT)-bound (pellet, P) and MT-unbound 
(supernatant, S) fractions, as described previously (Yoshiyama et al., 2007).  Immunoblot 
of the MT-bound and MT-unbound fractions confirmed a decrease in tau levels detected 
in the supernatant (MT-unbound) fraction with a corresponding increase in tau levels 
detected in the pellet (MT-bound) fraction (Fig. 44A-B), which is consistent with our 
previous MT-binding data in PS19 mice (Apicco et a. 2017).  These results suggest that 
reducing TIA1 not only decreases cytoplasmic SGs, but rescues tau localization and 
binding to the microtubule system.   
 
Figure 43: TIA1 reduction in PS19 mice enhances the interaction of tau with the 
cytoskeleton 
Keyword functional annotation terms significantly enriched (FDR < 0.05) in the list of proteins increasing 
their association (>5-fold) in 6 month P301S TIA1+/- compared to P301S TIA1+/+ cortex.   
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Figure 44: TIA1 reduction enhancing the interaction of tau with microtubules in PS19 mice 
A. Immunoblot of microtubule (MT)-bound (pellet, P) and MT-unbound (supernatant, S) tau (Tau13) in 6 
month MT fractionated P301S TIA1+/+ and P301S TIA1+/- brain homogenates. α-tubulin (bottom panel) 
was also immunoblotted to confirm successful fractionation of MTs in the pellet (P) fraction. B. 
Quantification of the ratio of MT-bound (P) to MT-unbound (S) tau in A. *p<0.05 by unpaired Student’s t-
test (n=4/group). 
 
We next constructed volcano plots of tau-binding proteins in P301S TIA1+/+ and 
P301S TIA1+/- cortex to understand how TIA1 reduction impacts specific tau-interacting 
proteins (Fig. 45).  Notably, TIA1 reduction strongly decreased the association of tau 
with various proteins that are genetically linked to Parkinson’s disease (i.e. PARK7, 
UCHL1).  In contrast, the individual proteins most significantly increasing their 
association with tau in P301S TIA1+/- compared to P301S TIA1+/+ cortex included 
proteins involved in axon stability/guidance (SLIT2) and synaptic structure (HOMER2) 
(Fig. 45).  Although the functional significance of these interactions are at this time 
unknown, it is likely that the reduced binding of tau to proteasomal proteins such as 
PARK7 and UCHL1 leads to alterations in the degradation and catabolism of tau.   
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Figure 45: Reducing TIA1 modulates the tau interactome in PS19 cortex 
Volcano plot showing proteins detected to co-immunoprecipitate with tau in 6 month PS19 cortex tissue, as 
detected by LC-MS/MS analysis. The iBAQ quantitative values for peptide spectra were normalized to the 
tau level detected in each sample. P values (y axis) were then plotted against the log2-transformed fold 
change (x axis) in the level of each protein detected to associate with tau in P301S TIA1+/- versus P301S 
TIA1+/+ cortex. Proteins with statistically significant changes (p < 0.05) in their interaction with tau are 
shown in blue. [Fig. 45 provided by C Zheng]   
 
Tau associates with RNA binding proteins in human Alzheimer’s disease brain 
 Our transcriptomic and proteomic studies in PS19 mice suggest a striking role for 
RBPs in tau-mediated neurodegeneration.  However, whether tau interacts with RBPs in 
human tauopathies is unknown.  Thus, we immunoprecipitated tau from healthy control 
and AD brain tissue (n=3/group) in order to analyze the tau-binding proteomes in human 
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tauopathy patients.  Bioinformatic analysis of the AD tau interactome revealed that tau-
binding proteins in disease were enriched for various annotation terms related to RNA 
metabolism, including poly(A) RNA binding (FDR = 8.74e-67) and RNA binding (FDR 
= 1.36e-23) (Appendix XI).  This result is consistent with studies in cell lines that have 
shown that disease-linked mutations in human tau enhance binding to ribonucleoproteins 
(Gunawardana et al., 2015).  Further, proteins increasing their association with tau in AD 
compared to control brain tissue were encompassed by only three significant GO 
annotation terms, including poly(A) RNA binding (FDR = 3.32e-7) and RNA binding 
(FDR = 2.65e-3) (Fig. 46).  Appendix XII summarizes the complete list of RBPs (128 in 
total) detected to associate with tau in human AD brain tissue.  We next investigated 
whether any of these tau-interacting RBPs co-deposited with insoluble tau in vivo.  
Biochemical fractionation studies of control and rTg4510 (mouse model of tauopathy) 
forebrain revealed that EWSR1, TAF15, HNRNP R/Q, and RPL7 all accumulated in the 
sarkosyl-insoluble fraction of rTg4510, but not control, tissues (Fig. 47).  These data 
suggest that RBPs strongly interact with tau in the AD brain, and reveal aggregation of 
RBPs as a novel component of disease pathology.   
  
133 
 
Figure 46: GO terms upregulated in the human AD tau interactome 
Gene ontology (GO) molecular function annotation terms significantly enriched (FDR < 0.05) in the list of 
proteins increasing their association with tau (>2-fold) in Alzheimer’s disease (AD) compared to healthy 
control cortex (n=3/group), as detected by LC-MS/MS analysis of proteins co-immunoprecipitating with 
tau.  
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Figure 47: RNA binding proteins accumulate in the sarkosyl-insoluble fraction of rTg4510 
cortex 
A. Immunoblot of various RNA binding proteins (EWS, TAF15, RPL7, hnRNP R/Q) in the 1% sarkosyl-
soluble (S3) fraction of non-transgenic (WT) and rTg4510 (TG) forebrain. B. Quantification of A. C. 
Immunoblot of EWS, TAF15, RPL7, hnRNP R/Q, and TAOK1 in the 1% sarkosyl-insoluble (P3) fraction 
of WT and TG forebrain. TAOK1 is a kinase that regulates microtubule stability via activation of MARK 
and subsequent phosphorylation of tau. D. Quantification of C. #p<0.10 *p<0.05 **p<0.01 ***p<0.001 by 
unpaired Student’s t-test.  
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Discussion 
 Abnormal aggregation of microtubule associated protein tau has long been 
considered to be the defining pathological hallmark of tauopathies such as AD.  
However, the cellular mechanisms that govern tau aggregation in disease remain largely 
unknown.  Recently, our lab demonstrated an essential role for the RBP TIA1 in the 
progression of tauopathy in vivo, with heterozygous reduction in TIA1 shifting the 
structural and biochemical properties of tau aggregates (Apicco et al. 2017).  Reducing 
TIA1 in PS19 transgenic tau mice decreased levels of soluble tau oligomers, while 
increasing levels of insoluble tau fibrils (Apicco et al. 2017).  Importantly, these changes 
in tau aggregation were associated with pronounced neuroprotection, improved memory, 
and increased lifespan.  These findings add to the growing body of literature 
demonstrating that NFTs alone are not sufficient to cause neurodegeneration (K., S., T., 
B., & B., 2013; Kuchibhotla et al., 2014; Rocher et al., 2010; Santacruz et al., 2005).   
 Recent studies link neurodegenerative disease processes to dysfunction of RBPs 
and RNA metabolism.  Several RBPs, including TDP-43 and FUS, represent the primary 
aggregating protein in neurodegenerative diseases, including ALS.  Further, RBPs 
associated with SGs have been reported to co-localize with disease pathology in ALS, 
FTD, AD, Spinocerebellar ataxias, and myopathies (Bentmann et al., 2013; Y. R. Li et 
al., 2013; Wolozin, 2012), which suggests dysfunction of RBPs as a common pathogenic 
feature of neurodegenerative diseases.  This idea is supported by the recent discovery that 
mutations in various RBPs cause autosomal dominant ALS, FTD, and myopathies 
(Couthouis et al., 2012; Hackman et al., 2013; King et al., 2012; Kwiatkowski et al., 
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2009; Neumann et al., 2006).  In the case of TDP-43, disease-linked mutations occur 
overwhelmingly in the LC domain, which increases the propensity of the protein to 
aggregate (Johnson et al., 2009).  In contrast, disease-linked mutations in FUS occur both 
in the LC domain and in the nuclear localization domain, which could confer either a 
gain-of-function (increased aggregation in the cytoplasm) or loss-of-function (impaired 
nuclear function) toxicity in the context of disease (Kwiatkowski et al., 2009).  In vitro 
studies highlight the importance of LC domains for mediating the reversible phase 
transition between soluble, liquid droplet, and amyloid-like states, with disease-linked 
mutations accelerating the formation of irreversible, amyloid-like fibrils (Lin et al., 2015; 
Molliex et al., 2015; Nott et al., 2015).  Nonetheless, the exact contributions of insoluble 
aggregates and abnormal cytoplasmic translocation of RBPs in neurodegenerative disease 
is unknown.     
 Our previous studies showed that PS19 mice heterozygous for Tia1 (P301S 
TIA1+/-) developed significantly less cytoplasmic SGs compared to P301S TIA1+/+ 
mice, and exhibited increased nuclear localization of RBPs, including TIA1 (Apicco et al. 
2017).  Further, P301S TIA1+/- mice exhibited reduced co-aggregation of RBPs with tau 
oligomers.  These findings raised the possibility that disaggregation of SGs by TIA1 
reduction might also rescue dysfunctional mRNA processing induced by tauopathy.  Our 
RNA-seq results confirmed that P301S TIA1+/+ mice exhibited a pronounced 
dysregulation of RBP functions in the brain, which manifested in widespread splicing 
abnormalities that predominantly affected synaptic proteins.  These findings corroborate 
with other studies that have reported alternative splicing of transcripts important for 
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neurotransmission and synaptic function in mouse models and human tauopathy patients 
(James D. Mills et al., 2013; James Dominic Mills & Janitz, 2012; Twine, Janitz, 
Wilkins, & Janitz, 2011).  Importantly, our results highlight glutamatergic excitatory 
neurotransmission as a particularly critical system underlying synaptic dysfunction in 
PS19 mice. 
 Alternative splicing analysis of our RNA-seq data combined with RT-PCR 
validation in independent samples confirmed that TIA1 reduction protected against many 
of the splicing alterations induced by P301S transgenic tau.  TIA1 reduction decreased 
the transgenic tau-induced changes in nearly 70% of all cassette exon alternative splicing 
events (Fig. 41, Appendix X), indicating an overwhelming net “rescue” effect.  We 
validated this finding for 3 of the top 10 most significant alternatively spliced transcripts 
in the P301S TIA1+/+ compared to non-transgenic (WT Tau TIA1+/+) samples—Gria2, 
Snap25, and Camk2b.  While the relative inclusion ratio for each of the affected exons 
was significantly different in the P301S TIA1+/+ cortex, P301S TIA1+/- mice exhibited 
no difference from non-transgenic mice for either Gria2 or Snap25 (Fig. 42A-C).  In the 
case of Camk2b, TIA1 reduction led to an over-correction of alternative splicing, further 
enhancing exon 13 exclusion in P301S TIA1+/- compared to control cortex (Fig. 42C).  
Together, these results suggest that normalization of alternative splicing is a critical 
contributor to the underlying neuroprotective mechanism in P301S TIA1+/- mice.   
 Our RNA-seq results highlight Gria2 as a particularly critical transcript that is 
dysregulated in tauopathies.  Gria2 encodes GluR2, one of 4 subunits (GluR1-4) that 
comprise AMPA glutamate receptors, which mediate the vast majority of fast excitatory 
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synaptic transmission in the brain (Kittler & Moss, 2006).  Inclusion of GluR2 in AMPA 
receptors makes them impermeable to calcium, which guards against excessively 
depolarizing post-synaptic currents.  Thus, GluR2 is especially critical for maintaining 
the proper balance between excitatory and inhibitory neurotransmission in the brain.  Our 
RNA-seq data indicate that mutually exclusive splicing of exons 14 and 15 in Gria2 is 
significantly altered in P301S TIA1+/+ cortex.  Inclusion of exon 14 or 15 of Gria2 
determines the desensitization kinetics of GluR2-containing AMPA receptors, which 
make up the vast majority of all AMPA receptors in the adult brain (Tanaka, Grooms, 
Bennett, & Zukin, 2000).  Inclusion of exon 15 (“Flop” isoform) encodes a receptor that 
rapidly desensitizes, causing the channel pore to close on the order of 1.18 ± 0.05 msec 
following extracellular treatment with 1 mM glutamate (Koike et al., 2000).  In contrast, 
inclusion of exon 14 (“Flip” isoform) encodes a receptor which desensitizes more slowly 
(5.89 ± 0.17 msec), producing larger depolarizing post-synaptic potentials (Koike et al., 
2000).  Flip GluR2-containg receptors have important developmental roles in neuronal 
differentiation and synaptogenesis (Tanaka et al., 2000).  The Flip isoform is exclusively 
expressed until postnatal day 8, while Flop Gria2 mRNA gradually becomes the 
predominant isoform by day 14, which persists in the adult brain (Monyer, Seeburg, & 
Wisden, 1991).  This is consistent with our RNA-seq results, which indicated a 2 to 1 
ratio in the expression level of Flop to Flip Gria2 (Appendix X).  Importantly, this ratio 
was reduced in P301S TIA1+/+ mice, suggesting that aberrant inclusion of exon 14 in 
Gria2 might underlie the selective vulnerability of cortical neurons in this mouse model.  
This is consistent with prior studies that have shown that overexpression of transgenic 
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Flip GluR2 in mice enhances neuronal susceptibility to epileptic or ischemic stress (Le et 
al., 1997).  This finding may also explain the increased incidence of seizures in patients 
with AD (Minkeviciene et al., 2009).   Importantly, TIA1 reduction in PS19 mice 
restored the correct ratio of Flip to Flop Gria2 isoforms (Fig. 41; Fig. 42A).  In contrast, 
TIA1 reduction had no effect in non-transgenic mice (WT Tau TIA1+/- compared to WT 
Tau TIA1+/+), suggesting that the decreased ratio of Flip to Flop Grai2 transcripts was 
not a direct effect of TIA1 expression level, but rather, reflected an indirect consequence 
of the biology of the disease.  Thus, we propose that the vast majority of dysfunctional 
RNA splicing events in tauopathy arise from the abnormal sequestration of RBPs and 
spliceosomal proteins in cytoplasmic SGs.  However, the exact contribution of tau and 
SGs, as well as other putative changes that occur in concert with disease, remains to be 
precisely determined.    
 Our RNA-seq results indicate that TIA1 reduction normalizes the transcriptome of 
PS19 mice.  This ‘normalizing’ effect of TIA1 reduction was also evident when we 
compared the tau-binding proteomes in non-transgenic, P301S TIA1+/+, and P301S 
TIA1+/- cortex.  As expected, the normal (non-transgenic) tau interactome was enriched 
for annotation terms related to tubulin-binding and the cytoskeleton (Fig. 44), and 9 of 
the top 10 most abundant tau-binding proteins detected by mass spectrometry were 
tubulin subunits (Appendix X).  The intimate interaction of tau with microtubules was 
strikingly reduced in 6 month P301S TIA1+/+ mice, with expression of P301S tau 
abrogating binding of tau to all 10 of the most abundant binding proteins in non-
transgenic brain, including the alpha- and beta-tubulin subunits (Appendix X).  
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Importantly, reducing TIA1 enhanced the interaction of tau with the cytoskeletal 
machinery, which was evident by bioinformatic analyses of the proteins increasing their 
binding to tau (>5-fold) in P301S TIA1+/- compared to P301S TIA1+/+ cortex, as well 
as by directly immunoblotting for tau protein in microtubule-bound and unbound 
fractions (Fig. 44A-B).  Our previous findings suggest a possible mechanism for the 
increased binding of tau to microtubules in P301S TIA1+/- mice.  We demonstrated that 
TIA1 reduction decreases the accumulation of soluble, misfolded tau oligomers 
(Vanderweyde et al., 2016; Apicco et al. 2017).  Previous groups have shown that 
pathologically misfolded tau conformations impair fast axonal transport by inhibiting tau 
binding to microtubules (Combs et al., 2016; Kanaan et al., 2012).  Thus, TIA1 reduction 
could enhance tau binding to microtubules by directly affecting the conformation of tau.  
Alternatively, the increased binding of tau to microtubules might be an indirect 
consequence of transcriptional changes induced by TIA1 reduction.  In this light, it is 
notable that knockdown of TIA1 in HeLa cells has been reported to upregulate pathways 
involved in cytoskeletal remodeling, including increasing beta-actin mRNA expression 
(Carrascoso, Sánchez-Jiménez, & Izquierdo, 2014).  However, the relevance of this 
phenomenon to non-differentiating neurons in the central nervous system is unknown.   
 The overwhelming majority of AD research over the last three decades has been 
predicated on the amyloid cascade hypothesis.  This hypothesis predicts that the inception 
and progression of disease follows a largely linear sequence of events that begins with 
abnormal processing of the amyloid precursor protein (APP) and culminates in 
intraneuronal accumulation of NFTs, which induce cell death (J. A. Hardy & Higgins, 
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1992; Karran et al., 2011; Tanzi & Bertram, 2005).  While the causative role of mutations 
affecting β-amyloid production in familial cases of AD is incontrovertible, a variety of 
recent findings challenge both the linearity of disease progression and the ultimate cause 
of neuronal demise.  For example, the spatiotemporal pattern and severity of 
neurodegeneration are largely unrelated to amyloid plaques (Braak & Braak, 1991), and 
β-amyloid-induced toxicity requires tau (Roberson et al., 2007).  Mounting evidence also 
indicates that soluble tau oligomers exert a greater influence on neurodegeneration than 
insoluble NFTs, the defining pathological hallmark of disease (Berger et al., 2007; K. et 
al., 2013; Rocher et al., 2010; Santacruz et al., 2005).  Further, at least 18 different strains 
of tau species have been purified from AD brain tissue, each with unique biological 
activity when injected into transgenic mice (Kaufman et al., 2016; Sanders et al., 2014).  
Inflammatory processes, especially microgliosis, are also elevated in the AD brain, 
although whether inflammation is a cause or consequence of disease pathology remains a 
topic of fervent debate (Chen et al., 2016; González, Elgueta, Montoya, & Pacheco, 
2014; Hong et al., 2016).  Thus, the sheer number of potential mechanisms proposed to 
play a role in β-amyloid- and tau-mediated neurodegeneration underscores the molecular 
complexity of AD, and highlights the inherent challenges prohibiting the discovery of 
new therapeutics.   
Our lab has discovered that RBPs and SGs progressively associate with tau in AD 
(Vanderweyde et al., 2012), which appears to unify the many seemingly disparate aspects 
of disease pathology.  For example, SGs are regulated by various stress-sensitive eIF2α 
kinases, including protein kinase R (PKR) and PKR-like endoplasmic reticulum kinase 
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(PERK), whose activation is elevated in the AD brain (Bell et al., 2016; Lourenco et al., 
2013; Ohno, 2014).  β-amyloid oligomers have been shown to increase eIF2α 
phosphorylation in cultured neurons, which leads to translational arrest, SG formation, 
and non-ATG dependent upregulation of stress response genes, including Bace1 (Devi & 
Ohno, 2014).  β-amyloid oligomers also activate intracellular tau kinases, such as Fyn, 
that lead to hyper-phosphorylation and mis-sorting of tau to the soma and dendrites 
(Haass & Mandelkow, 2010; Ittner et al., 2010).  Our lab has shown that mis-sorted tau 
functions to facilitate SG formation (Vanderweyde et al., 2016).  Although SGs are 
transient under normal physiological conditions, somatodendritic SGs containing hyper-
phosphorylated and misfolded tau are abnormally stable and insoluble (which we have 
termed ‘pathological SGs’) (Vanderweyde et al., 2016).  The stability of SG aggregates 
might be further exacerbated by the chronic stress of disease.  Studies in primary neurons 
from our group and others demonstrate that pathological SGs are particularly toxic to 
neurons (Brunello et al., 2016; Vanderweyde et al., 2016).  This is underlined by our 
studies in PS19 transgenic tau mice, which demonstrate an essential role for SGs in the 
progression of tau-mediated neurodegeneration in vivo.  SG proteins, including RBPs 
important for RNA splicing, co-aggregate with tau oligomers in the cytoplasm, which is 
reduced by heterozygous knockout of TIA1.  The results in the present study now show 
that the reduction in SG aggregates in P301S TIA1+/- mice is associated with a 
corresponding restoration of RBP functions in the nucleus, including proper splicing of 
synaptic mRNAs.  We therefore propose a new model of tau pathophysiology whereby 
the interaction of tau with RBPs in SGs is a potent driver of neurotoxicity in AD.  More 
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importantly, our results highlight modulation of SG formation as a promising therapeutic 
avenue for the treatment of a range of neurodegenerative diseases, including tauopathies.  
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CHAPTER FOUR 
RNA binding protein aggregation is a novel therapeutic target in tauopathies 
 
Summary of Results 
 An accumulating body of evidence links neurodegenerative disease processes to 
dysfunction of RNA binding proteins (RBPs).  Previous work from our laboratory has 
demonstrated that various RBPs, particularly those associated with stress granules (SGs), 
progressively aggregate in the brains of human patients and animal models of 
tauopathies.  These RBP aggregates also co-localize with phosphorylated tau inclusions, 
one of the major pathological hallmarks of disease.  We have now demonstrated a 
functional role for tau in mediating SG formation in primary cultured neurons.  Tau 
regulates: 1) the subcellular localization of SG proteins (such as TIA1), 2) the number 
and size of SGs that form in response to exogenous stress (i.e. sodium arsenite, 
salubrinal, puromycin), 3) the movements and stability of TIA1 granules in dendrites, and 
4) the protein composition of RNA granules in vivo.  More importantly, the interaction of 
tau with SGs promotes tau pathophysiology and toxicity in primary cultured neurons.  
Reducing TIA1 expression by either genetic knockout or shRNA mediated knockdown of 
endogenous TIA1 decreases tau granules, tau misfolding, and tau-induced 
neurodegeneration.  In contrast, co-overexpression of TIA1 with tau promotes the 
formation of misfolded tau granules in neuronal dendrites, producing a synergistic 
increase in toxicity.  Further, the neurotoxicity of tau granules can be modulated by 
pharmacological treatments that increase (puromycin, salubrinal) or decrease 
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(cycloheximide, inhibitors of PERK, PKR, proline-directed tau kinases) SG formation, 
respectively.  These results suggest that a significant component of tau pathophysiology 
and toxicity may require the interaction of tau with SGs, and points to modulation of SG 
formation as a novel therapeutic target in tauopathies.   
 Our findings in primary neurons led us to hypothesize that reducing SG formation 
via genetic knockdown of endogenous TIA1 might alleviate the progression of tauopathy 
in vivo.  We tested this hypothesis by crossing PS19 transgenic tau mice with Tia1-/- or 
background strain (C57BL/6J) mice, and evaluated the effect of heterozygous TIA1 
reduction on various functional outcomes of disease, including neurodegeneration, 
memory, and lifespan.  TIA1 reduction decreased presynaptic degeneration, improved 
microtubule stability and memory performance, increased neuron numbers and cortical 
thickness, and prolonged survival.  Together, our results clearly demonstrate that TIA1 
reduction confers robust neuroprotection against tauopathy in PS19 mice.   
 Analysis of the biochemical and structural properties of tau aggregation revealed 
a surprising role for TIA1 in disease pathophysiology.  Despite their robust behavioral 
protection, P301S TIA1+/- mice developed increased levels of phosphorylated (as 
detected by the AT8, CP13, and PHF1 antibodies) and sarkosyl-insoluble tau, which 
resulted in increased neurofibrillary tangle accumulation (as detected by Gallyas silver 
and Thioflavin S histological stains).  Further, there was no correlation between the 
tangle burden and extent of neuronal loss in either P301S TIA1+/+ or P301S TIA1+/- 
mice.  Biochemical fractionation studies revealed that the increase in fibrillar tau in 
P301S TIA1+/- mice coincided with a corresponding decrease in the levels of soluble tau 
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oligomers (as detected by the oligomeric conformation-specific TOC1 antibody).  This 
result punctuates the rapidly growing literature suggesting that soluble tau oligomers, and 
not insoluble neurofibrillary tangles, are the primary neurotoxic species in tauopathies 
(Kuchibhotla et al., 2014; Rocher et al., 2010; Santacruz et al., 2005).  More importantly, 
our findings identify a novel pathway that regulates the accumulation of oligomeric tau in 
vivo, which points to new therapeutic avenues for intervention in disease.   
 The ability of TIA1 reduction to decrease cytoplasmic SGs and rescue nuclear 
localization of TIA1 led us to hypothesize that P301S tau-induced deficits in mRNA 
metabolism might also be rescued in P301S TIA1+/- mice.  RNA-seq analysis of the 
brain transcriptome in 9 month P301S TIA1+/+ compared to non-transgenic (WT Tau 
TIA1+/+) mice revealed a massive dysregulation of mRNA processing and splicing as a 
core feature of tauopathy.  This included a net downregulation of various RBPs and core 
components of the spliceosome, which resulted in more than 350 aberrant mRNA 
splicing events that predominantly affected synaptic proteins.  Importantly, TIA1 
reduction rescued the majority of these aberrant RNA splicing events, thereby 
‘normalizing’ the transcriptome of PS19 mice.  This rescue effect of TIA1 reduction was 
particularly striking for alternatively spliced transcripts related to glutamatergic 
excitatory neurotransmission, including Gria2, Camk2b, and Snap25.  These results 
suggest that abnormal mRNA splicing in tauopathies predominantly affects the 
glutamatergic neurotransmission system.  Although purely correlative at this time, our 
results point to abnormal sequestration of RBPs in cytoplasmic SGs as the primary cause 
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of aberrant mRNA splicing in PS19 mice, which might either potentiate or directly cause 
neurodegeneration.   
 
Conclusions 
 The findings described in this dissertation support a new model of tauopathy 
whereby RNA binding proteins are a central participant in the progression of disease 
(Fig. 47).  In neurons, cellular stress induces tau to interact with TIA1 in order to 
facilitate the formation of SGs in neuronal soma and dendrites.  However, in the face of a 
chronic stress, such as that which occurs in disease, tau/TIA1 SGs are no longer transient, 
and over time become stable aggregates, which we have termed ‘pathological SGs’.  The 
interaction of tau with TIA1 in SGs appears to stabilize tau oligomers, preventing them 
from further aggregating into PHFs and NFTs.  This is important since a growing body of 
evidence strongly suggests that soluble tau oligomers exert a much greater influence on 
neurodegeneration that insoluble fibrils.  However, pathological SGs have a second 
mechanism of neurotoxicity beyond their role in stabilizing tau oligomers.  Mature SGs 
are known to recruit many additional RBPs via protein-protein interaction of their 
intrinsically disordered, low-complexity (LC) domains.  This abnormal sequestration of 
RBPs impairs their biological functions elsewhere in the cell, including in the nucleus.  
This leads to a massive dysregulation of mRNA processing and splicing, which produces 
a neuronal transcriptome that predisposes the cell for synaptic dysfunction and 
neurodegeneration.  Our findings suggest that inhibition of RBP aggregation in SGs, such 
as by reducing TIA1 expression, confers robust behavioral protection in tauopathies, 
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which is achieved by both returning RBPs to the nucleus (thereby correcting aberrant 
synaptic mRNA splicing) and preventing the accumulation of toxic tau oligomers.   
 
Figure 48: Working model for the role of RNA binding proteins in tau mediated 
neurodegeneration 
RNA binding proteins (RBPs), such as TIA1, are normally localized predominantly in the nucleus, where 
they mediate mRNA processing and splicing. Upon stress (i.e. Aβ accumulation, inflammation, vascular 
dysfunction, the unfolded protein response, oxidative stress), tau gets phosphorylated and detaches from 
microtubules, while TIA1 translocates from the nucleus to the cytoplasm where it associates with tau, 
forming stress granules (SGs).  The interaction of TIA1 with tau stabilizes toxic tau oligomers, which 
inhibits the further aggregation of tau into fibrils. Additional RBPs become sequestered with TIA1 and tau 
oligomers as SGs mature. Importantly, sequestration of RBPs in persistent pathological SGs disrupts the 
function of RBPs elsewhere in the cell, such as in the nucleus, leading to dysregulation of RNA splicing 
and neurodegeneration. 
 
Future directions 
 The research findings described in this dissertation uncover novel insights into the 
basic biology of Alzheimer’s disease and related tauopathies.  However, they also raise 
many new questions that have important therapeutic implications.  These remaining 
questions, as well as future strategies for addressing them, are discussed in detail below. 
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1. Our studies in PS19 mice clearly demonstrate that inhibition of SG formation by 
heterozygous knockout of TIA1 is protective against the progression of disease.  
Our studies in primary cultured neurons suggest that one possible mechanism 
underlying the behavioral protection associated with TIA1 reduction is a cell-
autonomous mechanism, whereby TIA1 reduction inhibits the translational 
response to stress, resulting in fewer SGs.  However, we also demonstrate that 
reducing TIA1 alters the structural and biochemical properties of tau aggregates.  
Therefore, the neuroprotective mechanism could also be non-cell-autonomous—
that is, TIA1 reduction alleviates neurotoxicity by producing tau species that are 
inherently less toxic.  One way to test this is to isolate tau aggregates from P301S 
TIA1+/+ and P301S TIA1+/- brain tissue (as well as Mapt-/- tissue as a negative 
control), and inject equal amounts of material from each genotype into P301S 
TIA1+/+ and P301S TIA1+/- mice.  This experimental paradigm has already been 
developed and described in detail by various other groups (Boluda et al., 2014; 
Kaufman et al., 2016; Kfoury et al., 2012).  This experiment will allow us to 
determine whether tau aggregates in P301S TIA1+/- are less toxic (material 
derived from P301S TIA1+/- induces less neurotoxicity in P301S TIA1+/+ mice 
than material derived from P301S TIA1+/+ mice) or whether P301S TIA1+/- 
neurons are less vulnerable to toxic tau aggregates (material derived from P301S 
TIA1+/+ mice produces less toxicity in P301S TIA1+/- mice than in P301S 
TIA1+/+ mice).   
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2. Our results clearly demonstrate that reducing TIA1 decreases levels of tau 
oligomers and increases tau fibrils.  However, the mechanisms governing the 
effects of TIA1 on tau aggregation remain largely unknown.  We have begun to 
address this using recombinant tau and TIA1.  Recombinant tau protein can be 
forced to aggregate into fibrils when incubated with heparin, dextran sulfate, or 
RNA in vitro (commonly referred to as the ‘tau assembly assay’).  We are in the 
process of performing these experiments with and without recombinant TIA1 in 
order to determine the effect of TIA1 on tau oligomers and fibrils, which can be 
analyzed by electron microscopy.  Preliminary results suggest that tau forms 
fewer and thinner fibrils in the presence of TIA1.  Double immuno-gold labeling 
of tau (total and oligomeric [TOC1]) reveals that virtually all of the recombinant 
TIA1 localizes to small tau aggregates co-labeled with TOC1.  In contrast, no 
TIA1 was found to be present in tau fibrils.  This is consistent with the hypothesis 
that TIA1 stabilizes tau oligomers, preventing their further aggregation into NFTs.  
However, this study is ongoing.     
3. Our proteomic studies have identified a variety of RBPs that interact with tau and 
form aggregates in disease.  However, whether any of these proteins are required 
for TIA1/tau-mediated neurotoxicity is unknown.  We have developed stable cell 
lines that inducibly express eGFP-tagged P301L mutant tau with or without 
mCherry-tagged TIA1, which produces robust co-localization of TIA1 and tau in 
SGs.  We are using these cells for a variety of high-throughput screens to identify 
novel proteins and compounds that regulate tau-induced SG formation in vitro, 
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including an RNAi screen of proteins detected in our mass spectrometry studies, a 
chemical library screen, and an unbiased CRISPR screen.  Validated targets and 
compounds will then be evaluated in vivo by methods similar to those described 
in Chapter 2.   
4. Unpublished studies from other groups have discovered novel mutations in TIA1 
that cause ALS.  Disease-linked SNPs occur in the LC domain of TIA1, and 
present with dementia (unpublished).  Thus, our group is highly interested in 
investigating the effects of ALS-causing TIA1 mutations on tau pathophysiology, 
both in vitro and in vivo.  Similarly, other groups have recently demonstrated that 
tau possesses the ability to undergo reversible phase transitions, and can cycle 
between soluble, liquid droplet, and amyloid-like states.  In other words, 
recombinant tau protein exhibits the biochemical behavior of RBPs with LC 
domains.  However, whether disease-linked tau mutations, or the presence of 
TIA1, impacts on its liquid phase separation properties is unknown.  These 
emerging data support the idea that accelerated phase separation of RNA granules 
is a shared pathogenic mechanism in a spectrum of neurodegenerative diseases, 
which includes ALS and tauopathies.   
5. Our RNA-seq studies show that reducing TIA1 has a profound effect on RNA 
metabolism and alternative splicing in tauopathies.  However, whether any of 
these changes reflect a direct effect of TIA1 is unknown.  CLIP (crosslinking 
followed by immunoprecipitation)-seq involves crosslinking RBPs to their mRNA 
targets, immunoprecipitating the RBP, and sequencing of the bound transcripts in 
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order to determine the consensus binding sequences for RBPs in the brain, as well 
as which transcripts they directly regulate (Huppertz et al., 2014; Nussbacher et 
al., 2015).  Our lab is actively developing protocols for performing CLIP-seq for a 
variety of RBPs in non-transgenic and PS19 brain tissues in collaboration with 
Gene Yeo at University of California San Diego.  Since tau has been proposed to 
bind mRNA (Kampers et al., 1996; X. Wang et al., 2006), we are pursuing this 
approach for tau as well as TIA1. 
6. Our alternative splicing analysis of our RNA-seq data strongly implicated 
dysfunctional excitatory neurotransmission as a core feature of PS19 mice.  
Specifically, our results point to the elevated ratio of Flip to Flop GluR2-containg 
AMPA receptors as a potential mechanism for excitotoxicity.  However, whether 
excitatory neurons in PS19 mice exhibit electrophysiological properties consistent 
with increased Flip GluR2-containg AMPA receptors is unknown.  We are 
currently engaged in a research collaboration with Dr. Jennifer Luebke (Boston 
University) to assess the morphological and electrophysiological properties of 
excitatory neurons in the dentate gyrus and entorhinal cortex of 6 month old non-
transgenic, P301S TIA1+/+, and P301S TIA1+/- mice.  We will also be 
performing field potential and paired pulse facilitation assays in slice cultures of 
these animals to determine how potentiation properties are affected by tauopathy.  
Further, the enhanced ratio of Flip- to Flop-containing GluR2 receptors in human 
tauopathies is will be confirmed by RT-PCR of AD and FTLD-tau brain tissues.   
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Dissertation highlights  
1. Various RNA binding proteins, which are frequently linked to the development of 
neurodegenerative diseases, associate with tau pathology in human patients and 
mouse models of tauopathies, including Alzheimer’s disease. 
 
2. Tau and various RNA binding proteins functionally interact in neurons.  Tau and 
TIA1, an RNA binding protein that nucleates cytoplasmic stress granules, 
reversibly co-immunoprecipitate.  Tau expression level regulates the subcellular 
distribution of TIA1, as well as the number, size, composition, and stability of 
TIA1-posiitve stress granules that form in response to exogenous stress.  The 
interaction of tau with TIA1 promotes the formation of misfolded tau granules 
that are toxic to hippocampal neurons.   
 
3. Reducing levels of endogenous TIA1 protects against the progression of 
tauopathy in vivo.  This protection includes reduced presynaptic degeneration, 
enhanced microtubule stability, improved spatial and recognition memory, 
reduced neurodegeneration, and prolonged survival.    
 
 
4. Reducing TIA1 shifts the structural and biochemical properties of tau 
aggregation, resulting in decreased accumulation of soluble tau oligomers that is 
concurrent with accelerated neurofibrillary tangle formation.  Importantly, the 
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increased accumulation of neurofibrillary tangles is associated with increased 
neuronal survival and behavioral protection.  
 
5. Reducing TIA1 in PS19 mice inhibits the formation of cytoplasmic stress 
granules and rescues nuclear localization of TIA1.  This restoration of the nuclear 
localization of TIA1 and other RNA binding proteins is associated with improved 
splicing of synaptic mRNA transcripts.  Notably, reducing TIA1 restores the 
correct ratio of exon 14 (Flip)- to exon 15 (Flop)-containing GluR2 AMPA 
receptors, thereby guarding against glutamatergic excitotoxicity.   
 
6. Reducing TIA1 restores functional interaction of tau with the cytoskeleton in 
PS19 mice, including increased binding of tau to microtubules.   
 
7. Taken together, these results highlight an essential role for RNA binding proteins 
in the progression of tauopathy, and identify inhibition of RNA binding protein 
aggregation in stress granules as a novel therapeutic target in Alzheimer’s disease 
and frontotemporal dementias.   
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APPENDIX I 
 
iBAQ quantitative values of proteins detected by LC-MS/MS in TIA1 IP samples  from 
WT and  Tau-/- cortex (n=3/group; normalized to TIA1 level = 1000 within each 
sample): 
 
Protein WT #1 WT #2 WT #3 WT Avg Tau-/- #1 Tau-/- #2 Tau-/- #3 Tau-/- Avg 
Tia1 1000.00 1000.00 1000.00 1000.00 1000.00 1000.00 1000.00 1000.00 
Uqcrc1 0.00 1323.50 2463.37 1262.29 0.00 1029.40 0.00 343.13 
Pkm 0.00 1132.13 721.85 617.99 0.00 890.55 0.00 296.85 
Rab14 0.00 685.21 668.88 451.36 0.00 312.12 0.00 104.04 
Aco2 0.00 818.23 163.51 327.24 0.00 421.02 0.00 140.34 
Mdh2 0.00 818.90 131.45 316.78 0.00 477.33 0.00 159.11 
Acot7 0.00 372.17 515.30 295.82 0.00 190.20 0.00 63.40 
Mog 0.00 132.65 607.08 246.58 0.00 75.99 0.00 25.33 
Snrpb 18.98 554.25 108.27 227.17 23.42 85.14 0.00 36.19 
Ubb 0.00 283.45 368.42 217.29 0.00 179.52 0.00 59.84 
Phb2 0.00 440.46 171.43 203.96 0.00 292.18 0.00 97.39 
Ran 0.00 364.72 221.23 195.32 0.00 161.39 0.00 53.80 
Glud1 0.00 402.03 161.59 187.87 0.00 364.73 0.00 121.58 
Psd3 0.00 555.14 0.00 185.05 0.00 132.63 0.00 44.21 
Rab5c 0.00 210.46 336.95 182.47 0.00 212.73 0.00 70.91 
Mapt 0.00 332.08 203.64 178.57 0.00 0.00 0.00 0.00 
Pura 0.00 264.08 269.05 177.71 0.00 39.73 0.00 13.24 
Tppp 0.00 298.71 219.76 172.82 0.00 40.41 0.00 13.47 
Slc1a2 0.00 187.28 297.73 161.67 0.00 96.41 0.00 32.14 
Hnrnpr 34.56 374.29 48.52 152.45 26.71 69.20 0.00 31.97 
Rab5a 0.00 126.47 301.84 142.77 0.00 184.70 0.00 61.57 
Ndufs3 0.00 365.70 60.81 142.17 0.00 36.94 0.00 12.31 
Prkacb 0.00 384.68 41.43 142.04 0.00 189.15 0.00 63.05 
Lrrc59 0.00 407.92 0.00 135.97 10.57 0.00 0.00 3.52 
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Atp6v1a 0.00 319.21 71.88 130.36 0.00 214.22 0.00 71.41 
Srsf2 0.00 305.88 71.08 125.65 0.00 67.13 0.00 22.38 
Atp5o 0.00 375.34 0.00 125.11 0.00 0.00 0.00 0.00 
Dlat 0.00 353.10 0.00 117.70 0.00 129.51 0.00 43.17 
Abat 0.00 272.18 79.39 117.19 0.00 111.58 0.00 37.19 
Atp6v0a1 0.00 107.70 239.52 115.74 0.00 12.99 0.00 4.33 
Add2 0.00 345.80 0.00 115.27 0.00 32.65 0.00 10.88 
Gstm1 0.00 285.75 57.43 114.39 0.00 91.11 0.00 30.37 
Cenpv 0.00 233.80 106.35 113.38 0.00 107.58 0.00 35.86 
Idh3a 0.00 185.85 137.61 107.82 0.00 154.69 0.00 51.56 
Prkaca 0.00 274.62 41.43 105.35 0.00 143.71 0.00 47.90 
Sept5 0.00 193.68 113.65 102.44 0.00 85.51 0.00 28.50 
Slc2a3 0.00 107.06 190.02 99.03 0.00 90.16 0.00 30.05 
Vdac1 0.00 184.41 101.14 95.18 0.00 0.00 0.00 0.00 
Hdgfrp2 0.00 282.33 0.00 94.11 0.00 97.14 0.00 32.38 
Atp2b4 0.00 273.92 0.00 91.31 0.00 143.72 0.00 47.91 
Slc4a10 0.00 268.53 0.00 89.51 0.00 0.00 0.00 0.00 
Syncrip 14.69 248.52 0.00 87.74 19.81 48.51 0.00 22.77 
Golgb1 0.00 0.00 258.62 86.21 0.00 0.00 0.00 0.00 
Suclg1 0.00 203.64 54.81 86.15 0.00 26.86 0.00 8.95 
Hspa9 0.00 172.66 77.45 83.37 0.00 100.92 0.00 33.64 
Clta 0.00 90.77 145.30 78.69 0.00 29.04 0.00 9.68 
Ap2a1 0.00 159.10 68.75 75.95 0.00 248.33 0.00 82.78 
Hmgb1 6.60 182.21 37.95 75.59 15.70 60.81 0.00 25.50 
Eif4a1 0.00 150.35 76.12 75.49 0.00 120.85 0.00 40.28 
Sirt2 0.00 175.43 48.22 74.55 0.00 0.00 0.00 0.00 
Mdh1 0.00 189.49 31.73 73.74 0.00 81.58 0.00 27.19 
Slc25a22 0.00 135.70 85.01 73.57 0.00 12.24 0.00 4.08 
Got1 0.00 203.53 16.98 73.50 0.00 135.88 0.00 45.29 
Ppp1cb 3.65 136.20 79.47 73.11 99.37 24.55 0.00 41.31 
Nipsnap1 0.00 219.24 0.00 73.08 0.00 27.03 0.00 9.01 
Lancl1 0.00 0.00 217.97 72.66 0.00 97.79 0.00 32.60 
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Phb 0.00 171.65 37.70 69.78 0.00 136.59 0.00 45.53 
Dpysl3 0.00 192.36 14.65 69.00 0.00 96.04 0.00 32.01 
Slc25a12 0.00 181.41 21.58 67.66 0.00 230.51 0.00 76.84 
Ddx5 3.76 199.07 0.00 67.61 47.41 34.09 0.00 27.16 
Ap2a2 0.00 127.96 68.75 65.57 0.00 185.73 0.00 61.91 
Acat1 0.00 175.36 18.11 64.49 0.00 70.30 0.00 23.43 
Rpl7 35.78 46.87 110.29 64.31 0.00 0.00 0.00 0.00 
Map2k1 0.00 108.35 83.73 64.03 0.00 67.82 0.00 22.61 
Ndufv1 0.00 178.52 0.00 59.51 0.00 0.00 0.00 0.00 
Homer1 0.00 37.80 137.05 58.28 0.00 59.61 0.00 19.87 
Ap2b1 0.00 105.08 67.77 57.62 0.00 102.06 0.00 34.02 
Cacnb4 0.00 172.40 0.00 57.47 0.00 31.05 0.00 10.35 
Sept4 0.00 94.69 75.58 56.76 0.00 52.68 0.00 17.56 
Gpi 0.00 131.59 34.92 55.50 0.00 162.31 0.00 54.10 
Snap25 0.00 164.88 0.00 54.96 0.00 137.92 0.00 45.97 
U2af2 0.00 162.47 0.00 54.16 0.00 106.85 0.00 35.62 
Atp6v1h 0.00 100.62 57.61 52.74 0.00 30.31 0.00 10.10 
Rps4x 5.82 152.38 0.00 52.73 2.94 0.00 0.00 0.98 
Pdhb 0.00 60.43 95.49 51.97 0.00 50.99 0.00 17.00 
Sucla2 0.00 61.67 86.35 49.34 0.00 48.97 0.00 16.32 
Prkcb 0.00 147.91 0.00 49.30 0.00 12.99 0.00 4.33 
Cpsf6 0.00 147.35 0.00 49.12 0.00 76.15 0.00 25.38 
Slc17a7 0.00 141.40 0.00 47.13 130.38 64.53 0.00 64.97 
Fscn1 0.00 137.78 0.00 45.93 0.00 66.60 0.00 22.20 
Ndufs2 0.00 136.80 0.00 45.60 0.00 26.97 0.00 8.99 
Serbp1 0.00 136.40 0.00 45.47 0.00 99.82 0.00 33.27 
Ddx17 0.00 134.77 0.00 44.92 0.00 34.09 0.00 11.36 
Hist1h1e 0.00 56.02 78.09 44.70 0.00 55.40 0.00 18.47 
Thy1 0.00 75.21 57.73 44.31 0.00 0.00 0.00 0.00 
Otub1 0.00 80.47 45.63 42.03 0.00 16.93 0.00 5.64 
Ahcyl2 2.62 76.33 45.15 41.37 8.48 72.49 0.00 26.99 
Add1 0.00 121.10 0.00 40.37 0.00 0.00 0.00 0.00 
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Map6 0.00 116.28 0.00 38.76 0.00 36.11 0.00 12.04 
Ctbp1 0.00 65.69 49.30 38.33 0.00 26.63 0.00 8.88 
Amph 0.00 113.39 0.00 37.80 0.00 0.00 0.00 0.00 
Mapk1 0.00 112.36 0.00 37.45 0.00 72.40 140.54 70.98 
Aldoc 0.00 69.51 41.59 37.03 0.00 43.21 0.00 14.40 
Idh3b 0.00 109.84 0.00 36.61 0.00 29.95 0.00 9.98 
Pcmt1 0.00 98.71 8.56 35.76 0.00 91.57 0.00 30.52 
Dld 0.00 107.17 0.00 35.72 0.00 31.31 0.00 10.44 
Trim2 0.00 105.50 0.00 35.17 0.00 0.00 0.00 0.00 
Immt 0.00 64.72 37.56 34.10 0.00 58.97 0.00 19.66 
Stx1b 0.00 99.71 0.00 33.24 0.00 26.85 0.00 8.95 
Pfkm 0.00 62.94 36.30 33.08 0.00 75.75 0.00 25.25 
Naca 0.00 98.89 0.00 32.96 10.51 0.00 474.12 161.54 
Pspc1 0.00 98.26 0.00 32.75 0.00 0.00 238.86 79.62 
Pip4k2a 0.00 75.35 18.79 31.38 0.00 6.90 0.00 2.30 
Camkv 0.00 92.06 0.00 30.69 0.00 0.00 0.00 0.00 
Actn4 0.00 77.02 14.50 30.51 0.00 28.78 0.00 9.59 
Hnrnpf 0.00 42.48 48.21 30.23 0.00 39.57 0.00 13.19 
Ca2 0.00 38.60 50.07 29.56 0.00 58.41 0.00 19.47 
Pacsin1 0.00 70.25 18.39 29.55 0.00 31.21 0.00 10.40 
Anxa7 0.00 42.35 44.81 29.05 0.00 71.89 1118.01 396.63 
Pdap1 0.00 86.00 0.00 28.67 0.00 15.74 0.00 5.25 
Ptk2 0.00 0.00 84.27 28.09 0.00 130.09 0.00 43.36 
Pdia3 0.00 69.17 13.77 27.65 0.00 36.04 0.00 12.01 
Gbas 0.00 81.01 0.00 27.00 0.00 0.00 0.00 0.00 
Lap3 0.00 80.49 0.00 26.83 0.00 28.37 0.00 9.46 
Pdxk 0.00 80.29 0.00 26.76 0.00 103.81 0.00 34.60 
Psmd8 80.27 0.00 0.00 26.76 4.11 0.00 0.00 1.37 
Prkce 0.00 78.71 0.00 26.24 0.00 0.00 0.00 0.00 
Rpl13 4.44 71.63 0.00 25.36 19.75 0.00 525.09 181.61 
Coro1a 0.00 74.20 0.00 24.73 0.00 30.96 0.00 10.32 
Tra2b 0.00 70.88 0.00 23.63 0.00 33.29 0.00 11.10 
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Hba 0.00 69.14 0.00 23.05 0.00 0.00 0.00 0.00 
Gda 0.00 0.00 68.52 22.84 0.00 75.26 0.00 25.09 
Sars 0.00 65.79 0.00 21.93 0.00 0.00 0.00 0.00 
Hnrnpul2 11.09 53.31 0.00 21.47 11.65 16.97 0.00 9.54 
Gnaz 0.00 59.44 0.00 19.81 0.00 0.00 0.00 0.00 
Cltc 0.00 58.45 0.00 19.48 0.00 45.22 0.00 15.07 
Fh 0.00 57.74 0.00 19.25 0.00 49.18 0.00 16.39 
Sept6 0.00 53.27 0.00 17.76 0.00 35.59 0.00 11.86 
Mrpl46 0.00 52.68 0.00 17.56 0.00 0.00 0.00 0.00 
Pabpc1 0.00 50.72 0.00 16.91 0.00 86.36 0.00 28.79 
Npepps 0.00 0.00 49.77 16.59 0.00 0.00 0.00 0.00 
Pcbp1 0.00 19.18 30.17 16.45 0.00 58.48 0.00 19.49 
Phactr1 0.00 48.18 0.00 16.06 0.00 0.00 0.00 0.00 
Sfxn3 0.00 46.08 0.00 15.36 0.00 43.04 0.00 14.35 
Srsf4 0.00 41.59 0.00 13.86 0.00 0.00 0.00 0.00 
Rph3a 0.00 40.42 0.00 13.47 16.96 0.00 0.00 5.65 
Atp1b2 0.00 15.12 25.29 13.47 0.00 30.71 0.00 10.24 
Prkcg 39.32 0.00 0.00 13.11 30.32 0.00 0.00 10.11 
Ewsr1 6.73 32.50 0.00 13.08 0.00 0.00 0.00 0.00 
Pip4k2c 0.00 36.63 0.00 12.21 0.00 0.00 0.00 0.00 
Atp2a2 0.00 36.58 0.00 12.19 0.00 21.49 0.00 7.16 
Gstp1 31.56 0.00 0.00 10.52 0.00 0.00 0.00 0.00 
Samm50 0.00 22.71 0.00 7.57 0.00 0.00 0.00 0.00 
Hprt1 0.00 20.98 0.00 6.99 0.00 54.13 0.00 18.04 
Pfkp 0.00 20.21 0.00 6.74 0.00 67.07 0.00 22.36 
Picalm 0.00 20.15 0.00 6.72 0.00 31.44 0.00 10.48 
Phyhip 0.00 17.13 0.00 5.71 0.00 54.67 0.00 18.22 
Epb41l2 16.67 0.00 0.00 5.56 25.76 0.00 0.00 8.59 
Rpl6 12.65 0.00 0.00 4.22 0.00 0.00 0.00 0.00 
Psma4 10.54 0.00 0.00 3.51 0.00 0.00 0.00 0.00 
Rpl13a 10.27 0.00 0.00 3.42 20.13 0.00 0.00 6.71 
Ctnnb1 9.46 0.00 0.00 3.15 122.78 0.00 0.00 40.93 
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Crym 8.50 0.00 0.00 2.83 0.00 0.00 0.00 0.00 
Ivd 7.28 0.00 0.00 2.43 5.22 0.00 0.00 1.74 
Snrnp70 6.22 0.00 0.00 2.07 0.00 0.00 0.00 0.00 
Htra1 5.71 0.00 0.00 1.90 7.66 0.00 0.00 2.55 
Rps3 4.38 0.00 0.00 1.46 67.09 0.00 0.00 22.36 
Cltb 3.53 0.00 0.00 1.18 0.00 0.00 0.00 0.00 
Rpl10a 3.24 0.00 0.00 1.08 8.16 0.00 0.00 2.72 
Gpd2 3.01 0.00 0.00 1.00 18.80 0.00 0.00 6.27 
Rbm17 1.59 0.00 0.00 0.53 0.00 0.00 0.00 0.00 
Ablim1 0.00 0.00 0.00 0.00 231.01 0.00 0.00 77.00 
Ablim2 0.00 0.00 0.00 0.00 225.32 0.00 0.00 75.11 
Acadm 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Acsbg1 0.00 0.00 0.00 0.00 7.72 0.00 0.00 2.57 
Acsl1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Actr3b 0.00 0.00 0.00 0.00 0.00 0.00 86.83 28.94 
Adam22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Adam23 0.00 0.00 0.00 0.00 0.00 0.00 192.53 64.18 
Add3 0.00 0.00 0.00 0.00 8.48 0.00 0.00 2.83 
Ago3 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Akr1b10 0.00 0.00 0.00 0.00 0.00 0.00 623.07 207.69 
Aldh2 0.00 0.00 0.00 0.00 0.00 0.00 3208.07 1069.36 
Aldh4a1 0.00 0.00 0.00 0.00 0.00 0.00 114.05 38.02 
Aldh7a1 0.00 0.00 0.00 0.00 0.00 0.00 277.84 92.61 
Amz2 0.00 0.00 0.00 0.00 7.91 0.00 0.00 2.64 
Ank2 0.00 0.00 0.00 0.00 23.16 0.00 0.00 7.72 
Anks1b 0.00 0.00 0.00 0.00 9.56 0.00 0.00 3.19 
Anxa5 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Anxa8 0.00 0.00 0.00 0.00 0.00 0.00 527.04 175.68 
Arpc1a 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Asap1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Ass1 0.00 0.00 0.00 0.00 13.99 0.00 0.00 4.66 
Atg7 0.00 0.00 0.00 0.00 0.00 0.00 52.25 17.42 
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Atp6v0d1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Baiap2 0.00 0.00 0.00 0.00 34.62 0.00 0.00 11.54 
Blvra 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Bphl 0.00 0.00 0.00 0.00 21.39 0.00 0.00 7.13 
C1qb 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
C3 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Camk4 0.00 0.00 0.00 0.00 0.00 0.00 462.58 154.19 
Capg 0.00 0.00 0.00 0.00 0.00 0.00 495.82 165.27 
Capn5 0.00 0.00 0.00 0.00 0.00 0.00 90.74 30.25 
Capzb 0.00 0.00 0.00 0.00 0.00 0.00 669.96 223.32 
Caskin1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Clic1 0.00 0.00 0.00 0.00 0.00 0.00 510.31 170.10 
Cmpk1 0.00 0.00 0.00 0.00 0.00 0.00 327.51 109.17 
Cn166 0.00 0.00 0.00 0.00 4.93 0.00 0.00 1.64 
Copa 0.00 0.00 0.00 0.00 0.00 0.00 801.85 267.28 
Coro1c 0.00 0.00 0.00 0.00 17.47 0.00 379.28 132.25 
Cpa4 0.00 0.00 0.00 0.00 0.00 0.00 525.88 175.29 
Crabp2 0.00 0.00 0.00 0.00 0.00 0.00 1217.98 405.99 
Ctnna2 0.00 0.00 0.00 0.00 27.85 0.00 0.00 9.28 
Dbn1 0.00 0.00 0.00 0.00 0.00 0.00 177.50 59.17 
Dctn1 0.00 0.00 0.00 0.00 0.00 0.00 1053.38 351.13 
Dip2b 0.00 0.00 0.00 0.00 0.00 0.00 171.07 57.02 
Dlg2 0.00 0.00 0.00 0.00 63.92 0.00 0.00 21.31 
Dlg4 0.00 0.00 0.00 0.00 179.75 0.00 0.00 59.92 
Dmtn 0.00 0.00 0.00 0.00 18.35 0.00 0.00 6.12 
Dmxl2 0.00 0.00 0.00 0.00 0.00 0.00 349.11 116.37 
Dnajb6 0.00 0.00 0.00 0.00 19.62 0.00 0.00 6.54 
Dnajc6 0.00 0.00 0.00 0.00 3.25 0.00 0.00 1.08 
Dync1h1 0.00 0.00 0.00 0.00 0.00 0.00 992.32 330.77 
Echs1 0.00 0.00 0.00 0.00 7.03 0.00 0.00 2.34 
Eci1 0.00 0.00 0.00 0.00 4.64 0.00 0.00 1.55 
Eef1b 0.00 0.00 0.00 0.00 0.00 0.00 774.12 258.04 
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Eef1d 0.00 0.00 0.00 0.00 0.00 0.00 678.46 226.15 
Efhd2 0.00 0.00 0.00 0.00 118.99 0.00 0.00 39.66 
Ehbp1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Eif2s3y 0.00 0.00 0.00 0.00 0.00 0.00 415.51 138.50 
Eif3a 0.00 0.00 0.00 0.00 0.00 0.00 351.80 117.27 
Eif3b 0.00 0.00 0.00 0.00 0.00 0.00 227.50 75.83 
Eif4b 0.00 0.00 0.00 0.00 0.00 75.99 0.00 25.33 
Eif6 0.00 0.00 0.00 0.00 0.00 0.00 177.02 59.01 
Fgg 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Flna 0.00 0.00 0.00 0.00 0.00 0.00 765.47 255.16 
Flnb 0.00 0.00 0.00 0.00 0.00 0.00 628.90 209.63 
G6pdx 0.00 0.00 0.00 0.00 0.00 0.00 312.32 104.11 
Gnb5 0.00 0.00 0.00 0.00 10.70 0.00 0.00 3.57 
Gpd1l 0.00 0.00 0.00 0.00 0.00 0.00 533.25 177.75 
Grm2 0.00 0.00 0.00 0.00 0.00 0.00 163.66 54.55 
Grm3 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Gsn 0.00 0.00 0.00 0.00 144.30 0.00 0.00 48.10 
Hadha 0.00 0.00 0.00 0.00 7.34 0.00 0.00 2.45 
Hist1h1b 0.00 0.00 0.00 0.00 0.00 0.00 613.79 204.60 
Hnrnpa1 0.00 0.00 0.00 0.00 0.00 0.00 149.78 49.93 
Hrg 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Hsd17b10 0.00 0.00 0.00 0.00 10.38 0.00 0.00 3.46 
Idh2 0.00 0.00 0.00 0.00 0.00 0.00 80.77 26.92 
Ilf2 0.00 0.00 0.00 0.00 14.05 0.00 0.00 4.68 
Iqgap1 0.00 0.00 0.00 0.00 0.00 0.00 455.87 151.96 
Iqsec2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Kcna3 0.00 0.00 0.00 0.00 0.00 0.00 462.86 154.29 
Kpnb1 0.00 0.00 0.00 0.00 0.00 0.00 739.27 246.42 
Lars 0.00 0.00 0.00 0.00 0.00 0.00 271.35 90.45 
Lmna 0.00 0.00 0.00 0.00 3.23 0.00 0.00 1.08 
Lmnb1 0.00 0.00 0.00 0.00 0.00 0.00 111.92 37.31 
Lrpprc 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
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Maoa 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Matr3 0.00 0.00 0.00 0.00 36.71 0.00 211.06 82.59 
Mmp9 0.00 0.00 0.00 0.00 16.77 0.00 0.00 5.59 
Mpst 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Mst1r 0.00 0.00 0.00 0.00 0.00 0.00 430.89 143.63 
Mtch2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Mut 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Myef2 0.00 0.00 0.00 0.00 9.62 0.00 0.00 3.21 
Myh10 0.00 0.00 0.00 0.00 24.87 0.00 0.00 8.29 
Nampt 0.00 0.00 0.00 0.00 0.00 0.00 1570.82 523.61 
Ngef 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Nme2 0.00 0.00 0.00 0.00 0.00 0.00 969.21 323.07 
Nomo1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Npm1 0.00 0.00 0.00 0.00 0.00 0.00 671.57 223.86 
Nufip2 0.00 0.00 0.00 0.00 9.75 0.00 0.00 3.25 
Oplah 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Pdia6 0.00 0.00 0.00 0.00 0.00 0.00 429.95 143.32 
Pkp3 0.00 0.00 0.00 0.00 0.00 0.00 529.72 176.57 
Plxna4 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Por 0.00 0.00 0.00 0.00 0.00 0.00 313.20 104.40 
Ppa1 0.00 0.00 0.00 0.00 0.00 0.00 280.14 93.38 
Ppib 0.00 0.00 0.00 0.00 0.00 0.00 1037.20 345.73 
Ppp2r2a 0.00 0.00 0.00 0.00 0.00 0.00 837.41 279.14 
Ppp2r2b 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Ppp5c 0.00 0.00 0.00 0.00 0.00 0.00 182.38 60.79 
Prkcd 0.00 0.00 0.00 0.00 0.00 0.00 204.05 68.02 
Psma2 0.00 0.00 0.00 0.00 0.00 0.00 100.63 33.54 
Psma5 0.00 0.00 0.00 0.00 0.00 0.00 278.43 92.81 
Psmc1 0.00 0.00 0.00 0.00 0.00 0.00 69.88 23.29 
Psmc5 0.00 0.00 0.00 0.00 0.00 0.00 499.78 166.59 
Rab18 0.00 0.00 0.00 0.00 0.00 0.00 362.31 120.77 
Rpl10 0.00 0.00 0.00 0.00 0.00 0.00 363.67 121.22 
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Rpl12 0.00 0.00 0.00 0.00 0.00 0.00 220.22 73.41 
Rpl15 0.00 0.00 0.00 0.00 0.00 0.00 469.62 156.54 
Rpl18a 0.00 0.00 0.00 0.00 0.00 0.00 697.77 232.59 
Rpl22 0.00 0.00 0.00 0.00 0.00 0.00 870.81 290.27 
Rpl26 0.00 0.00 0.00 0.00 0.00 0.00 517.94 172.65 
Rpl3 0.00 0.00 0.00 0.00 0.00 0.00 504.57 168.19 
Rpl36 0.00 0.00 0.00 0.00 0.00 0.00 279.76 93.25 
Rpl7a 0.00 0.00 0.00 0.00 0.00 0.00 1829.66 609.89 
Rpl9 0.00 0.00 0.00 0.00 0.00 0.00 745.86 248.62 
Rps11 0.00 0.00 0.00 0.00 0.00 0.00 1065.68 355.23 
Rps12 0.00 0.00 0.00 0.00 0.00 0.00 677.20 225.73 
Rps13 0.00 0.00 0.00 0.00 0.00 0.00 1597.29 532.43 
Rps15a 0.00 0.00 0.00 0.00 0.00 0.00 688.67 229.56 
Rps16 0.00 0.00 0.00 0.00 0.00 0.00 2001.12 667.04 
Rps19 0.00 0.00 0.00 0.00 0.00 0.00 1128.52 376.17 
Rps23 0.00 0.00 0.00 0.00 0.00 0.00 158.67 52.89 
Rps27 0.00 0.00 0.00 0.00 0.00 0.00 270.03 90.01 
Rps28 0.00 0.00 0.00 0.00 0.00 0.00 895.86 298.62 
Rps5 0.00 0.00 0.00 0.00 0.00 0.00 212.42 70.81 
Rtcb 0.00 0.00 0.00 0.00 0.00 0.00 794.47 264.82 
Sacm1l 0.00 0.00 0.00 0.00 0.00 0.00 301.11 100.37 
Sdcbp 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Selenbp1 0.00 0.00 0.00 0.00 0.00 0.00 428.75 142.92 
Serpinb6 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Slc4a4 0.00 0.00 0.00 0.00 0.00 0.00 181.40 60.47 
Slc6a11 0.00 0.00 0.00 0.00 24.18 0.00 0.00 8.06 
Srcin1 0.00 0.00 0.00 0.00 93.67 0.00 0.00 31.22 
Sri 0.00 0.00 0.00 0.00 37.59 0.00 0.00 12.53 
Srsf6 0.00 0.00 0.00 0.00 0.00 0.00 188.94 62.98 
Stx8 0.00 0.00 0.00 0.00 0.00 337.07 0.00 112.36 
Tagln2 0.00 0.00 0.00 0.00 0.00 0.00 2315.12 771.71 
Taok1 0.00 0.00 0.00 0.00 19.62 0.00 0.00 6.54 
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Tardbp 0.00 0.00 0.00 0.00 0.00 0.00 320.37 106.79 
Tbc1d24 0.00 0.00 0.00 0.00 0.00 0.00 112.20 37.40 
Th 0.00 0.00 0.00 0.00 0.00 0.00 404.58 134.86 
Tln2 0.00 0.00 0.00 0.00 0.00 0.00 341.37 113.79 
Tmod1 0.00 0.00 0.00 0.00 25.00 0.00 0.00 8.33 
Tmod2 0.00 0.00 0.00 0.00 357.59 0.00 0.00 119.20 
Tom1l2 0.00 0.00 0.00 0.00 0.00 0.00 48.18 16.06 
Tpm2 0.00 0.00 0.00 0.00 51.84 0.00 0.00 17.28 
Twf1 0.00 0.00 0.00 0.00 3.99 0.00 0.00 1.33 
Txnrd1 0.00 0.00 0.00 0.00 0.00 0.00 36.36 12.12 
Usp5 0.00 0.00 0.00 0.00 8.73 0.00 0.00 2.91 
Vars 0.00 0.00 0.00 0.00 0.00 0.00 215.69 71.90 
Wars 0.00 0.00 0.00 0.00 11.58 0.00 0.00 3.86 
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APPENDIX II 
 
iBAQ quantitative values of proteins detected in the S1p biochemical fraction (‘tau 
oligomer fraction’) of non-transgenic and PS19 cortex by LC-MS/MS (only top 100 
shown): 
 
Protein ID WT Tau TIA1+/+ Avg PS301S TIA+/+ Avg PS301S TIA1+/- Avg 
Tubb4a 6.05E+10 7.76E+10 7.75E+10 
Tuba3a 3.50E+10 4.46E+10 4.21E+10 
Actg1 2.55E+10 2.43E+10 2.48E+10 
Dpysl2 1.51E+10 1.51E+10 1.45E+10 
Gapdh 1.47E+10 1.37E+10 1.37E+10 
Syp 1.08E+10 1.32E+10 1.16E+10 
Glul 1.38E+10 1.18E+10 1.25E+10 
Vamp2 9.39E+09 1.12E+10 1.15E+10 
Mbp 8.51E+09 1.06E+10 1.08E+10 
Camk2a 1.20E+10 9.94E+09 7.48E+09 
Pkm 8.31E+09 6.26E+09 6.32E+09 
Ckb 7.62E+09 6.19E+09 6.16E+09 
Camk2b 6.70E+09 5.59E+09 4.22E+09 
Camk2d 6.04E+09 5.26E+09 3.67E+09 
Hspa8 5.17E+09 5.17E+09 4.69E+09 
Atp6v1a 4.69E+09 5.00E+09 4.67E+09 
Atp6v1b2 5.01E+09 4.13E+09 4.20E+09 
Ppia 3.41E+09 3.76E+09 4.12E+09 
Cltc 2.88E+09 3.66E+09 4.14E+09 
Syt1 3.08E+09 3.65E+09 2.96E+09 
Mal2 2.83E+08 3.28E+09 2.87E+09 
Aldoa 3.60E+09 3.26E+09 3.73E+09 
Atp6v0a1 2.23E+09 3.24E+09 2.44E+09 
Pura 3.23E+09 3.19E+09 3.67E+09 
Syngr1 3.56E+09 3.11E+09 3.47E+09 
Crmp1 2.75E+09 2.95E+09 2.53E+09 
Eno1 3.50E+09 2.66E+09 2.77E+09 
Scamp5 2.21E+09 2.64E+09 2.00E+09 
Eef1a1 3.72E+09 2.62E+09 3.04E+09 
Dnajc5 3.70E+09 2.51E+09 2.72E+09 
Pdhb 1.52E+09 2.49E+09 2.36E+09 
  
167 
Vcp 3.00E+09 2.43E+09 2.58E+09 
Cct3 3.01E+09 2.28E+09 2.38E+09 
Stxbp1 2.34E+09 2.27E+09 1.82E+09 
Atp6v1e1 2.29E+09 2.26E+09 2.29E+09 
Atp6v0d1 2.09E+09 2.23E+09 2.38E+09 
Eef1a2 3.62E+09 2.23E+09 2.98E+09 
Cct2 2.84E+09 2.19E+09 2.41E+09 
Nsf 2.00E+09 2.15E+09 1.78E+09 
Pfkm 2.11E+09 2.12E+09 1.91E+09 
Cct5 2.69E+09 2.11E+09 2.43E+09 
Ywhaz 2.36E+09 2.08E+09 2.10E+09 
Eef1g 3.34E+09 2.07E+09 2.33E+09 
Mdh1 2.14E+09 2.01E+09 1.95E+09 
Ldhb 2.15E+09 1.99E+09 1.53E+09 
Cct8 2.46E+09 1.97E+09 2.15E+09 
Rps8 2.16E+09 1.94E+09 2.17E+09 
Hist1h1e 1.83E+09 1.93E+09 2.16E+09 
Rtn3 2.59E+09 1.91E+09 2.58E+09 
Cct6a 2.24E+09 1.91E+09 1.77E+09 
Syngr3 1.40E+09 1.90E+09 1.58E+09 
Plp1 1.69E+09 1.83E+09 2.22E+09 
Dlat 1.41E+09 1.81E+09 1.70E+09 
Syn2 1.48E+09 1.81E+09 1.45E+09 
Cnp 1.70E+09 1.81E+09 1.73E+09 
Rps3 2.00E+09 1.78E+09 1.67E+09 
Cct4 2.20E+09 1.77E+09 2.05E+09 
Rpl4 1.85E+09 1.76E+09 2.00E+09 
Dpysl3 2.06E+09 1.74E+09 1.80E+09 
Rab3a 1.40E+09 1.73E+09 1.22E+09 
Rps25 1.88E+09 1.73E+09 2.43E+09 
Tcp1 2.18E+09 1.73E+09 1.90E+09 
Syt2 1.79E+09 1.69E+09 1.62E+09 
Aldoc 1.89E+09 1.67E+09 1.70E+09 
Rpl27 1.54E+09 1.65E+09 2.19E+09 
Cct7 2.20E+09 1.61E+09 1.80E+09 
Rtn1 1.12E+09 1.58E+09 1.50E+09 
Glud1 1.63E+09 1.58E+09 1.60E+09 
Atp6v1g2 1.19E+09 1.55E+09 1.22E+09 
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Syn1 1.67E+09 1.53E+09 1.34E+09 
Pdha1 1.19E+09 1.50E+09 1.45E+09 
Rack1 1.47E+09 1.44E+09 1.36E+09 
Hsp90ab1 1.65E+09 1.43E+09 1.20E+09 
Pgrmc1 1.10E+09 1.43E+09 1.51E+09 
Rpl8 6.69E+08 1.42E+09 1.32E+09 
Got1 1.53E+09 1.42E+09 1.57E+09 
Atp6v1h 1.45E+09 1.38E+09 1.25E+09 
Slc17a7 1.48E+09 1.36E+09 1.02E+09 
Rpsa 1.82E+09 1.36E+09 1.62E+09 
Rplp0 1.37E+09 1.29E+09 1.38E+09 
Rpl7a 1.69E+09 1.28E+09 1.86E+09 
Gpi 1.68E+09 1.27E+09 1.31E+09 
Hsp90aa1 1.53E+09 1.27E+09 1.12E+09 
Thy1 9.43E+08 1.25E+09 1.11E+09 
Gdi1 1.49E+09 1.22E+09 1.18E+09 
Rpl6 1.49E+09 1.21E+09 1.36E+09 
Gnb1 8.41E+08 1.21E+09 1.25E+09 
Rplp1 1.02E+09 1.19E+09 1.38E+09 
Pfkl 1.26E+09 1.18E+09 1.13E+09 
Pgam1 1.58E+09 1.18E+09 1.13E+09 
Dynll2 1.79E+09 1.18E+09 1.19E+09 
Rpl10a 1.09E+09 1.18E+09 1.44E+09 
Pfkp 1.28E+09 1.17E+09 1.13E+09 
Rpl13 1.22E+09 1.17E+09 1.30E+09 
Basp1 8.59E+08 1.14E+09 1.21E+09 
Vamp1 1.14E+09 1.13E+09 1.41E+09 
Atp6v1d 1.34E+09 1.13E+09 1.31E+09 
Rps3a 1.12E+09 1.12E+09 1.36E+09 
 
 
GO Molecular Function and Interpro protein domain terms enriched in the list of protein 
accumulating in the S1p biochemical fraction (‘tau oligomer fraction’) of PS19 cortex: 
 
Reference No. GO term Count FDR 
GO:0044822 poly(A) RNA binding 373 1.33E-106 
GO:0003723 RNA binding 215 4.02E-42 
GO:0005515 protein binding 657 1.07E-40 
GO:0000166 nucleotide binding 382 3.02E-39 
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GO:0098641 cadherin binding involved in cell-cell adhesion 114 2.28E-38 
GO:0003735 structural constituent of ribosome 89 3.42E-22 
GO:0003729 mRNA binding 60 9.65E-20 
GO:0032403 protein complex binding 100 2.33E-18 
GO:0005524 ATP binding 264 1.67E-17 
GO:0003824 catalytic activity 111 5.38E-14 
GO:0051082 unfolded protein binding 37 8.57E-14 
GO:0051015 actin filament binding 47 1.85E-11 
GO:0019904 protein domain specific binding 72 1.06E-09 
GO:0019901 protein kinase binding 94 1.80E-09 
GO:0003779 actin binding 79 2.51E-09 
GO:0019899 enzyme binding 86 2.77E-09 
GO:0051287 NAD binding 27 3.23E-09 
GO:0042802 identical protein binding 116 1.39E-07 
GO:0008017 microtubule binding 52 4.58E-07 
GO:0004812 aminoacyl-tRNA ligase activity 20 1.63E-06 
GO:0019905 syntaxin binding 29 2.58E-06 
GO:0005516 calmodulin binding 47 4.62E-06 
GO:0005200 structural constituent of cytoskeleton 28 6.65E-06 
GO:0019900 kinase binding 30 2.06E-05 
GO:0008022 protein C-terminus binding 50 2.06E-05 
GO:0003743 translation initiation factor activity 25 3.12E-05 
GO:0051087 chaperone binding 26 5.92E-05 
GO:0004298 threonine-type endopeptidase activity 14 7.54E-05 
GO:0005543 phospholipid binding 28 1.23E-04 
GO:0031072 heat shock protein binding 21 1.31E-04 
GO:0008092 cytoskeletal protein binding 24 1.53E-04 
GO:0003924 GTPase activity 48 1.58E-04 
GO:0031625 ubiquitin protein ligase binding 59 1.97E-04 
GO:0051020 GTPase binding 15 3.12E-04 
GO:0016787 hydrolase activity 215 3.84E-04 
GO:0016491 oxidoreductase activity 101 5.83E-04 
GO:0000149 SNARE binding 22 9.79E-04 
GO:0016874 ligase activity 68 0.001024 
GO:0043531 ADP binding 16 0.001239 
GO:0008565 protein transporter activity 23 0.001613 
GO:0005096 GTPase activator activity 49 0.002355 
GO:0008289 lipid binding 54 0.002451 
GO:0003730 mRNA 3'-UTR binding 19 0.003527 
GO:0019003 GDP binding 20 0.006102 
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GO:0016616 oxidoreductase activity, acting on the CH-OH group of donors, 
NAD or NADP as acceptor 
14 0.009583 
GO:0046961 proton-transporting ATPase activity, rotational mechanism 12 0.012492 
GO:0005525 GTP binding 67 0.01534 
GO:0048306 calcium-dependent protein binding 21 0.01546 
GO:0042803 protein homodimerization activity 119 0.017901 
GO:0042277 peptide binding 25 0.018844 
GO:0031369 translation initiation factor binding 12 0.020279 
GO:0051117 ATPase binding 24 0.022766 
GO:0044325 ion channel binding 29 0.0288 
GO:0070180 large ribosomal subunit rRNA binding 9 0.029713 
GO:1990446 U1 snRNP binding 7 0.040193 
 
Reference No. Protein domain term Count FDR 
IPR016024 Armadillo-type fold 94 1.34E-18 
IPR000504 RNA recognition motif domain 72 9.95E-17 
IPR012677 Nucleotide-binding, alpha-beta plait 76 4.63E-15 
IPR017986 WD40-repeat-containing domain 79 2.15E-14 
IPR015943 WD40/YVTN repeat-like-containing domain 81 1.38E-12 
IPR001680 WD40 repeat 69 1.38E-12 
IPR016040 NAD(P)-binding domain 56 3.83E-11 
IPR011989 Armadillo-like helical 59 5.84E-11 
IPR020472 G-protein beta WD-40 repeat 33 9.62E-09 
IPR000717 Proteasome component (PCI) domain 14 1.94E-08 
IPR019775 WD40 repeat, conserved site 43 3.31E-07 
IPR001353 Proteasome, subunit alpha/beta 14 4.58E-06 
IPR013766 Thioredoxin domain 18 3.40E-05 
IPR006595 CTLH, C-terminal LisH motif 9 2.93E-04 
IPR011993 Pleckstrin homology-like domain 70 4.88E-04 
IPR012336 Thioredoxin-like fold 33 6.21E-04 
IPR017998 Chaperone tailless complex polypeptide 1 (TCP-1) 9 9.90E-04 
IPR002939 Chaperone DnaJ, C-terminal 8 0.002617 
IPR008971 HSP40/DnaJ peptide-binding 8 0.002617 
IPR009068 S15/NS1, RNA-binding 7 0.006146 
IPR002194 Chaperonin TCP-1, conserved site 8 0.008037 
IPR027410 TCP-1-like chaperonin intermediate domain 8 0.008037 
IPR006195 Aminoacyl-tRNA synthetase, class II 10 0.008593 
IPR027417 P-loop containing nucleoside triphosphate hydrolase 123 0.008951 
IPR011990 Tetratricopeptide-like helical 40 0.009598 
IPR000727 Target SNARE coiled-coil domain 12 0.011981 
IPR027409 GroEL-like apical domain 9 0.014052 
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IPR027413 GroEL-like equatorial domain 9 0.014052 
IPR002553 Clathrin/coatomer adaptor, adaptin-like, N-terminal 9 0.014052 
IPR013816 ATP-grasp fold, subdomain 2 10 0.015805 
IPR002423 Chaperonin Cpn60/TCP-1 9 0.027718 
IPR014729 Rossmann-like alpha/beta/alpha sandwich fold 15 0.034309 
IPR000008 C2 calcium-dependent membrane targeting 32 0.038752 
IPR016159 Cullin repeat-like-containing domain 8 0.045051 
 
 
GO molecular function annotations significantly enriched (FDR < 0.05) for proteins 
increasing (>2-fold) in the S1p biochemical fraction of P301S TIA1+/+ compared to 
non-transgenic (WT Tau TIA1+/+) cortex: 
 
Reference No. GO term Count FDR 
GO:0044822 poly(A) RNA binding 41 2.25E-05 
GO:0000166 nucleotide binding 53 0.001636 
GO:0032403 protein complex binding 18 0.012489 
GO:0005515 protein binding 86 0.016728 
 
 
GO molecular function annotations significantly enriched (FDR < 0.05) for proteins 
decreasing (>2-fold) in the S1p biochemical fraction of P301S TIA1+/- compared to 
P301S TIA1+/+ cortex: 
 
Reference No. GO term Count FDR 
GO:0044822 poly(A) RNA binding 34 1.21E-04 
GO:0005515 protein binding 72 0.0078 
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Differentially expressed genes in 9 month PS19 compared to non-transgenic mouse 
cortex: 
 
Gene Base Mean log2FoldChange FDR 
F630042J09Rik 26.51212722 1.517573967 1.98153E-06 
Manf 782.8821301 -0.626567453 7.15037E-05 
Gm8615 176.818618 0.952305863 8.97562E-05 
P4ha1 1343.370436 -0.434290683 8.97562E-05 
Pcdhga5 78.83404972 -1.026568791 8.97562E-05 
Chid1 905.6311128 0.582695024 0.000100987 
6330403A02Rik 3214.446237 0.90905274 0.000208786 
Fosl2 1139.501076 -1.128136595 0.000254131 
Bcor 533.2109758 -1.010725774 0.000259055 
Kcnab3 790.3023101 -1.01949637 0.000259055 
Tppp3 323.5793221 1.001628994 0.000308497 
Tenm1 1187.757628 0.793184258 0.000354391 
Arhgef28 586.6365915 0.914741637 0.000355218 
Ypel1 360.3993439 0.857619041 0.000355218 
Fxyd6 1317.467794 0.823226453 0.000514194 
Ccnf 123.5564045 -1.010482961 0.000514194 
Cdk18 213.9597454 0.922802163 0.000569289 
Med7 364.7728049 -0.518789985 0.000569289 
Nov 1615.942498 0.94414021 0.000596831 
Camkv 6219.771951 0.517603756 0.000663916 
Hspa5 7024.914418 -0.752729741 0.000700034 
Hspa1a 218.9177449 -0.872429474 0.000793976 
Ptar1 438.1532667 -0.552446432 0.000832059 
Kdm7a 2428.125149 -0.728289319 0.000832059 
Cry1 490.4423063 -0.857450657 0.001173812 
Chordc1 1375.24166 -0.41487055 0.001628985 
Dnajb5 1573.689644 -0.730352338 0.001791032 
Usp35 216.217468 0.720472717 0.001794326 
Ints8 730.2699505 -0.400782096 0.001862769 
Cast 216.1150986 -0.732692761 0.001932371 
Numb 744.6181811 -0.603142201 0.002082591 
Fosb 354.2378803 -1.090007252 0.002199628 
Thbs4 60.38451012 1.108780346 0.002541103 
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Pappa2 44.97733182 1.038661687 0.002541103 
Rin1 644.4094778 0.466274375 0.002594558 
Tra2a 967.1702257 -0.787485195 0.002594558 
Lypd1 122.6102341 1.055444764 0.002652267 
Rnd3 655.2579757 -1.058315361 0.002652267 
Slc7a4 859.8228784 0.682813025 0.00279344 
A930011O12Rik 1190.168788 -0.43815895 0.00279344 
Chpf2 878.6378047 0.44646576 0.002795511 
Ikbkg 1065.221126 0.316187783 0.002795511 
Baz1a 188.585978 -1.063576686 0.002795511 
Gstz1 467.6106113 0.427894879 0.003089046 
Pim1 74.6760442 -1.067066463 0.00325234 
Gadd45b 315.2724166 -0.99996296 0.003544604 
Hpcal4 14198.83794 0.478406401 0.003740666 
Rsph4a 44.28492324 1.006107733 0.003742313 
Wnt7b 368.0075758 0.85124556 0.004057823 
Cyb5r4 928.6747306 -0.459246365 0.004080612 
Fancd2 81.48080071 0.922578377 0.005338348 
Zfp941 833.6775698 0.506652794 0.005459245 
Pwwp2a 751.7417534 -0.332890847 0.005459245 
Map3k14 73.45255951 -0.83723035 0.005459245 
6430584L05Rik 87.96195204 0.784120773 0.00550284 
Cux1 1621.272496 -0.513524285 0.00550284 
Creld2 262.8896772 -0.742832354 0.00550284 
Cdh13 710.4901321 0.738138658 0.005611716 
Itgax 25.82234761 0.792975298 0.005648558 
Rbm12b2 582.6856348 -0.435393563 0.005648558 
Sertad1 280.8473157 -0.8682833 0.005648558 
Akr1c18 63.65442799 -1.03266829 0.005648558 
Dnajb11 1032.139841 -0.512694918 0.005759398 
Chrm2 379.9590881 -0.959699629 0.0058036 
Zbtb40 250.3121005 -0.547186725 0.005858232 
B230217C12Rik 566.9684169 -0.786570269 0.006120675 
6330419J24Rik 334.9858038 0.678197149 0.006194617 
Ptpre 434.3911266 0.638937741 0.006194617 
Ddn 9654.5969 0.393786102 0.006194617 
Cds2 11397.08043 0.255995907 0.006194617 
Ostc 494.604275 -0.404795233 0.006194617 
Caap1 180.9569394 -0.514121558 0.006194617 
Sdf2l1 190.1443208 -0.694839516 0.006194617 
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Rab37 163.5841745 -0.999557359 0.006194617 
Cdkn1a 300.0660686 -0.88961994 0.006251908 
Nfil3 267.4395354 -0.942293877 0.006251908 
Hspa1b 217.7200952 -0.854580436 0.006719725 
Clec7a 22.44107266 0.800986357 0.006780176 
Srrt 1068.667995 -0.356987572 0.006780176 
Fam181b 309.4793246 -0.948643508 0.006780176 
Glra3 145.0899427 0.826035716 0.006899197 
Cox7c 1792.838897 -0.344080746 0.006899197 
Nptx2 1122.025322 -0.974826746 0.006899197 
Maml3 340.9803307 -1.004948449 0.006899197 
Slc25a22 1245.639445 0.625789278 0.00690403 
Nlrx1 88.71211599 0.711072457 0.006953582 
Trpc5 345.9369463 0.535582158 0.006953582 
Usp22 3923.228185 0.344926845 0.007050207 
Elovl6 1414.3909 -0.423811872 0.007087431 
Xbp1 1872.578979 -0.546393945 0.007087431 
Mpp3 976.0758219 -0.477413944 0.007306959 
Smc5 871.3598535 -0.370979452 0.007312272 
Ppp1r3c 1453.40786 -0.409101509 0.007312272 
Sik2 457.1206018 -0.627317162 0.007395357 
Ybx1 1736.627216 -0.773114998 0.007534432 
Tnfaip8l3 122.8609605 0.866535929 0.007868366 
Cstf2 1623.462446 -0.241703066 0.008131875 
Mapk4 1621.158741 -0.488689078 0.008131875 
Per2 617.5809869 -0.617178253 0.008131875 
E2f4 239.7409489 -0.498945558 0.008654743 
Nlrp5-ps 286.1111611 -0.961608907 0.008654743 
Pdlim2 91.22658184 0.67891362 0.008853367 
Lrrc55 504.6929262 -0.954194235 0.009021971 
Hey2 154.4802225 -0.952655063 0.009213407 
Dsel 625.617128 0.638162871 0.009361685 
Dlg1 5268.863033 -0.316259806 0.009990247 
Htr1a 255.51687 0.806038085 0.010143611 
Pdia3 2833.035386 -0.288153835 0.010143611 
Kitl 1342.314788 -0.560886961 0.010143611 
Pygm 451.1541653 -0.58685368 0.010143611 
Syt17 316.4462794 0.648327143 0.011946489 
Hnrnpf 1886.129251 -0.447836716 0.012264244 
Mt1 1555.741142 0.438640112 0.012413052 
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Rbm41 325.0631068 -0.588593884 0.012413052 
Cav1 276.6478169 -0.806201693 0.012413052 
Ythdc1 1491.51896 -0.429353038 0.013185512 
Zfp830 259.2861214 -0.472778557 0.013185512 
Oscp1 488.6358626 0.460017694 0.013375957 
Dusp5 167.6745831 -0.886883098 0.013375957 
Mycn 108.2085696 -0.759120925 0.013463405 
Bcl2 614.514211 -0.476331127 0.014182115 
Ank1 684.3318411 -0.706372842 0.014182115 
Adamts18 26.70930965 0.936020237 0.01455358 
Cox5a 1839.89347 -0.277785047 0.01455358 
Igf1 310.1305428 -0.894138753 0.01455358 
Mia3 2709.64286 -0.243637971 0.014602132 
Cnih2 983.9529801 0.467187324 0.015281821 
Auh 905.6863478 -0.407468309 0.015389496 
Cerk 1415.457263 -0.500965232 0.015944471 
Mxd1 464.4069498 -0.408911653 0.016434804 
Srsf11 1105.278026 -0.277581005 0.016477129 
Prpf39 761.7631334 -0.358561202 0.016477129 
8030462N17Rik 1030.147779 -0.402880179 0.016477129 
Zfp143 271.4076017 -0.433467176 0.016477129 
Pdia4 1201.014032 -0.499719873 0.016477129 
Ubash3b 583.4517445 -0.759691655 0.016477129 
Galntl6 668.2956815 -0.568081306 0.018120799 
Trpm3 1067.422247 -0.734483904 0.018615235 
Cc2d1b 325.8136409 0.450421356 0.018769438 
Mapkapk5 505.5011829 -0.365279668 0.018804466 
Fndc5 1275.824839 -0.588010052 0.018804466 
Tiparp 989.6326816 -0.781442063 0.019126151 
Top1 1858.643289 -0.472769698 0.01956196 
Irs1 724.2485886 -0.542225756 0.01956196 
Neu4 116.0515226 0.586709301 0.01989761 
Il1rapl1 706.6163079 -0.527432731 0.01989761 
Zfp326 464.3356036 -0.406100089 0.020176013 
Dnajc3 1647.231949 -0.406321831 0.020176013 
Rftn1 130.3617029 0.867612686 0.020195828 
Rogdi 691.0616893 0.458500441 0.020195828 
Sema6b 1237.625666 0.382098708 0.020195828 
Tpt1 6264.988129 -0.370047136 0.020195828 
Papola 1772.536456 -0.418513487 0.020195828 
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Srsf10 1756.663084 -0.547621455 0.020195828 
Fgf9 423.9681715 -0.553870519 0.020195828 
Dnajc1 766.5166016 -0.40600237 0.02052791 
Gaa 2707.445419 0.538032324 0.020843292 
Phf21b 115.3917094 -0.680766451 0.021417209 
Hsph1 4819.457116 -0.329467221 0.021488731 
Rbm17 829.7085295 -0.284464496 0.021589857 
Krt12 261.0125587 0.896808489 0.021930793 
Plekho1 521.8174457 -0.609392529 0.022343382 
Cpe 27233.68576 0.328122927 0.02270279 
Fndc3a 1615.790375 -0.402954365 0.0228005 
Cyp7b1 224.0137763 0.428471435 0.02310509 
Ppp1r15b 1403.155763 -0.312077084 0.02310509 
Stard10 692.6298122 -0.564070861 0.02374632 
Rpp25 240.2738983 -0.79809403 0.023976022 
Col10a1 18.18915978 -0.805953273 0.023976022 
Igfbp2 544.4655887 -0.820766891 0.023976022 
Gpsm2 364.2498578 -0.654856466 0.024106849 
Areg 19.85767053 -0.69187616 0.024106849 
Pdgfra 1060.305272 0.499950436 0.024587172 
Ythdf3 1891.402715 -0.363088182 0.024587172 
Lysmd3 348.0722338 -0.548768791 0.024587172 
Cpsf6 2417.769128 -0.320168071 0.024698281 
Tra2b 1568.24314 -0.402700098 0.024698281 
Hspb1 80.6242152 -0.857745365 0.024698281 
Chmp1a 1318.735035 0.380327565 0.024725208 
Gabrb1 658.9731087 0.505029557 0.025705541 
Cacng7 376.1711145 -0.502209341 0.025705541 
Neo1 2215.019173 0.20152668 0.026507952 
Rsph9 155.3292476 0.582329625 0.026659431 
Dennd5b 3783.921112 -0.366364587 0.026954444 
Rnf19a 1004.853187 -0.377429473 0.026954444 
Rbm12b1 449.2363087 -0.504171759 0.026954444 
Smek1 984.7752422 -0.364605786 0.027711233 
Snhg8 246.6151475 -0.416700987 0.027711233 
Magoh 310.3041355 -0.505549247 0.027711233 
Bmp3 351.9228628 0.765809026 0.02774677 
Hrk 487.0330453 0.684743247 0.02774677 
Nrros 110.3605722 0.600677288 0.02774677 
Cpt1c 964.1664782 0.482260455 0.02774677 
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Rps6ka4 460.9347838 0.393808822 0.02774677 
Akap17b 655.8453252 -0.358041119 0.02774677 
Nans 199.197132 -0.512051024 0.02774677 
6430573F11Rik 218.6197001 -0.73548024 0.02774677 
Clu 7530.744839 0.519497229 0.027823168 
Tpm1 2786.743433 -0.491499518 0.027823168 
Adck3 565.2982204 0.499756904 0.027868829 
Slc17a5 391.2202548 0.547797841 0.027921107 
Arl6ip1 4289.919453 0.352531432 0.027921107 
Xpot 2107.018276 0.207939087 0.027921107 
Vegfa 805.1546476 -0.371929253 0.027921107 
Man2b2 258.5863889 0.390910065 0.028271224 
Exosc3 152.4800071 -0.497124741 0.028357065 
Eltd1 395.6325185 -0.52977388 0.028389105 
Pik3ip1 468.025014 0.388620416 0.028439076 
Nup98 1285.267212 -0.322417086 0.028551502 
Nup153 1421.653106 -0.367691941 0.028551502 
Ccdc134 158.7103308 -0.787755484 0.028551502 
Mdm2 941.9052843 -0.32292037 0.029137546 
Rac3 180.0261134 0.530270946 0.029773561 
Tet3 896.9351707 -0.532687861 0.030279672 
Brat1 235.6976647 0.420208287 0.030759703 
Islr2 723.9084508 0.739827919 0.030846104 
2410127L17Rik 301.5526957 -0.432364826 0.031708926 
Lonrf3 846.2696951 -0.80057899 0.031915514 
Cmpk2 415.6062872 0.488629 0.032003828 
Leo1 526.8677348 -0.393828729 0.032003828 
Thoc7 652.9222824 -0.437782052 0.03235322 
Grasp 583.3144468 -0.757160376 0.033006315 
Pcdh19 711.3553905 0.671477474 0.033297824 
Slc35f1 1273.900198 0.573201416 0.033297824 
L1cam 1431.054409 0.547917319 0.033649795 
Bdp1 1523.292224 -0.267606339 0.033649795 
Nab2 654.5677173 -0.467814878 0.033649795 
Trip11 1175.713382 -0.250642246 0.033910045 
Rnf216 804.5499351 -0.267186055 0.033910045 
Nomo1 1429.700899 0.272024445 0.034503147 
Pacsin2 1431.462723 -0.811241091 0.034554526 
Sclt1 315.4463764 -0.470375296 0.034669996 
Polq 111.0309126 -0.672405648 0.034669996 
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Etnppl 267.868431 -0.808619688 0.035032743 
Homer1 6175.966392 -0.591564496 0.035804397 
Ulk4 153.5694947 0.577954279 0.036384502 
Dsc3 19.07079114 0.617234294 0.036395254 
Safb 1198.108232 -0.233503237 0.036395254 
Arf6 1206.915741 -0.340710142 0.036833396 
Wisp1 284.0597352 -0.821129541 0.036833396 
Atg4d 346.7710562 -0.335021514 0.037003664 
Zfp334 668.0717103 -0.37324865 0.037003664 
Macrod1 92.37965427 -0.6127139 0.037003664 
Tpm4 611.9413651 -0.620607707 0.037003664 
Pcsk1 1622.814869 -0.625529329 0.037003664 
Eif1b 1057.062299 -0.392935774 0.03726989 
Fermt1 23.49651781 0.64203991 0.037741723 
Sla 157.7181719 0.761698607 0.037821413 
Vps54 908.4517066 -0.262131621 0.038176775 
Pnpla7 255.2539407 0.600818769 0.038430922 
Fst 74.75035124 -0.756646733 0.038545633 
Rbm12 645.9292839 -0.517472414 0.038787741 
Lsp1 60.36884356 0.637321032 0.040473264 
Btaf1 2049.640715 -0.485640918 0.040476961 
Rxfp1 177.8981938 0.792486359 0.040666532 
Csnk1g3 1429.198895 -0.423862244 0.040666532 
Nrip3 4947.985375 -0.790893302 0.040666532 
Tmem125 71.77060272 0.758371365 0.040671604 
Thtpa 494.8582559 0.349000728 0.040794623 
Prpf4b 1922.783934 -0.242666693 0.040794623 
Fbxl4 444.0242118 0.396986405 0.040954035 
Lrrc3 151.5238843 0.649258363 0.041192794 
Tcta 402.4993815 0.417356667 0.041192794 
Itgav 2611.745724 -0.522043736 0.041264724 
Glra2 264.2334171 0.766560508 0.041528244 
Crim1 1056.087269 0.433275457 0.041528244 
Bloc1s2 314.2896689 0.416468542 0.041528244 
Stxbp4 374.1884635 0.408046186 0.041528244 
Fastkd5 269.4321439 -0.485749953 0.041528244 
Hnrnpu 6756.010541 -0.202286759 0.041761233 
Ubxn4 1304.02424 -0.301593839 0.041761233 
Dot1l 282.4733137 -0.716663507 0.041789512 
Nasp 405.153679 -0.380904223 0.042009721 
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Arhgap5 6491.552685 -0.331082054 0.042244797 
Ly86 136.7343978 0.776980113 0.042435467 
Rgs14 546.0434137 0.628295866 0.042435467 
Ldhb 7538.778797 -0.3280831 0.042435467 
Ak6 157.9706359 -0.471063639 0.042435467 
Pappa 100.6720228 -0.56765568 0.042435467 
Mrgpre 78.94840937 0.668193834 0.042511733 
Aldh3a2 929.7738615 0.263342391 0.042511733 
Ccdc104 1741.008565 -0.262963675 0.042511733 
Ptpn2 678.3198282 -0.426861383 0.042511733 
Nab1 1115.259625 -0.460481998 0.042511733 
Parva 918.2988977 -0.476155573 0.042511733 
Zfp191 1077.878655 -0.488629724 0.042511733 
Fam129b 496.8007282 -0.51705798 0.042511733 
Eml5 2608.820476 -0.750043632 0.042511733 
Greb1 47.69709523 -0.813857478 0.042511733 
Mfge8 2063.985328 0.401355351 0.042540618 
Slc22a4 93.45429817 0.575932397 0.042545504 
Zfp688 99.267847 0.562869735 0.042545504 
Fam196a 283.2949386 -0.659058547 0.042545504 
9330158H04Rik 25.38967161 -0.801255535 0.042545504 
Ccar1 1138.437452 -0.405281064 0.042586064 
Sipa1l2 1074.107026 -0.434816824 0.042586064 
Tbxas1 33.00259622 0.779718748 0.042615894 
Rft1 192.4199222 0.446528809 0.042615894 
Rasgef1a 3848.428841 0.337996506 0.042615894 
Slc25a5 3821.692315 -0.279478029 0.042615894 
Ago3 753.1660453 -0.32145039 0.042615894 
Sfpq 1901.158922 -0.507601749 0.042615894 
Ddit3 401.9402025 -0.519394424 0.042884087 
Acin1 1217.975804 -0.351500216 0.043263642 
Orc4 935.9536075 -0.270464098 0.043610871 
Plxnb3 175.18908 0.569915857 0.04454409 
Cdkn1b 590.2571227 -0.465405105 0.04454409 
Gap43 2668.243286 0.51561217 0.044950541 
2810403A07Rik 1022.802103 -0.415314854 0.045055454 
Emd 421.7707151 -0.345148952 0.04533296 
Nkain2 1126.791657 0.471477623 0.04611416 
Dock9 2963.775171 0.380575182 0.04611416 
Aplp1 8272.014902 0.283936484 0.04611416 
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Fabp7 1393.986882 -0.683279548 0.04611416 
Epha2 38.25201826 -0.793212492 0.04611416 
Grn 470.6072881 0.531058742 0.046305225 
Cnp 3078.772429 0.490129348 0.046503566 
Ush1g 49.55456416 -0.734045148 0.046503566 
Kcng1 79.66458746 0.757117053 0.046922956 
Cnot4 813.6003365 -0.318948152 0.046922956 
Spag6 109.8793921 0.607310294 0.047256863 
Col24a1 80.57677881 -0.77171647 0.047256863 
Mcl1 1420.34159 -0.384350851 0.04794459 
Bche 77.84517263 0.645421499 0.048088238 
Gjd2 192.2906061 -0.798691058 0.048088238 
Dusp15 93.08014013 0.602060747 0.048603877 
Nkain1 366.4661956 0.426587335 0.048603877 
Ubp1 1064.921365 -0.241855636 0.048603877 
Erp44 647.6499607 -0.271740281 0.048603877 
Fam107a 5694.50116 0.532829983 0.048700958 
Eid2b 345.0538968 0.357047847 0.048700958 
Ece1 721.7328285 -0.435949571 0.048700958 
Tmtc2 412.0719401 -0.636079498 0.048700958 
Eml4 956.7595135 -0.310697123 0.049158362 
Hexb 1651.600503 0.520716735 0.049532179 
Arhgef7 1783.426782 -0.360189327 0.049532179 
G530011O06Rik 131.6423811 0.670340822 0.04963007 
Srsf3 3345.101232 -0.447099697 0.04963007 
Naa16 154.3510831 -0.547603529 0.04963007 
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Biocarta pathways downregulated in PS19 compared to non-transgenic cortex: 
 
BIOCARTA PATHWAY TERM Genes FDR 
PRE-MRNA SPLICING 127 0.000271653 
EPIGENETIC REGULATION OF GENE EXPRESSION 97 0.000362203 
PROCESSING OF CAPPED INTRON-CONTAINING PRE-MRNA 180 0.000543305 
MRNA SPLICING 134 0.000659793 
ACTIVATION OF HOX GENES DURING DIFFERENTIATION 80 0.009012016 
POSITIVE EPIGENETIC REGULATION OF RRNA EXPRESSION 76 0.009790198 
ACTIVATION OF ANTERIOR HOX GENES IN HINDBRAIN DEVELOPMENT DURING 
EARLY EMBRYOGENESIS 
80 0.010145887 
REGULATION OF NUCLEAR SMAD2 3 SIGNALING 66 0.010635647 
B-WICH COMPLEX POSITIVELY REGULATES RRNA EXPRESSION 52 0.010723694 
MUS MUSCULUS BIOLOGICAL PROCESSES 159 0.010807234 
NEGATIVE EPIGENETIC REGULATION OF RRNA EXPRESSION 66 0.010870594 
PRC2 METHYLATES HISTONES AND DNA 32 0.011775125 
POST-ELONGATION PROCESSING OF INTRON-CONTAINING PRE-MRNA 45 0.01726189 
E2F TRANSCRIPTION FACTOR NETWORK 60 0.01748339 
MRNA 3'-END PROCESSING 45 0.017818727 
MEIOTIC SYNAPSIS 64 0.017958378 
NORC NEGATIVELY REGULATES RRNA EXPRESSION 58 0.018208152 
MEIOTIC SYNAPSIS 64 0.018228175 
HATS ACETYLATE HISTONES 57 0.018274944 
NORC NEGATIVELY REGULATES RRNA EXPRESSION 59 0.01910769 
RNA POLYMERASE I PROMOTER OPENING 24 0.0209542 
CHROMATIN MODIFYING ENZYMES 145 0.02395577 
U12 DEPENDENT SPLICING 49 0.025673987 
DNA METHYLATION 46 0.025912846 
CHROMATIN ORGANIZATION 145 0.026157314 
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CLEAVAGE OF GROWING TRANSCRIPT IN THE TERMINATION REGION 53 0.02623047 
RNA POLYMERASE II TRANSCRIPTION TERMINATION 53 0.026399141 
ASSEMBLY OF COLLAGEN FIBRILS AND OTHER MULTIMERIC STRUCTURES 36 0.026487887 
POST-ELONGATION PROCESSING OF THE TRANSCRIPT 53 0.026895802 
RNA POLYMERASE II TRANSCRIPTION 116 0.027187131 
ACTIVATION OF RRNA EXPRESSION BY ERCC6 (CSB) AND EHMT2 (G9A) 45 0.029685078 
HDMS DEMETHYLATE HISTONES 40 0.035132237 
NOTCH1 INTRACELLULAR DOMAIN REGULATES TRANSCRIPTION 11 0.035509612 
MEIOTIC RECOMBINATION 56 0.036008976 
ATTENUATION PHASE 11 0.036743816 
TRANSPORT OF MATURE MRNA DERIVED FROM AN INTRON-CONTAINING 
TRANSCRIPT 
61 0.040467944 
MEIOSIS 75 0.042069327 
RNA POLYMERASE I CHAIN ELONGATION 51 0.0427764 
DIRECT P53 EFFECTORS 104 0.045629337 
TRANSPORT OF MATURE TRANSCRIPT TO CYTOPLASM 61 0.045926675 
SIRT1 NEGATIVELY REGULATES RRNA EXPRESSION 28 0.04623263 
IL5-MEDIATED SIGNALING EVENTS 11 0.049118035 
EPHA-MEDIATED GROWTH CONE COLLAPSE 24 0.049477573 
 
GO Biological Process terms significantly down-regulated in the transcriptome of PS19 
compared to non-transgenic cortex: 
 
GO BIOLOGICAL PROCESS TERM GENES FDR 
ENDOPLASMIC RETICULUM UNFOLDED PROTEIN RESPONSE 39 0.009888 
RNA SPLICING 167 0.011023 
MRNA METABOLIC PROCESS 277 0.017846 
RNA SPLICING, VIA TRANSESTERIFICATION REACTIONS 143 0.018357 
POST-EMBRYONIC CAMERA-TYPE EYE DEVELOPMENT 9 0.018628 
RNA SPLICING, VIA TRANSESTERIFICATION REACTIONS WITH BULGED ADENOSINE AS 
NUCLEOPHILE 
142 0.019134 
RESPONSE TO UNFOLDED PROTEIN 53 0.019336 
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REGULATION OF EPITHELIAL CELL DIFFERENTIATION 92 0.019872 
MRNA SPLICING, VIA SPLICEOSOME 142 0.021428 
CHEMICAL HOMEOSTASIS WITHIN A TISSUE 10 0.021699 
MRNA PROCESSING 192 0.022582 
TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 147 0.02464 
RNA PROCESSING 446 0.027469 
REGULATION OF EPITHELIAL CELL APOPTOTIC PROCESS 54 0.027701 
REGULATION OF ENDOTHELIAL CELL APOPTOTIC PROCESS 30 0.030094 
EMBRYONIC CAMERA-TYPE EYE MORPHOGENESIS 20 0.034615 
CARDIAC SEPTUM MORPHOGENESIS 38 0.034866 
SENSORY ORGAN MORPHOGENESIS 190 0.034955 
PULMONARY VALVE DEVELOPMENT 8 0.035016 
SKELETAL MUSCLE CELL DIFFERENTIATION 43 0.035701 
NEGATIVE REGULATION OF HEART CONTRACTION 18 0.035904 
MRNA TRANSPORT 43 0.035988 
POST-EMBRYONIC ORGAN DEVELOPMENT 17 0.036036 
MRNA-CONTAINING RIBONUCLEOPROTEIN COMPLEX EXPORT FROM NUCLEUS 37 0.038596 
EAR MORPHOGENESIS 82 0.040618 
NUCLEAR EXPORT 84 0.040893 
PROTEIN LOCALIZATION TO NUCLEUS 140 0.040907 
EAR DEVELOPMENT 157 0.041356 
PULMONARY VALVE MORPHOGENESIS 8 0.041625 
REGULATION OF EPIDERMIS DEVELOPMENT 43 0.04174 
PYRAMIDAL NEURON DEVELOPMENT 8 0.041928 
LENS DEVELOPMENT IN CAMERA-TYPE EYE 45 0.042083 
NEGATIVE REGULATION OF NOTCH SIGNALING PATHWAY 26 0.042171 
REGULATION OF MRNA PROCESSING 97 0.04221 
EMBRYONIC EYE MORPHOGENESIS 22 0.042369 
CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS 83 0.042628 
MRNA EXPORT FROM NUCLEUS 37 0.044195 
CELLULAR RESPONSE TO UNFOLDED PROTEIN 41 0.045278 
POSITIVE REGULATION OF EPITHELIAL CELL DIFFERENTIATION 38 0.045617 
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MRNA DESTABILIZATION 12 0.046078 
PROTEIN-DNA COMPLEX SUBUNIT ORGANIZATION 109 0.046311 
CANONICAL WNT SIGNALING PATHWAY INVOLVED IN NEGATIVE REGULATION OF 
APOPTOTIC PROCESS 
5 0.048363 
PROTEIN-DNA COMPLEX ASSEMBLY 84 0.049643 
REGULATION OF MRNA METABOLIC PROCESS 112 0.049835 
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Gene ontology (GO) Biological Process annotation terms enriched in the list of 
significantly alternatively spliced transcripts in PS19 compared to non-transgenic cortex: 
 
Reference No. GO Biological Process term FDR 
GO:0045202 synapse 4.55E-12 
GO:0042734 presynaptic membrane 3.84E-09 
GO:0016020 membrane 3.14E-08 
GO:0014069 postsynaptic density 5.61E-08 
GO:0005737 cytoplasm 1.50E-07 
GO:0031410 cytoplasmic vesicle 3.72E-07 
GO:0030425 dendrite 3.29E-06 
GO:0030054 cell junction 4.61E-06 
GO:0043025 neuronal cell body 7.79E-05 
GO:0043005 neuron projection 1.19E-04 
GO:0005886 plasma membrane 2.39E-04 
GO:0030426 growth cone 4.25E-04 
GO:0045211 postsynaptic membrane 0.002472 
GO:0008021 synaptic vesicle 0.002838 
GO:0043209 myelin sheath 0.003718 
GO:0043195 terminal bouton 0.006267 
GO:0030424 axon 0.008127 
GO:0043234 protein complex 0.049322 
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APPENDIX VI 
 
Quantification of exon inclusion indices for alternatively spliced transcripts in PS19 
compared to non-transgenic cortex: 
 
Gene P301S TIA1+/+ P301S TIA1+/- WT Tau TIA1+/- WT Tau TIA1+/+ Rescue? 
6430573F11Rik 0.0596 0.2312 0.3063 0.0019 No 
Aak1 0.8632 0.8960 0.9448 0.7750 No 
Abi2 0.3012 0.3759 0.2520 0.2839 No 
Acvr2a 0.1680 0.1474 0.1951 0.4101 No 
Adcyap1r1 0.4085 0.6231 0.4712 0.5312 Yes 
Adcyap1r1 0.3074 0.5137 0.3812 0.4082 Yes 
Add1 0.1672 0.2956 0.1974 0.2086 Yes 
Add1 0.1005 0.1886 0.1289 0.1410 Yes 
Aftph 0.8443 0.5766 0.8224 0.7747 Yes 
Alcam 0.5983 0.6842 0.6238 0.5132 No 
Ank2 0.2362 0.2926 0.2625 0.2707 Yes 
Ankrd12 0.9541 0.9340 0.9466 0.9696 No 
Anxa7 0.9282 0.8259 0.8981 0.9015 Yes 
Aplp2 0.8494 0.8697 0.8756 0.9015 Yes 
App 0.0194 0.0309 0.0212 0.0301 Yes 
App 0.0141 0.0224 0.0149 0.0205 Yes 
Arl6 0.0373 0.0804 0.1192 0.1316 Yes 
Armcx1 0.2381 0.6674 0.7202 0.2516 Yes 
Arpp21 0.0558 0.0263 0.0466 0.0280 Yes 
Atp2b1 0.9758 0.9387 0.9662 0.9482 Yes 
Atp5d 0.9834 0.9783 0.9890 0.9499 Yes 
Atp8a1 0.8795 0.7289 0.8261 0.8330 Yes 
Bin1 0.7475 0.7982 0.7145 0.8527 Yes 
Bin1 0.7918 0.8341 0.7517 0.8958 Yes 
Bin1 0.6517 0.8096 0.6307 0.7030 Yes 
Bin1 0.7695 0.7152 0.6572 0.7633 Yes 
Bsg 0.0032 0.0169 0.0039 0.0145 Yes 
Btbd9 0.9483 0.9239 0.7885 0.8140 Yes 
Btbd9 0.9314 0.9000 0.7446 0.7651 Yes 
Cacna1d 0.4259 0.1547 0.2597 0.2883 Yes 
Cacnb4 0.0478 0.0718 0.0361 0.0771 Yes 
Cadm1 0.3321 0.3673 0.3641 0.4517 Yes 
Cadm1 0.2981 0.3530 0.2689 0.3795 Yes 
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Cadps 0.4063 0.4309 0.4502 0.5597 Yes 
Cadps 0.1109 0.0500 0.0908 0.0645 Yes 
Cadps2 0.0117 0.1212 0.0210 0.0241 Yes 
Caly 0.0823 0.0865 0.0920 0.0539 No 
Camk2b 0.9914 0.8811 0.9765 0.9080 Yes 
Camk2b 0.8749 0.9107 0.8589 0.8475 No 
Camk2g 0.3147 0.4880 0.3772 0.4238 Yes 
Camk2g 0.5861 0.4758 0.5608 0.5455 Yes 
Camk2g 0.7633 0.6576 0.7973 0.7954 No 
Cask 0.6671 0.7709 0.6680 0.8578 Yes 
Cd47 0.0262 0.0564 0.0175 0.0157 No 
Cdk4 0.6495 0.7578 0.5861 0.8748 Yes 
Cdk4 0.8009 0.8631 0.7493 0.9261 Yes 
Chd5 0.9745 0.8706 0.9004 0.8630 Yes 
Chl1 0.0292 0.1061 0.0323 0.0862 Yes 
Clasp2 0.1949 0.2873 0.1815 0.2790 Yes 
Clcn3 0.0103 0.0237 0.0172 0.0080 No 
Clcn3 0.0094 0.0215 0.0146 0.0058 No 
Clstn1 0.4578 0.5674 0.5179 0.5288 Yes 
Clta 0.8795 0.9280 0.8857 0.8749 No 
Cltb 0.8506 0.7697 0.7870 0.7898 Yes 
Cltc 0.1651 0.1509 0.1685 0.2023 No 
Csde1 0.4481 0.4022 0.4869 0.4007 Yes 
Csgalnact1 0.0000 0.2039 0.1212 0.0857 Yes 
Csnk1a1 0.3641 0.3707 0.3852 0.3189 No 
Ctnna2 0.0791 0.1326 0.0842 0.1175 Yes 
Dbn1 0.9397 0.5560 0.8777 0.6740 Yes 
Dclk1 0.7200 0.5749 0.6899 0.6639 Yes 
Dctn2 0.9590 0.9717 0.9632 0.9284 No 
Dctn6 0.0122 0.0462 0.0316 0.0070 No 
Dctn6 0.0122 0.0602 0.0416 0.0070 No 
Dctn6 0.0137 0.0540 0.0361 0.0084 No 
Dcun1d2 0.9067 0.8758 0.9596 0.7867 Yes 
Dcun1d4 0.0059 0.0078 0.0033 0.0307 Yes 
Ddx39 0.2352 0.1949 0.2664 0.0682 Yes 
Dgkb 0.4532 0.6230 0.5523 0.6981 Yes 
Dlg1 0.3377 0.2708 0.3640 0.2704 Yes 
Dlg2 0.4045 0.9030 0.4423 0.7573 Yes 
Dlg2 0.0660 0.2862 0.0941 0.1864 Yes 
Dlg3 0.6327 0.6482 0.6336 0.4847 No 
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Dlgap1 0.8883 0.7230 0.7931 0.7488 Yes 
Dnm1l 0.6292 0.5199 0.6510 0.5312 Yes 
Dock10 0.3966 0.8278 0.6397 0.8938 Yes 
Dpf1 0.7221 0.8744 0.8172 0.7663 Yes 
Dtna 0.2646 0.2091 0.2242 0.1545 Yes 
Dync1i1 0.8662 0.6032 0.8040 0.6919 Yes 
Edem3 0.2655 0.2720 0.3128 0.1259 No 
Eef1d 0.2473 0.1395 0.3490 0.2063 Yes 
Eif2a 0.9141 0.9364 0.9377 0.8089 No 
Eif2a 0.8383 0.8948 0.8867 0.6821 No 
Eif3k 0.9871 0.9649 0.9423 0.9956 No 
Eif3k 0.9942 0.9839 0.9749 0.9981 No 
Eif4a2 0.0069 0.0060 0.0030 0.0044 Yes 
Eif4a2 0.0038 0.0038 0.0028 0.0030 No 
Eif4h 0.6746 0.7181 0.6959 0.6455 No 
Eml2 0.9267 0.7739 0.8785 0.8359 Yes 
Epb41l3 0.8451 0.7140 0.8049 0.7637 Yes 
Epha5 0.6490 0.4735 0.6127 0.4652 Yes 
Erc2 0.0620 0.2939 0.1365 0.2401 Yes 
Evl 0.1628 0.1983 0.1224 0.1093 No 
Ext2 0.0477 0.0765 0.0273 0.2032 Yes 
Fam107a 0.1322 0.1318 0.1384 0.1508 No 
Fam179b 0.0116 0.1116 0.1407 0.0366 Yes 
Fam49b 0.3083 0.2889 0.3068 0.3942 No 
Fbxo34 0.8736 0.7589 0.7853 0.9531 No 
Fibp 0.9706 0.7933 0.9608 0.9082 Yes 
Fkbp1a 0.0431 0.0450 0.0632 0.0657 Yes 
Fkbp1a 0.0352 0.0371 0.0548 0.0565 Yes 
Flywch1 0.6204 0.5252 0.5677 0.6561 No 
Flywch1 0.5570 0.4330 0.5082 0.5875 No 
G3bp2 0.9080 0.8616 0.9041 0.8422 Yes 
Gabrg2 0.5387 0.3873 0.5647 0.4891 Yes 
Gnb1 0.8292 0.7547 0.8253 0.8098 Yes 
Golga1 0.6876 0.6120 0.5504 0.9014 No 
Gphn 0.3022 0.1847 0.1938 0.2039 Yes 
Gpm6b 0.3615 0.4187 0.3485 0.3787 Yes 
Gria2 0.3834 0.4884 0.4947 0.5244 Yes 
Gria2 0.0072 0.0145 0.0126 0.0102 Yes 
Gria2 0.3578 0.2407 0.2596 0.2389 Yes 
Gria3 0.1084 0.1352 0.1415 0.1553 Yes 
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Gria3 0.7857 0.6965 0.7236 0.6214 Yes 
Grm5 0.9022 0.7819 0.8926 0.8846 Yes 
Hnrnpc 0.7446 0.6503 0.7232 0.7573 No 
Hnrnpc 0.6221 0.5163 0.5908 0.6316 No 
Ica1 0.7980 0.8265 0.7824 0.6199 No 
Ift57 0.9827 0.9015 0.9587 0.9452 Yes 
Immt 0.9515 0.9346 0.9334 0.8688 Yes 
Immt 0.9160 0.8922 0.8864 0.7857 Yes 
Kank1 0.9231 0.3929 0.4000 0.2857 Yes 
Kat5 0.4322 0.5931 0.5018 0.4022 No 
Kcnc2 0.2597 0.3923 0.2240 0.3830 Yes 
Kcnd3 0.3253 0.6899 0.3418 0.4208 Yes 
Kcnip1 0.3550 0.1935 0.3887 0.2935 Yes 
Kctd17 0.2129 0.2080 0.2902 0.1151 Yes 
Kctd17 0.2159 0.2081 0.2911 0.1145 Yes 
Kidins220 0.1081 0.1425 0.0852 0.1422 Yes 
Kidins220 0.5185 0.4816 0.4637 0.5960 No 
Kif1a 0.5837 0.5263 0.6299 0.6075 No 
Kif1a 0.3945 0.5090 0.4269 0.3813 No 
Kif1b 0.9380 0.8659 0.9007 0.8576 Yes 
Klc1 0.8368 0.7871 0.7685 0.8429 No 
Klhl13 0.5964 0.5080 0.7835 0.4818 Yes 
Ktn1 0.5575 0.5956 0.6059 0.4343 No 
Limch1 0.9653 0.8347 0.9282 0.8620 Yes 
Lime1 0.7639 0.8592 0.7576 0.5500 No 
Lmbr1 0.0897 0.2112 0.1919 0.2599 Yes 
Mag 0.7353 0.7615 0.7994 0.6333 No 
Magi1 0.9757 0.7691 0.7260 0.9717 Yes 
Map4 0.2953 0.4287 0.2714 0.4193 Yes 
Map4 0.5038 0.4269 0.4721 0.3861 Yes 
Matk 0.0315 0.0071 0.0202 0.0215 Yes 
Max 0.4519 0.3797 0.2687 0.5685 No 
Mcf2l 0.8977 0.6635 0.9038 0.7067 Yes 
Mcf2l 0.7046 0.5590 0.6772 0.4886 Yes 
Mcf2l 0.5910 0.4128 0.5608 0.3677 Yes 
Mettl23 0.3977 0.3823 0.2467 0.5518 No 
Mettl23 0.3985 0.3249 0.1409 0.4619 No 
Mff 0.7131 0.5891 0.6335 0.6897 Yes 
Mff 0.6992 0.6010 0.6168 0.6572 Yes 
Mgat1 0.4842 0.5311 0.5731 0.7829 Yes 
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Morf4l2 0.1615 0.1704 0.1611 0.2340 Yes 
Morf4l2 0.0753 0.0887 0.0788 0.1105 Yes 
Mprip 0.6515 0.7525 0.7698 0.6374 No 
Mtf2 0.5205 0.4825 0.4103 0.7441 No 
Mtmr1 0.2465 0.3959 0.2896 0.4828 Yes 
Mtmr1 0.7494 0.5736 0.5044 0.4812 Yes 
Myt1l 0.0000 0.0389 0.0303 0.0000 Yes 
Nae1 0.9369 0.9200 0.9261 0.7557 Yes 
Ncam1 0.7171 0.4721 0.6170 0.4998 Yes 
Ncdn 0.1021 0.1339 0.1188 0.1190 Yes 
Nckap1 0.7137 0.6070 0.6800 0.6427 Yes 
Ndrg2 0.2336 0.2369 0.2941 0.2932 Yes 
Ndrg4 0.8296 0.6776 0.8692 0.6734 Yes 
Neurl4 0.2117 0.3563 0.2440 0.3184 Yes 
Neurl4 0.1080 0.2339 0.1253 0.1631 Yes 
Nin 0.1609 0.5468 0.3824 0.3171 Yes 
Nnat 0.5201 0.6480 0.4374 0.6939 Yes 
Nnat 0.5239 0.6475 0.4393 0.6826 Yes 
Nnat 0.6189 0.7583 0.5570 0.7733 Yes 
Nptn 0.6476 0.5475 0.6700 0.5737 Yes 
Nrsn1 0.0162 0.0437 0.0290 0.0409 Yes 
Nrxn1 0.3689 0.4826 0.4587 0.4544 Yes 
Nrxn1 0.4295 0.3526 0.4355 0.4196 Yes 
Nrxn2 0.3147 0.6257 0.3814 0.5334 Yes 
Nrxn2 0.4256 0.2797 0.4601 0.2787 Yes 
Nrxn2 0.5756 0.4068 0.6035 0.3982 Yes 
Nrxn3 0.5679 0.7686 0.6565 0.7515 Yes 
Nt5c2 0.0638 0.1729 0.1555 0.1839 Yes 
Numb 0.0320 0.1043 0.0607 0.1815 Yes 
Ocel1 0.3384 0.3768 0.2447 0.1448 No 
Oxr1 0.8301 0.8748 0.8025 0.7564 No 
Paip2 0.0568 0.0338 0.0335 0.0214 Yes 
Palm 0.2057 0.1579 0.2726 0.1468 Yes 
Papss1 0.0046 0.2687 0.1411 0.0832 Yes 
Pcbp3 0.0599 0.4290 0.2051 0.3290 Yes 
Pcbp3 0.0206 0.0649 0.0073 0.1054 Yes 
Pdlim7 0.7392 0.4449 0.7487 0.6050 Yes 
Pdp1 0.7288 0.7585 0.6933 0.8155 Yes 
Penk 0.9992 0.9837 0.9936 0.9241 Yes 
Picalm 0.6478 0.5286 0.7118 0.5396 Yes 
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Pkp4 0.4640 0.3649 0.3790 0.3497 Yes 
Pla2g6 0.3259 0.5396 0.3884 0.2143 No 
Ppfibp1 0.4243 0.7452 0.4882 0.7984 Yes 
Ppp1r12a 0.4231 0.5780 0.4407 0.5548 Yes 
Ppp3ca 0.8396 0.8535 0.8756 0.8312 No 
Ppp3cb 0.0497 0.1135 0.0591 0.1049 Yes 
Prepl 0.0565 0.0394 0.0601 0.0879 No 
Prepl 0.0648 0.0484 0.0677 0.0961 No 
Prepl 0.0807 0.0597 0.0872 0.1111 No 
Prkar1a 0.9246 0.8711 0.9168 0.9099 Yes 
Prnp 0.0053 0.0027 0.0045 0.0094 No 
Prpf18 0.7790 0.5824 0.7918 0.6073 Yes 
Prpf3 0.1007 0.1233 0.2903 0.0401 No 
Ptprt 0.2946 0.1428 0.2821 0.2292 Yes 
R3hdm1 0.9224 0.8107 0.8719 0.7686 Yes 
Rab28 0.2192 0.1809 0.2027 0.3098 No 
Rbm39 0.1243 0.1188 0.1055 0.0795 Yes 
Reps2 0.8052 0.8166 0.8297 0.6730 No 
Rgs7 0.7574 0.5123 0.5326 0.6468 Yes 
Rgs7 0.7905 0.6073 0.5973 0.6403 Yes 
Rian 0.5143 0.5236 0.4751 0.6135 Yes 
Rims2 0.2090 0.2783 0.2331 0.2420 Yes 
Rnf114 0.1727 0.3916 0.2281 0.3337 Yes 
Rnf114 0.1140 0.2924 0.1710 0.2617 Yes 
Rnf13 0.0945 0.0797 0.1272 0.1454 No 
Robo2 0.3476 0.2394 0.3571 0.3649 No 
Rpe 0.2298 0.0739 0.1830 0.1913 Yes 
Rpl17 0.1169 0.0609 0.2549 0.0615 Yes 
Rps24 0.2555 0.3287 0.4463 0.3955 Yes 
Rtn3 0.1894 0.1395 0.1721 0.1935 No 
Sars 0.2690 0.2386 0.2741 0.2146 Yes 
Sbf1 0.1573 0.3402 0.2132 0.2498 Yes 
Sbf2 0.2943 0.0438 0.1447 0.2451 Yes 
Scnm1 0.9885 0.8113 0.8340 0.9912 No 
Senp7 0.7508 0.8512 0.8302 0.6235 No 
Setd3 0.9114 0.8681 0.9003 0.9367 No 
Sf3b1 0.0388 0.0685 0.0483 0.0453 Yes 
Sgip1 0.7772 0.5960 0.7767 0.6548 Yes 
Shisa7 0.0554 0.3822 0.0963 0.0768 Yes 
Shisa9 0.7274 0.4832 0.5151 0.2880 Yes 
  
192 
Slc12a6 0.0584 0.1005 0.1646 0.0563 No 
Slc30a9 0.9559 0.9303 0.9720 0.8864 Yes 
Slc30a9 0.9204 0.8695 0.9505 0.8022 Yes 
Slc4a10 0.2234 0.1356 0.2278 0.2554 No 
Slc4a4 0.3228 0.5042 0.4927 0.4599 Yes 
Snap91 0.9924 0.9858 0.9806 0.9536 Yes 
Snrnp70 0.1734 0.2186 0.2067 0.1172 No 
Snrnp70 0.1746 0.2221 0.2046 0.1107 No 
Son 0.0912 0.0933 0.0798 0.0464 No 
Sorbs1 0.8768 0.5938 0.7730 0.6434 Yes 
Sorbs1 0.7201 0.1664 0.4020 0.3967 Yes 
Sptan1 0.8813 0.7609 0.8462 0.8360 Yes 
Sptan1 0.0440 0.0236 0.0541 0.0715 No 
Ssbp4 0.9923 0.6993 0.6945 0.9967 No 
Stoml1 0.0519 0.0714 0.0483 0.1237 Yes 
Stx3 0.7565 0.4063 0.8455 0.3972 Yes 
Stxbp5l 0.3791 0.2388 0.2415 0.3006 Yes 
Stxbp5l 0.6743 0.8391 0.6713 0.6641 No 
Synpo 0.4067 0.3664 0.4819 0.5832 No 
Syt6 0.5543 0.8349 0.6539 0.8206 Yes 
Syt7 0.3925 0.2422 0.3516 0.2374 Yes 
Tbc1d19 0.0978 0.0364 0.1086 0.1590 No 
Tecr 0.3467 0.3698 0.4009 0.3050 No 
Tma7 0.9390 0.9499 0.9419 0.8491 No 
Tmem222 0.0219 0.0351 0.0272 0.0745 Yes 
Tmem57 0.1391 0.1394 0.1128 0.0775 No 
Tnk2 0.9691 0.8994 0.9008 0.8583 Yes 
Tnrc18 0.3556 0.5501 0.4949 0.0885 No 
Tom1l2 0.1025 0.2215 0.1541 0.2327 Yes 
Tor1aip1 0.0032 0.0259 0.0634 0.3454 Yes 
Tor1aip2 0.3530 0.1699 0.2602 0.2404 Yes 
Trank1 0.1207 0.1881 0.1801 0.2018 Yes 
Trp53bp1 0.2378 0.3521 0.2801 0.4143 Yes 
Ttc3 0.2161 0.2847 0.2292 0.3400 Yes 
Ttc3 0.0673 0.0939 0.0789 0.1031 Yes 
Ttc3 0.3265 0.2602 0.2759 0.3508 No 
Ttyh1 0.9363 0.9272 0.8993 0.9492 No 
Tusc3 0.9981 0.9773 0.9817 0.9975 Yes 
Ubp1 0.7710 0.7553 0.7374 0.5921 Yes 
Uhrf1bp1l 0.1147 0.3703 0.2032 0.2521 Yes 
  
193 
Unc80 0.8966 0.7395 0.8230 0.8445 Yes 
Unkl 0.8108 0.4725 0.7568 1.0000 No 
Usp47 0.5425 0.3680 0.5277 0.4318 Yes 
Vopp1 0.0786 0.1536 0.1913 0.1008 Yes 
Wdr37 0.0441 0.0691 0.0372 0.1488 Yes 
Ybx1 0.6216 0.7237 0.6111 0.8114 Yes 
Ypel3 0.9731 0.9127 0.9674 0.9401 Yes 
Zfp266 0.9098 0.8833 0.7951 0.9774 No 
Zfp385b 0.9504 0.7091 0.8483 0.8885 Yes 
Zfp638 0.3117 0.3829 0.3007 0.2840 No 
Zfp869 0.0000 0.3751 0.2468 0.0326 Yes 
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GO Cellular Component annotation terms enriched in the list of transcripts significantly 
alternatively spliced in P301S TIA1+/- compared to P301S TIA1+/+ cortex: 
 
Reference No. GO annotation term FDR 
GO:0045202 synapse 3.86E-12 
GO:0014069 postsynaptic density 4.33E-12 
GO:0042734 presynaptic membrane 1.14E-10 
GO:0005737 cytoplasm 1.56E-09 
GO:0030054 cell junction 9.92E-08 
GO:0016020 membrane 1.49E-07 
GO:0005913 cell-cell adherens junction 6.72E-07 
GO:0043005 neuron projection 5.61E-06 
GO:0030425 dendrite 5.79E-06 
GO:0043025 neuronal cell body 3.35E-05 
GO:0045211 postsynaptic membrane 1.04E-04 
GO:0008021 synaptic vesicle 2.29E-04 
GO:0005856 cytoskeleton 2.57E-04 
GO:0043231 intracellular membrane-bounded organelle 0.020258 
GO:0005905 clathrin-coated pit 0.024042 
GO:0005829 cytosol 0.028241 
GO:0043195 terminal bouton 0.035357 
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APPENDIX VIII 
 
iBAQ Quantitative values (normalized to Mapt = 1000 within each sample) detected by 
OrbiTrap LC-MS/MS following tau IP from 6 month non-transgenic (WT Tau TIA1+/+) 
cortex (listed in descending order of average abundance): 
 
Gene ID Sample #1 Sample #2 Sample #3 Avg 
Mapt 1000.0 1000.0 1000.0 1000.0 
Tubb3 624.1 894.3 936.7 818.4 
Tuba4a 449.3 679.1 737.6 622.0 
Tubb2a 391.6 549.9 581.4 507.7 
Tubb2b 389.9 546.0 574.7 503.5 
Tubb4b 381.1 540.1 561.1 494.1 
Tubb5 342.7 501.0 520.4 454.7 
Tubb4a 344.4 483.4 509.0 445.6 
Tuba8 264.0 397.3 425.3 362.2 
Tubb6 178.3 246.6 269.2 231.4 
Epb41l3 124.1 117.4 176.5 139.3 
Tubb1 82.2 101.8 113.1 99.0 
Synj1 59.4 47.0 76.9 61.1 
Atp2b4 43.7 54.8 83.7 60.7 
Psd3 38.5 48.9 92.8 60.0 
Cpne6 50.7 54.8 72.4 59.3 
Hnrnpu 24.5 56.8 70.1 50.5 
Adam22 24.5 58.7 58.8 47.3 
Tf 31.5 39.1 58.8 43.1 
Actn1 24.5 17.6 67.9 36.7 
Ctnnb1 31.5 23.5 36.2 30.4 
Gs 22.7 37.2 29.4 29.8 
Plcb1 0.0 47.0 36.2 27.7 
Sfpq 24.5 31.3 27.1 27.6 
Atp2b3 17.5 23.5 36.2 25.7 
Lta4h 22.7 29.4 20.4 24.1 
Nars 15.7 23.5 24.9 21.4 
Map1b 17.5 23.5 22.6 21.2 
Psmd1 10.5 27.4 22.6 20.2 
Inpp4a 17.5 19.6 18.1 18.4 
Syt7 15.7 27.4 11.3 18.1 
Aldh6a1 14.0 19.6 20.4 18.0 
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Ptpn11 15.7 11.7 22.6 16.7 
Prpsap2 17.5 13.7 18.1 16.4 
Trim2 15.7 17.6 13.6 15.6 
Pip4k2b 8.7 19.6 18.1 15.5 
Actn4 10.5 7.8 24.9 14.4 
Fus 10.5 27.4 4.5 14.1 
Nmt1 7.0 9.8 24.9 13.9 
Maob 10.5 15.7 13.6 13.2 
Capzb 8.7 19.6 11.3 13.2 
Pip4k2a 8.7 15.7 13.6 12.7 
Etfdh 8.7 15.7 13.6 12.7 
Csnk2a1 8.7 17.6 11.3 12.6 
Syncrip 8.7 13.7 13.6 12.0 
Arfgap1 8.7 13.7 13.6 12.0 
Nono 7.0 19.6 9.0 11.9 
Hnrnpr 8.7 9.8 15.8 11.5 
Capn2 8.7 9.8 15.8 11.5 
Dctn2 8.7 11.7 13.6 11.4 
Tmx2 10.5 9.8 13.6 11.3 
Acsl1 12.2 9.8 11.3 11.1 
Tu52 7.0 7.8 18.1 11.0 
Cpne5 12.2 13.7 6.8 10.9 
Camkk1 10.5 3.9 18.1 10.8 
Hnrnpl 10.5 9.8 11.3 10.5 
Slc6a1 10.5 9.8 11.3 10.5 
Mpi 10.5 11.7 9.0 10.4 
Exog 10.5 11.7 9.0 10.4 
Kcna1 7.0 7.8 15.8 10.2 
Coro1b 5.2 13.7 11.3 10.1 
Adam23 8.7 5.9 13.6 9.4 
Xpnpep1 7.0 9.8 11.3 9.4 
Tmpo 7.0 11.7 9.0 9.3 
Lingo1 8.7 9.8 9.0 9.2 
Slc6a11 10.5 7.8 9.0 9.1 
Cops6 8.7 11.7 6.8 9.1 
Psip1 5.2 7.8 13.6 8.9 
Sccpdh 5.2 9.8 11.3 8.8 
Arl6ip5 7.0 7.8 11.3 8.7 
Prep 5.2 11.7 9.0 8.7 
Thop1 5.2 11.7 9.0 8.7 
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Serbp1 1.7 9.8 13.6 8.4 
Slc25a18 3.5 9.8 11.3 8.2 
Ap1m1 3.5 11.7 9.0 8.1 
Sugt1 7.0 7.8 9.0 8.0 
Icam5 7.0 7.8 9.0 8.0 
Gsr 7.0 7.8 9.0 8.0 
Hexb 7.0 7.8 9.0 8.0 
Wasf3 7.0 7.8 9.0 8.0 
Slc6a17 7.0 7.8 9.0 8.0 
Nfasc 8.7 7.8 6.8 7.8 
Hdgf 5.2 3.9 13.6 7.6 
Tceal5 14.0 3.9 4.5 7.5 
Slc30a3 3.5 3.9 13.6 7.0 
Flot1 0.0 11.7 9.0 6.9 
Psmc2 3.5 5.9 11.3 6.9 
Hdgfrp3 3.5 7.8 9.0 6.8 
Cpne4 5.2 5.9 9.0 6.7 
Gucy1b3 5.2 5.9 9.0 6.7 
Dusp3 5.2 7.8 6.8 6.6 
Cacnb4 7.0 5.9 6.8 6.6 
Mtpn 7.0 7.8 4.5 6.4 
Iqsec1 0.0 9.8 9.0 6.3 
Fkbp4 1.7 7.8 9.0 6.2 
Maoa 3.5 5.9 9.0 6.1 
Nlgn3 5.2 3.9 9.0 6.1 
Srsf3 3.5 7.8 6.8 6.0 
Rars 3.5 7.8 6.8 6.0 
Cstb 5.2 5.9 6.8 6.0 
Asns 5.2 5.9 6.8 6.0 
Scamp5 5.2 5.9 6.8 6.0 
Bzw1 5.2 5.9 6.8 6.0 
Tmem163 5.2 5.9 6.8 6.0 
Cars 5.2 7.8 4.5 5.9 
Srsf1 7.0 5.9 4.5 5.8 
Sec14l2 0.0 7.8 9.0 5.6 
Ndufa11 1.7 5.9 9.0 5.6 
Cenpv 3.5 3.9 9.0 5.5 
U2af2 3.5 3.9 9.0 5.5 
Tpp2 3.5 3.9 9.0 5.5 
Mapk10 1.7 7.8 6.8 5.5 
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Atl2 1.7 7.8 6.8 5.5 
Ncs1 5.2 2.0 9.0 5.4 
Kpna3 3.5 5.9 6.8 5.4 
Srpk2 3.5 5.9 6.8 5.4 
Ap3m2 1.7 9.8 4.5 5.4 
Alyref 5.2 3.9 6.8 5.3 
Snrpb 5.2 3.9 6.8 5.3 
Them4 5.2 3.9 6.8 5.3 
Acot1 3.5 7.8 4.5 5.3 
Gclc 3.5 7.8 4.5 5.3 
Nudt21 5.2 5.9 4.5 5.2 
Mccc2 5.2 5.9 4.5 5.2 
Rpl27 7.0 3.9 4.5 5.1 
Slc4a4 1.7 3.9 9.0 4.9 
Chm 3.5 3.9 6.8 4.7 
Pcyt2 3.5 3.9 6.8 4.7 
Upf1 1.7 7.8 4.5 4.7 
Wbp2 1.7 7.8 4.5 4.7 
Lypla1 5.2 2.0 6.8 4.7 
Ppp6c 5.2 2.0 6.8 4.7 
Ilf2 3.5 5.9 4.5 4.6 
Hnrnpll 3.5 5.9 4.5 4.6 
Akr7a2 3.5 5.9 4.5 4.6 
Rpl11 3.5 5.9 4.5 4.6 
Cat 3.5 5.9 4.5 4.6 
Rabggta 3.5 5.9 4.5 4.6 
Rpl23 3.5 5.9 4.5 4.6 
Vta1 3.5 5.9 4.5 4.6 
Puf60 5.2 3.9 4.5 4.6 
Aqp4 5.2 3.9 4.5 4.6 
Coro1c 3.5 7.8 2.3 4.5 
Kpna1 3.5 7.8 2.3 4.5 
Coasy 7.0 2.0 4.5 4.5 
Gnl1 1.7 2.0 9.0 4.3 
Fxr2 1.7 3.9 6.8 4.1 
Snx27 1.7 3.9 6.8 4.1 
Stk32c 1.7 3.9 6.8 4.1 
Ap3d1 1.7 3.9 6.8 4.1 
Uba3 0.0 7.8 4.5 4.1 
Tssc1 0.0 7.8 4.5 4.1 
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Bub3 3.5 2.0 6.8 4.1 
Aldh1b1 3.5 2.0 6.8 4.1 
Kcna3 3.5 2.0 6.8 4.1 
Chordc1 3.5 2.0 6.8 4.1 
Snrpa 3.5 3.9 4.5 4.0 
Ddx17 3.5 3.9 4.5 4.0 
Prkcd 3.5 3.9 4.5 4.0 
Gsn 3.5 3.9 4.5 4.0 
Hint3 3.5 3.9 4.5 4.0 
mKIAA1101 3.5 3.9 4.5 4.0 
Sord 3.5 3.9 4.5 4.0 
Clic4 3.5 3.9 4.5 4.0 
Sec23a 1.7 7.8 2.3 3.9 
Dctn3 5.2 2.0 4.5 3.9 
Ppp4c 3.5 5.9 2.3 3.9 
Pgm3 3.5 5.9 2.3 3.9 
Dhrs4 5.2 3.9 2.3 3.8 
Fmr1 5.2 3.9 2.3 3.8 
Arpc5l 5.2 3.9 2.3 3.8 
Cds2 1.7 2.0 6.8 3.5 
Anxa11 1.7 2.0 6.8 3.5 
Rpl23a 1.7 3.9 4.5 3.4 
Cmas 1.7 3.9 4.5 3.4 
Srsf7 1.7 3.9 4.5 3.4 
Fkbp2 1.7 3.9 4.5 3.4 
Gmppb 0.0 7.8 2.3 3.4 
Serpinb6 3.5 2.0 4.5 3.3 
Lppr4 3.5 2.0 4.5 3.3 
Rabggtb 3.5 2.0 4.5 3.3 
Prune 1.7 5.9 2.3 3.3 
Rps15 3.5 3.9 2.3 3.2 
Ckap4 3.5 3.9 2.3 3.2 
Fam126b 3.5 3.9 2.3 3.2 
Slc17a6 3.5 3.9 2.3 3.2 
Ephx2 1.7 7.8 0.0 3.2 
C3 5.2 2.0 2.3 3.2 
Trim9 3.5 5.9 0.0 3.1 
Srsf5 0.0 3.9 4.5 2.8 
Hdac2 0.0 3.9 4.5 2.8 
Snrpd1 1.7 2.0 4.5 2.7 
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Rpl22 1.7 2.0 4.5 2.7 
Abhd16a 1.7 2.0 4.5 2.7 
Aldh3b1 1.7 2.0 4.5 2.7 
Mfn2 1.7 2.0 4.5 2.7 
Ptbp2 1.7 2.0 4.5 2.7 
Csnk2a2 0.0 5.9 2.3 2.7 
Prepl 0.0 5.9 2.3 2.7 
Rps7 1.7 3.9 2.3 2.6 
Ndufs4 1.7 3.9 2.3 2.6 
Pdap1 1.7 3.9 2.3 2.6 
Trove2 1.7 3.9 2.3 2.6 
Sec31a 1.7 3.9 2.3 2.6 
Smpd3 1.7 3.9 2.3 2.6 
Vps53 1.7 3.9 2.3 2.6 
Opa3 3.5 2.0 2.3 2.6 
Abhd6 3.5 2.0 2.3 2.6 
Cpt1c 3.5 2.0 2.3 2.6 
Fxyd7 3.5 2.0 2.3 2.6 
Nucb1 3.5 2.0 2.3 2.6 
Lphn3 5.2 2.0 0.0 2.4 
Rangap1 5.2 2.0 0.0 2.4 
Serpina1a 0.0 0.0 6.8 2.3 
Dhx15 0.0 2.0 4.5 2.2 
Acot11 0.0 2.0 4.5 2.2 
Nmt2 0.0 2.0 4.5 2.2 
Gm5414 1.7 0.0 4.5 2.1 
Actn2 1.7 0.0 4.5 2.1 
Srsf2 1.7 0.0 4.5 2.1 
Hdgfrp2 1.7 0.0 4.5 2.1 
Mecp2 1.7 0.0 4.5 2.1 
Capn5 1.7 0.0 4.5 2.1 
Copb2 1.7 0.0 4.5 2.1 
Gmpr2 1.7 0.0 4.5 2.1 
Klhl22 1.7 0.0 4.5 2.1 
Lpcat4 1.7 0.0 4.5 2.1 
Numbl 1.7 0.0 4.5 2.1 
Gria1 0.0 3.9 2.3 2.1 
Rbbp7 0.0 3.9 2.3 2.1 
Lphn1 0.0 3.9 2.3 2.1 
Mogs 0.0 3.9 2.3 2.1 
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Ncln 0.0 3.9 2.3 2.1 
Trappc4 0.0 3.9 2.3 2.1 
Glrx3 1.7 2.0 2.3 2.0 
Na 1.7 2.0 2.3 2.0 
Csnk2b 1.7 2.0 2.3 2.0 
Snrpe 1.7 2.0 2.3 2.0 
Vgf 1.7 2.0 2.3 2.0 
Rpl38 1.7 2.0 2.3 2.0 
Sh3bgrl 1.7 2.0 2.3 2.0 
Pithd1 1.7 2.0 2.3 2.0 
Nefm 1.7 2.0 2.3 2.0 
Vim 1.7 2.0 2.3 2.0 
Cpne7 1.7 2.0 2.3 2.0 
Rpl13a 1.7 2.0 2.3 2.0 
Nckipsd 0.0 5.9 0.0 2.0 
Prodh 3.5 0.0 2.3 1.9 
Txnrd2 3.5 0.0 2.3 1.9 
Top1 1.7 3.9 0.0 1.9 
Elavl1 1.7 3.9 0.0 1.9 
Pa2g4 1.7 3.9 0.0 1.9 
Scn1b 1.7 3.9 0.0 1.9 
Serpinh1 1.7 3.9 0.0 1.9 
Snrpd3 3.5 2.0 0.0 1.8 
H3f3c 3.5 2.0 0.0 1.8 
Pepd 3.5 2.0 0.0 1.8 
Cyld 3.5 2.0 0.0 1.8 
Lrrc47 3.5 2.0 0.0 1.8 
Sdhc 3.5 2.0 0.0 1.8 
Slc6a3 3.5 2.0 0.0 1.8 
Mrpl46 0.0 0.0 4.5 1.5 
Apeh 0.0 0.0 4.5 1.5 
Srsf6 0.0 2.0 2.3 1.4 
Srsf4 0.0 2.0 2.3 1.4 
Capza1 0.0 2.0 2.3 1.4 
Dctn4 0.0 2.0 2.3 1.4 
Usp7 0.0 2.0 2.3 1.4 
Slc39a10 0.0 2.0 2.3 1.4 
Ap3s2 0.0 2.0 2.3 1.4 
Twf1 0.0 3.9 0.0 1.3 
Metap2 0.0 3.9 0.0 1.3 
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U2af1 1.7 2.0 0.0 1.2 
Fxr1 1.7 2.0 0.0 1.2 
Ubap2l 1.7 2.0 0.0 1.2 
 
 
Keyword functional annotation terms significantly enriched (FDR < 0.05) in the non-
transgenic (WT Tau TIA1+/+) tau interactome: 
 
Keyword functional annotation term FDR 
Acetylation 4.91E-45 
Phosphoprotein 9.51E-33 
Cytoplasm 5.52E-21 
RNA-binding 8.55E-13 
Methylation 6.45E-12 
mRNA splicing 1.15E-11 
Ribonucleoprotein 3.54E-11 
mRNA processing 2.70E-10 
Cytoskeleton 1.34E-05 
Isopeptide bond 3.07E-04 
Microtubule 0.003569 
Viral nucleoprotein 0.005842 
Transport 0.009956 
Spliceosome 0.011854 
Nucleotide-binding 0.016928 
Virion 0.01708 
Hydrolase 0.020885 
Synapse 0.026073 
GTP-binding 0.047148 
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iBAQ quantitative values (normalized to MAPT = 1000) detected in tau IP samples 
(n=3/genotype) of 6 month P301S TIA1+/+ and P301S TIA1+/- cortex by OrbiTrap LC-
MS/MS: 
 
Protein ID TIA1+/
+ #1 
TIA1+/
+ #2 
TIA1+/
+ #3 
TIA1+/
+ Avg 
TIA1+/- 
#1 
TIA1+/- 
#2 
TIA1+/- 
#3 
TIA1+/- 
Avg 
Fold 
Change 
MAPT 1000.00
0 
1000.00
0 
1000.00
0 
1000.00
0 
1000.00
0 
1000.00
0 
1000.00
0 
1000.00
0 
1.000 
PLP1 85.034 29.973 71.267 62.091 168.750 77.002 58.296 101.349 1.632 
GLUL 71.629 16.576 44.234 44.146 51.273 117.214 55.580 74.689 1.692 
DCTN2 39.216 10.899 21.550 23.888 25.521 84.959 23.430 44.637 1.869 
ACTR1A 28.511 8.364 19.197 18.691 12.397 55.441 11.771 26.537 1.420 
ACTR1B 24.610 7.668 17.769 16.683 11.202 52.105 9.081 24.129 1.446 
PPP3CA 11.485 5.975 10.851 9.437 24.479 6.853 11.883 14.405 1.527 
CAPZA2 8.723 2.744 5.803 5.757 13.508 15.683 4.634 11.275 1.958 
HTRA1 4.162 1.314 8.431 4.635 43.576 13.270 22.085 26.311 5.676 
PPP3CB 5.122 3.163 4.858 4.381 8.420 3.670 3.924 5.338 1.218 
DLST 6.122 1.129 4.083 3.778 10.658 8.830 4.559 8.015 2.122 
2210010C04R
IK 
9.684 1.061 0.000 3.582 12447.9
17 
2.695 6.876 4152.49
6 
1159.41
9 
SNAP25 3.942 0.770 5.085 3.266 15.171 6.391 2.900 8.154 2.497 
HBAT1 3.081 1.333 4.915 3.110 2.030 2.143 1.913 2.029 0.652 
CAPZB 4.642 1.294 3.138 3.025 7.188 9.292 2.920 6.466 2.138 
DCTN4 6.242 1.168 1.580 2.997 1.124 7.546 1.016 3.229 1.077 
PPP2R1A 4.582 1.635 2.703 2.973 5.361 3.491 1.767 3.539 1.190 
DPYSL3 2.901 1.216 3.554 2.557 6.827 5.493 2.209 4.843 1.894 
ACTR10 4.722 0.705 2.155 2.527 0.000 4.825 0.200 1.675 0.663 
ARF3 3.822 0.572 2.873 2.422 13.219 4.569 1.021 6.270 2.588 
SRSF7 3.061 0.408 3.478 2.316 5.529 4.030 3.121 4.227 1.825 
Q8BPF4 2.092 1.100 3.270 2.154 4.950 3.285 2.377 3.537 1.642 
GSTM1 3.541 0.255 2.042 1.946 0.844 2.926 0.935 1.568 0.806 
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HSPA4 3.661 0.748 1.148 1.852 0.392 6.340 0.952 2.561 1.383 
RPL35 2.461 0.751 2.042 1.751 11.781 2.926 6.390 7.032 4.015 
DCTN3 1.839 1.917 1.157 1.638 0.214 2.132 0.430 0.925 0.565 
EIF4A2 2.041 0.561 2.155 1.585 6.060 2.251 1.869 3.393 2.140 
EIF4A1 1.856 0.675 1.928 1.487 5.394 2.175 2.009 3.193 2.148 
GPM6A 3.021 0.475 0.857 1.451 4.164 1.914 2.185 2.754 1.898 
ACTN1 2.240 0.620 1.440 1.433 3.240 2.686 1.436 2.454 1.712 
PPP1CC 1.465 0.520 1.749 1.245 5.073 1.544 0.519 2.379 1.911 
HSPH1 2.000 0.853 0.780 1.211 0.444 2.313 0.750 1.169 0.965 
RPL17 1.046 0.983 1.436 1.155 1.362 0.706 1.113 1.060 0.918 
UCHL1 1.386 0.741 1.015 1.047 0.000 0.394 0.000 0.131 0.125 
HRG 0.000 0.000 3.119 1.040 0.092 0.000 4.821 1.637 1.575 
PPP1CA 1.184 0.534 1.388 1.035 4.511 2.157 0.395 2.354 2.275 
ACTN4 1.559 0.428 0.994 0.994 2.943 1.878 1.020 1.947 1.959 
HSPA4L 1.722 0.521 0.573 0.939 0.058 2.772 0.605 1.145 1.220 
RAB2A 0.895 0.598 1.288 0.927 0.581 0.065 0.000 0.215 0.232 
PDXK 1.197 0.692 0.777 0.889 0.000 1.834 0.399 0.744 0.838 
HPRT1 1.840 0.536 0.165 0.847 0.000 0.364 0.000 0.121 0.143 
GLUD1 1.093 0.141 1.197 0.810 0.633 1.017 0.475 0.708 0.874 
H1F0 1.677 0.000 0.713 0.797 3.595 1.067 1.586 2.083 2.614 
HIST1H2BP 1.758 0.199 0.382 0.780 9.407 0.858 0.000 3.422 4.388 
PCBP2 0.943 0.271 1.072 0.762 2.338 1.322 0.811 1.490 1.955 
SEPT4 0.952 0.234 0.955 0.714 3.157 1.685 1.404 2.082 2.916 
RIMS1 0.543 0.249 1.350 0.714 5.444 1.269 4.397 3.703 5.189 
GPD2 1.020 0.346 0.743 0.703 0.638 1.203 0.312 0.718 1.021 
SFXN1 0.876 0.281 0.885 0.681 0.000 1.499 1.073 0.857 1.260 
GPM6B 1.341 0.368 0.310 0.673 1.911 1.012 0.673 1.199 1.780 
VIM 0.675 0.328 1.001 0.668 6.011 1.486 1.698 3.065 4.589 
KRAS 0.608 0.281 1.039 0.643 2.182 0.935 0.000 1.039 1.616 
GNA13 0.000 1.849 0.000 0.616 0.000 2.823 0.000 0.941 1.527 
DHPS 0.958 0.373 0.448 0.593 0.000 2.071 0.000 0.690 1.164 
SLC2A1 0.730 0.322 0.716 0.589 0.000 0.000 0.000 0.000 0.000 
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AMPH 0.763 0.068 0.935 0.589 1.923 1.266 0.647 1.279 2.173 
IDH3A 0.794 0.567 0.355 0.572 0.000 1.526 0.774 0.767 1.340 
BASP1 0.262 0.000 1.376 0.546 0.000 0.000 0.688 0.229 0.420 
Q8BL94 0.713 0.268 0.654 0.545 1.823 0.960 0.500 1.094 2.009 
NDUFV2 0.898 0.206 0.518 0.541 0.373 0.094 0.000 0.156 0.288 
CAPZA1 0.751 0.653 0.184 0.529 0.000 5.724 0.000 1.908 3.605 
UBA1 0.680 0.348 0.545 0.525 0.505 0.525 0.328 0.453 0.863 
EIF4A3 0.604 0.236 0.717 0.519 2.016 0.750 0.967 1.244 2.398 
ALDH2 0.724 0.248 0.565 0.512 0.839 1.363 0.672 0.958 1.871 
H2AFY 1.521 0.009 0.000 0.510 0.000 0.000 0.000 0.000 0.000 
ANKRD6 1.527 0.000 0.000 0.509 0.000 0.418 1.011 0.476 0.935 
ASS1 0.779 0.149 0.535 0.488 1.613 0.450 0.424 0.829 1.699 
RPS7 0.234 0.708 0.423 0.455 0.000 0.000 0.000 0.000 0.000 
NRAS 0.451 0.247 0.665 0.454 0.479 0.598 0.671 0.582 1.281 
DBN1 0.226 0.156 0.977 0.453 4.325 0.454 1.012 1.930 4.261 
RPL24 0.309 0.390 0.638 0.446 1.024 0.198 0.778 0.667 1.495 
NDRG2 0.555 0.715 0.059 0.443 0.088 0.415 0.427 0.310 0.700 
CAP2 0.667 0.129 0.411 0.403 0.186 1.161 0.158 0.502 1.246 
ALDOC 0.456 0.031 0.696 0.394 0.247 0.508 0.422 0.392 0.995 
AHCY 0.586 0.159 0.395 0.380 1.498 0.439 0.037 0.658 1.733 
CA2 0.780 0.152 0.199 0.377 0.000 0.013 0.000 0.004 0.011 
FAM213A 0.439 0.266 0.358 0.354 0.000 0.000 0.000 0.000 0.000 
SFXN5 0.594 0.113 0.314 0.340 0.000 0.578 0.000 0.193 0.566 
ACTN2 0.442 0.111 0.459 0.337 1.123 0.585 0.265 0.658 1.951 
PFN2 0.000 0.653 0.358 0.337 0.000 0.000 0.000 0.000 0.000 
ASPA 0.611 0.123 0.269 0.334 0.000 0.465 0.000 0.155 0.464 
GSTZ1 0.535 0.105 0.325 0.322 0.000 0.000 0.000 0.000 0.000 
IMPA1 0.462 0.145 0.351 0.319 0.000 1.647 0.334 0.660 2.068 
SIRT2 0.616 0.134 0.203 0.318 0.498 0.567 0.371 0.479 1.508 
CCT8 0.443 0.113 0.396 0.317 1.488 0.822 0.587 0.966 3.046 
ESD 0.470 0.129 0.326 0.308 0.935 0.352 0.381 0.556 1.802 
KCTD12 0.416 0.129 0.363 0.303 0.000 0.400 0.000 0.133 0.440 
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CCT7 0.582 0.084 0.226 0.297 0.430 0.300 0.109 0.279 0.939 
ARHGDIA 0.742 0.000 0.141 0.295 0.000 0.000 0.000 0.000 0.000 
DSTN 0.445 0.314 0.125 0.294 0.000 0.255 0.196 0.151 0.512 
NDRG3 0.353 0.216 0.313 0.294 0.000 0.345 0.000 0.115 0.391 
COPS6 0.440 0.105 0.332 0.292 0.380 0.694 0.149 0.408 1.395 
ALDH5A1 0.416 0.160 0.277 0.284 0.218 0.748 0.081 0.349 1.228 
PPP2R2D 0.401 0.163 0.277 0.280 0.954 0.313 0.097 0.455 1.623 
ECHS1 0.312 0.047 0.458 0.272 0.665 0.597 0.060 0.440 1.616 
ATP5J2 0.370 0.000 0.432 0.268 0.974 1.187 0.000 0.720 2.693 
CRYM 0.447 0.136 0.214 0.266 1.032 1.218 0.222 0.824 3.099 
PRPS1 0.528 0.257 0.000 0.262 1.093 0.655 0.290 0.679 2.594 
GSTM5 0.491 0.182 0.111 0.261 0.000 0.233 0.042 0.091 0.350 
PGAM5 0.559 0.046 0.175 0.260 0.476 0.545 0.140 0.387 1.488 
ACTR3B 0.475 0.082 0.222 0.260 0.000 0.980 0.155 0.378 1.458 
FLOT2 0.532 0.121 0.120 0.258 0.485 0.247 0.232 0.321 1.246 
EEF1B 0.288 0.086 0.369 0.248 0.460 0.530 0.112 0.367 1.483 
PAICS 0.344 0.103 0.271 0.239 0.053 0.542 0.085 0.227 0.949 
GLS 0.125 0.147 0.439 0.237 0.730 0.311 0.042 0.361 1.525 
RAB18 0.227 0.235 0.241 0.235 0.365 0.175 0.127 0.223 0.949 
DNPEP 0.537 0.106 0.034 0.226 0.000 0.678 0.000 0.226 1.001 
RTN3 0.384 0.000 0.280 0.221 4.338 0.269 0.000 1.536 6.935 
SDHB 0.164 0.039 0.456 0.220 0.000 0.629 0.103 0.244 1.109 
RPL15 0.535 0.060 0.061 0.219 0.492 0.276 0.474 0.414 1.891 
PGRMC1 0.374 0.083 0.197 0.218 0.000 0.314 0.000 0.105 0.480 
USP5 0.379 0.080 0.180 0.213 0.315 0.414 0.000 0.243 1.142 
CPNE6 0.231 0.145 0.252 0.210 0.215 0.340 0.235 0.263 1.256 
TPM3 0.222 0.067 0.339 0.209 0.000 0.474 0.637 0.370 1.769 
ETFA 0.330 0.057 0.237 0.208 0.376 0.453 0.070 0.299 1.439 
SOD2 0.444 0.055 0.118 0.206 0.000 0.000 0.000 0.000 0.000 
SPR 0.213 0.191 0.204 0.203 0.000 0.222 0.000 0.074 0.364 
ACIN1 0.117 0.000 0.480 0.199 0.525 0.127 0.461 0.371 1.862 
RPL29 0.473 0.104 0.000 0.192 0.000 0.000 0.000 0.000 0.000 
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CYFIP2 0.267 0.081 0.217 0.188 0.650 0.342 12.481 4.491 23.830 
FAM49A 0.300 0.099 0.158 0.186 0.000 0.384 0.000 0.128 0.689 
MTCH2 0.067 0.128 0.356 0.184 0.244 0.112 0.000 0.119 0.646 
PAFAH1B2 0.365 0.065 0.116 0.182 0.760 0.206 0.169 0.378 2.080 
ASRGL1 0.223 0.171 0.141 0.179 0.000 0.331 0.000 0.110 0.618 
WASF1 0.130 0.080 0.294 0.168 0.686 0.828 0.143 0.553 3.290 
DNAJC6 0.146 0.068 0.289 0.168 0.000 0.030 0.154 0.061 0.367 
MYO1D 0.023 0.274 0.182 0.160 0.432 0.031 0.011 0.158 0.989 
VPS26B 0.383 0.000 0.044 0.142 0.000 0.351 0.000 0.117 0.823 
PARK7 0.111 0.105 0.201 0.139 0.000 0.000 0.000 0.000 0.000 
GSK3B 0.276 0.139 0.000 0.138 0.000 0.260 0.000 0.087 0.628 
GPX4 0.116 0.151 0.136 0.134 0.067 0.000 0.057 0.042 0.309 
GSN 0.000 0.009 0.390 0.133 1.342 0.047 0.000 0.463 3.486 
GABRA1 0.055 0.033 0.301 0.129 0.173 0.381 0.077 0.211 1.627 
RPS15A 0.186 0.065 0.138 0.129 0.000 0.215 0.195 0.137 1.057 
CYB5R3 0.137 0.000 0.241 0.126 0.454 0.117 0.000 0.190 1.513 
MRPL24 0.252 0.027 0.091 0.123 0.891 0.574 0.188 0.551 4.461 
NAPG 0.180 0.027 0.147 0.118 0.368 0.064 0.089 0.174 1.471 
GDI1 0.167 0.000 0.184 0.117 0.349 0.219 0.000 0.189 1.621 
PSMA7 0.348 0.000 0.000 0.116 0.421 0.155 0.201 0.259 2.232 
NDUFA4 0.000 0.117 0.230 0.116 0.000 0.000 0.000 0.000 0.000 
ARL8B 0.108 0.084 0.147 0.113 0.401 0.229 0.160 0.263 2.325 
SPTAN1 0.142 0.036 0.156 0.112 2.695 0.696 0.995 1.462 13.109 
TRA2A 0.141 0.000 0.193 0.111 1.646 0.154 0.000 0.600 5.397 
CAMK4 0.244 0.027 0.058 0.109 0.267 0.097 0.000 0.121 1.111 
ARHGAP1 0.123 0.137 0.063 0.107 0.000 0.175 0.000 0.058 0.543 
ETFB 0.000 0.110 0.211 0.107 0.368 0.288 0.180 0.279 2.603 
SORCS2 0.239 0.032 0.034 0.102 0.000 0.483 0.000 0.161 1.581 
MAG 0.111 0.019 0.169 0.100 0.181 0.072 0.060 0.105 1.050 
BIN1 0.070 0.095 0.111 0.092 0.157 0.061 0.000 0.073 0.792 
RUVBL1 0.094 0.035 0.144 0.091 0.000 0.520 0.000 0.173 1.906 
GPD1L 0.112 0.072 0.088 0.091 0.000 0.111 0.000 0.037 0.408 
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ALDH1L1 0.155 0.050 0.067 0.090 0.000 0.413 0.074 0.162 1.793 
KIAA1045 0.154 0.064 0.053 0.090 0.066 0.225 0.047 0.113 1.251 
HYOU1 0.150 0.044 0.071 0.088 0.169 0.149 0.086 0.135 1.529 
MAT2A 0.176 0.074 0.000 0.083 0.000 0.378 0.000 0.126 1.518 
CORO1C 0.048 0.031 0.170 0.083 0.000 0.274 0.044 0.106 1.278 
GDAP1L1 0.203 0.044 0.000 0.082 0.351 0.234 0.041 0.209 2.542 
TOMM70A 0.085 0.083 0.078 0.082 0.120 0.000 0.019 0.046 0.564 
APPL1 0.098 0.021 0.116 0.079 0.000 0.181 0.000 0.060 0.765 
PSMD5 0.079 0.025 0.112 0.072 0.214 0.150 0.000 0.121 1.679 
RAP2B 0.064 0.018 0.134 0.072 0.000 0.671 0.625 0.432 5.999 
PSMA6 0.157 0.006 0.053 0.072 0.232 0.000 0.000 0.077 1.075 
MGLL 0.094 0.067 0.050 0.071 0.000 0.028 0.094 0.041 0.575 
DSG1B 0.174 0.005 0.034 0.071 0.105 0.000 0.000 0.035 0.493 
RPL11 0.000 0.212 0.000 0.071 0.000 0.167 0.000 0.056 0.790 
UGP2 0.171 0.040 0.000 0.070 0.000 0.348 0.000 0.116 1.650 
KIF2A 0.096 0.031 0.081 0.070 0.106 0.147 0.027 0.094 1.344 
RHOT1 0.144 0.064 0.000 0.069 0.149 0.042 0.000 0.064 0.916 
ACSBG1 0.113 0.053 0.042 0.069 0.030 0.144 0.117 0.097 1.399 
PPME1 0.092 0.047 0.066 0.068 0.000 0.000 0.000 0.000 0.000 
IDH2 0.087 0.012 0.105 0.068 0.000 0.152 0.024 0.059 0.861 
RPS11 0.151 0.049 0.000 0.067 0.000 0.000 0.000 0.000 0.000 
ATP5H 0.064 0.136 0.000 0.067 0.632 0.116 0.000 0.249 3.739 
RUVBL2 0.079 0.000 0.118 0.066 0.000 0.186 0.000 0.062 0.944 
PRMT5 0.112 0.022 0.060 0.065 0.154 0.309 0.084 0.183 2.829 
GRHPR 0.136 0.052 0.000 0.063 0.000 0.000 0.000 0.000 0.000 
PDK3 0.103 0.051 0.033 0.062 0.000 0.140 0.000 0.047 0.750 
GAD2 0.088 0.074 0.022 0.061 0.000 0.000 0.000 0.000 0.000 
AGK 0.101 0.000 0.081 0.061 0.000 0.037 0.000 0.012 0.205 
ACSF2 0.055 0.033 0.094 0.061 0.000 0.000 0.000 0.000 0.000 
DYNC1LI1 0.056 0.021 0.099 0.059 0.000 0.124 0.048 0.057 0.979 
GPS1 0.076 0.018 0.079 0.058 0.000 0.283 0.000 0.094 1.636 
PAFAH1B1 0.172 0.000 0.000 0.057 0.000 0.198 0.000 0.066 1.150 
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SLC8A1 0.112 0.023 0.037 0.057 0.128 0.069 0.031 0.076 1.326 
PGP 0.086 0.050 0.033 0.056 0.000 0.056 0.000 0.019 0.331 
FN3K 0.000 0.161 0.000 0.054 0.000 0.000 0.033 0.011 0.208 
FXR2 0.000 0.160 0.000 0.053 0.000 0.615 0.000 0.205 3.845 
ALDH6A1 0.067 0.021 0.069 0.053 0.136 0.138 0.106 0.127 2.413 
NMRAL1 0.037 0.000 0.117 0.051 0.000 0.000 0.000 0.000 0.000 
EIF3F 0.053 0.003 0.097 0.051 0.460 0.122 0.000 0.194 3.800 
NPM1 0.000 0.000 0.152 0.051 1.812 0.000 0.000 0.604 11.923 
MAT2B 0.081 0.071 0.000 0.050 0.000 0.065 0.000 0.022 0.427 
EFHD2 0.087 0.000 0.062 0.050 0.104 0.021 0.000 0.042 0.840 
KPNA4 0.119 0.030 0.000 0.050 1.301 0.000 0.000 0.434 8.759 
PLCB4 0.000 0.026 0.121 0.049 1.134 0.012 0.423 0.523 10.669 
ROGDI 0.087 0.000 0.058 0.048 0.140 0.074 0.000 0.071 1.478 
CHORDC1 0.000 0.016 0.126 0.047 0.000 0.141 0.000 0.047 0.999 
NDRG4 0.106 0.035 0.000 0.047 0.000 0.000 0.000 0.000 0.000 
BCAN 0.042 0.000 0.098 0.047 0.185 0.057 0.079 0.107 2.291 
GABRG2 0.059 0.021 0.060 0.046 0.000 0.000 0.007 0.002 0.052 
DCLK2 0.082 0.017 0.036 0.045 0.061 0.063 0.000 0.042 0.922 
TSN 0.134 0.000 0.000 0.045 0.000 0.000 0.000 0.000 0.000 
HADHA 0.044 0.020 0.066 0.044 0.000 0.000 0.000 0.000 0.000 
RIMBP2 0.028 0.000 0.102 0.043 0.075 0.000 0.172 0.082 1.903 
ACADVL 0.089 0.011 0.029 0.043 0.526 0.075 0.000 0.201 4.658 
ACLY 0.050 0.030 0.048 0.043 0.000 0.126 0.034 0.054 1.251 
HSD17B8 0.010 0.023 0.093 0.042 0.000 0.053 0.000 0.018 0.421 
PPM1H 0.086 0.023 0.018 0.042 0.000 0.000 0.000 0.000 0.000 
GSK3A 0.060 0.000 0.062 0.040 0.000 0.157 0.000 0.052 1.298 
SERPINB1A 0.017 0.020 0.083 0.040 0.000 0.129 0.000 0.043 1.073 
TMOD2 0.000 0.000 0.119 0.040 1.924 0.072 0.168 0.721 18.242 
LAP3 0.051 0.023 0.044 0.039 0.000 0.000 0.000 0.000 0.000 
FARSA 0.023 0.040 0.054 0.039 0.000 0.033 0.000 0.011 0.279 
VSNL1 0.035 0.080 0.000 0.038 0.176 0.181 0.000 0.119 3.091 
AP3M2 0.113 0.000 0.000 0.038 0.000 0.069 0.000 0.023 0.610 
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SH3GLB2 0.012 0.000 0.100 0.037 0.076 0.121 0.000 0.066 1.752 
PPM1E 0.047 0.021 0.045 0.037 0.073 0.134 0.000 0.069 1.853 
ATP1B3 0.080 0.032 0.000 0.037 0.000 0.342 0.000 0.114 3.073 
SIRPA 0.071 0.000 0.039 0.037 0.000 0.016 0.000 0.005 0.145 
NDRG1 0.047 0.000 0.062 0.037 0.000 0.184 0.095 0.093 2.539 
FERMT2 0.056 0.016 0.033 0.035 0.000 0.071 0.000 0.024 0.677 
OPLAH 0.094 0.010 0.000 0.035 0.000 0.150 0.000 0.050 1.447 
ERLIN2 0.104 0.000 0.000 0.035 0.437 0.247 0.000 0.228 6.589 
CAPN2 0.024 0.053 0.025 0.034 0.000 0.000 0.000 0.000 0.000 
EIF3L 0.058 0.007 0.036 0.034 0.000 0.079 0.105 0.061 1.825 
CORO2B 0.033 0.024 0.039 0.032 0.274 0.013 0.067 0.118 3.659 
RARS 0.045 0.022 0.029 0.032 0.000 0.024 0.000 0.008 0.247 
NT5C2 0.084 0.010 0.000 0.032 0.000 0.013 0.000 0.004 0.141 
SPTBN1 0.023 0.008 0.062 0.031 0.280 0.033 0.121 0.144 4.662 
ABCB7 0.054 0.003 0.035 0.031 0.000 0.115 0.000 0.038 1.243 
HNRNPLL 0.045 0.011 0.036 0.031 0.000 0.000 0.000 0.000 0.000 
DLG2 0.000 0.000 0.091 0.030 0.434 0.019 0.060 0.171 5.669 
HIBADH 0.053 0.012 0.024 0.030 0.000 0.201 0.000 0.067 2.264 
GIT1 0.013 0.000 0.076 0.029 0.000 0.000 0.000 0.000 0.000 
STOML2 0.037 0.052 0.000 0.029 0.188 0.063 0.000 0.084 2.839 
FSD1 0.057 0.000 0.028 0.028 0.000 0.127 0.000 0.042 1.497 
ABLIM1 0.030 0.020 0.033 0.027 0.667 0.000 0.245 0.304 11.120 
ATAD3 0.035 0.016 0.030 0.027 0.000 0.061 0.000 0.020 0.752 
TOLLIP 0.000 0.000 0.079 0.026 0.000 0.321 0.135 0.152 5.757 
MPST 0.059 0.016 0.000 0.025 0.000 0.306 0.000 0.102 4.106 
KPNA3 0.059 0.015 0.000 0.025 1.194 0.000 0.000 0.398 16.074 
DECR1 0.069 0.000 0.000 0.023 0.000 0.110 0.000 0.037 1.590 
PDE1B 0.000 0.030 0.038 0.023 0.000 0.066 0.000 0.022 0.967 
PTPRS 0.050 0.018 0.000 0.023 0.051 0.074 0.000 0.042 1.838 
PPM1F 0.037 0.000 0.031 0.023 0.194 0.106 0.182 0.160 7.080 
PDE1A 0.000 0.000 0.068 0.023 0.000 0.143 0.000 0.048 2.119 
ABHD12 0.031 0.017 0.019 0.022 0.086 0.042 0.000 0.042 1.908 
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ENDOD1 0.037 0.012 0.015 0.022 0.071 0.037 0.000 0.036 1.665 
SNX27 0.040 0.025 0.000 0.022 0.000 0.019 0.000 0.006 0.292 
OGT 0.023 0.006 0.033 0.021 0.000 0.017 0.035 0.017 0.832 
HPCA 0.000 0.059 0.000 0.020 0.000 0.033 0.000 0.011 0.552 
DDX41 0.000 0.000 0.059 0.020 0.038 0.028 0.087 0.051 2.601 
HSD17B4 0.039 0.006 0.013 0.019 0.000 0.035 0.000 0.012 0.606 
NFS1 0.048 0.009 0.000 0.019 0.000 0.101 0.000 0.034 1.759 
PSMC1 0.020 0.004 0.031 0.018 0.140 0.558 0.000 0.233 12.800 
KBTBD11 0.022 0.031 0.000 0.018 0.000 0.000 0.000 0.000 0.000 
SUGT1 0.000 0.000 0.052 0.017 0.000 0.182 0.000 0.061 3.518 
GRB2 0.000 0.051 0.000 0.017 0.105 0.000 0.000 0.035 2.052 
PTPRD 0.021 0.008 0.019 0.016 0.182 0.146 0.009 0.112 6.895 
TARS 0.031 0.004 0.013 0.016 0.115 0.079 0.000 0.065 4.000 
TMEM33 0.048 0.000 0.000 0.016 0.360 0.000 0.000 0.120 7.461 
MAN2C1 0.023 0.015 0.008 0.015 0.000 0.060 0.012 0.024 1.544 
NECAB2 0.026 0.006 0.013 0.015 0.000 0.764 0.000 0.255 16.569 
CUL5 0.013 0.014 0.019 0.015 0.000 0.000 0.000 0.000 0.000 
RAP1GAP 0.025 0.011 0.010 0.015 0.000 0.051 0.000 0.017 1.117 
STIP1 0.015 0.011 0.020 0.015 0.000 0.088 0.000 0.029 1.928 
BSN 0.000 0.003 0.041 0.015 0.186 0.006 0.103 0.098 6.712 
RPN2 0.000 0.000 0.044 0.015 0.000 0.000 0.000 0.000 0.000 
ABLIM2 0.000 0.005 0.038 0.014 0.125 0.015 0.012 0.051 3.523 
RNH1 0.000 0.021 0.018 0.013 0.000 0.047 0.000 0.016 1.213 
EIF3E 0.000 0.000 0.037 0.012 0.153 0.025 0.023 0.067 5.465 
RPS16 0.036 0.000 0.000 0.012 0.742 0.204 0.396 0.447 37.290 
TU52 0.036 0.000 0.000 0.012 0.000 0.040 0.000 0.013 1.128 
ALDH9A1 0.023 0.013 0.000 0.012 0.000 0.118 0.000 0.039 3.354 
MAOA 0.000 0.034 0.000 0.011 0.183 0.000 0.000 0.061 5.340 
VAPA 0.000 0.034 0.000 0.011 0.000 0.000 0.000 0.000 0.000 
DCTN1 0.034 0.000 0.000 0.011 0.000 0.067 0.048 0.039 3.439 
GMPS 0.008 0.010 0.016 0.011 0.000 0.004 0.000 0.001 0.124 
G6PDX 0.000 0.019 0.012 0.010 0.000 0.054 0.000 0.018 1.746 
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ATXN10 0.012 0.016 0.000 0.010 0.000 0.000 0.000 0.000 0.000 
USP7 0.012 0.006 0.010 0.009 0.000 0.006 0.000 0.002 0.197 
TRIM3 0.000 0.028 0.000 0.009 0.000 0.000 0.000 0.000 0.000 
FBXL16 0.000 0.026 0.000 0.009 0.000 0.035 0.000 0.012 1.348 
BSG 0.025 0.000 0.000 0.008 0.000 0.069 0.000 0.023 2.718 
MKIAA0617 0.022 0.000 0.002 0.008 0.000 0.004 0.000 0.001 0.167 
RPN1 0.000 0.004 0.018 0.007 0.000 0.000 0.000 0.000 0.000 
CTNND2 0.008 0.000 0.013 0.007 0.000 0.004 0.000 0.001 0.201 
ENPP6 0.004 0.000 0.017 0.007 0.230 0.022 0.000 0.084 12.387 
G6PD2 0.000 0.019 0.000 0.006 0.000 0.054 0.000 0.018 2.792 
PDK1 0.000 0.004 0.015 0.006 0.000 0.074 0.000 0.025 4.030 
ANK2 0.004 0.005 0.009 0.006 0.091 0.010 0.032 0.044 7.319 
HOMER2 0.000 0.000 0.018 0.006 0.232 0.136 0.151 0.173 29.506 
GANAB 0.004 0.000 0.012 0.005 0.000 0.000 0.000 0.000 0.000 
FAM126B 0.008 0.007 0.000 0.005 0.000 0.000 0.000 0.000 0.000 
PSMD11 0.000 0.015 0.000 0.005 0.000 0.005 0.000 0.002 0.310 
CLASP2 0.011 0.000 0.004 0.005 0.000 0.000 0.000 0.000 0.000 
MYH10 0.000 0.000 0.015 0.005 0.022 0.000 0.018 0.013 2.694 
COPS5 0.015 0.000 0.000 0.005 0.000 0.569 0.000 0.190 39.221 
MADD 0.012 0.001 0.000 0.004 0.000 0.000 0.000 0.000 0.000 
CMPK1 0.000 0.012 0.000 0.004 0.000 0.000 0.000 0.000 0.000 
PPP1R9A 0.006 0.000 0.006 0.004 0.022 0.056 0.119 0.066 16.279 
TTC7B 0.000 0.003 0.009 0.004 0.000 0.025 0.000 0.008 2.090 
RTN1 0.000 0.011 0.000 0.004 0.112 0.224 0.000 0.112 29.881 
ABR 0.000 0.010 0.000 0.003 0.000 0.000 0.000 0.000 0.000 
PSMC3 0.000 0.010 0.000 0.003 0.129 0.168 0.000 0.099 29.832 
TRAPPC12 0.008 0.000 0.000 0.003 0.000 0.021 0.000 0.007 2.548 
PSMC6 0.000 0.006 0.000 0.002 0.000 0.147 0.000 0.049 23.211 
HAPLN4 0.000 0.005 0.000 0.002 0.000 0.000 0.000 0.000 0.000 
RBM15 0.000 0.000 0.004 0.001 0.083 0.000 0.007 0.030 22.002 
SACM1L 0.000 0.002 0.000 0.001 0.000 0.039 0.000 0.013 18.819 
HIST1H2AB 0.000 0.000 0.000 0.000 16.039 0.940 8.857 8.612 Infinite 
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RTN4 0.000 0.000 0.000 0.000 0.000 0.112 0.052 0.055 Infinite 
PCMT1 0.000 0.000 0.000 0.000 1.388 0.000 0.523 0.637 Infinite 
Q3THB2 0.000 0.000 0.000 0.000 0.000 0.826 0.192 0.339 Infinite 
COPS4 0.000 0.000 0.000 0.000 0.000 0.212 0.038 0.083 Infinite 
SLIT2 0.000 0.000 0.000 0.000 0.000 0.005 0.028 0.011 Infinite 
AGL 0.000 0.000 0.000 0.000 0.000 0.000 0.059 0.020 Infinite 
ANXA1 0.000 0.000 0.000 0.000 1.905 0.000 0.000 0.635 Infinite 
CCAR2 0.000 0.000 0.000 0.000 0.000 0.023 0.000 0.008 Infinite 
CYCS 0.000 0.000 0.000 0.000 0.000 0.000 0.773 0.258 Infinite 
DNAJB6 0.000 0.000 0.000 0.000 0.000 0.343 0.000 0.114 Infinite 
ELAVL2 0.000 0.000 0.000 0.000 0.000 0.144 0.000 0.048 Infinite 
FARP1 0.000 0.000 0.000 0.000 0.000 0.020 0.000 0.007 Infinite 
GBE1 0.000 0.000 0.000 0.000 0.433 0.000 0.000 0.144 Infinite 
GRIA2 0.000 0.000 0.000 0.000 0.000 0.053 0.000 0.018 Infinite 
MAPK9 0.000 0.000 0.000 0.000 0.000 0.123 0.000 0.041 Infinite 
SDR39U1 0.000 0.000 0.000 0.000 0.000 0.182 0.000 0.061 Infinite 
TRIM21 0.000 0.000 0.000 0.000 0.000 0.538 0.000 0.179 Infinite 
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APPENDIX X 
Keyword functional annotation terms enriched in the list of proteins increasing their 
association with tau (>2-fold) in P301S TIA1+/- compared to P301S TIA1+/+ cortex, as 
detected by LC-MS/MS of tau IPs: 
 
Keyword functional annotation term FDR 
Acetylation 1.20E-16 
Cytoplasm 7.49E-12 
Phosphoprotein 2.57E-09 
Synapse 2.46E-05 
Actin-binding 5.31E-04 
Actin capping 0.001485 
Cell junction 0.004851 
Cytoskeleton 0.004936 
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APPENDIX XI 
 
GO Molecular Function annotation terms significantly enriched (FDR<0.05) in the tau 
interactome of human AD cortex, as detected by OrbiTrap LC-MS/MS analysis of Tau IP 
samples: 
 
Reference No. GO annotation Count FDR 
GO:0044822 poly(A) RNA binding 263 1.13E-66 
GO:0005515 protein binding 884 2.74E-45 
GO:0098641 cadherin binding involved in cell-cell adhesion 97 1.85E-35 
GO:0005524 ATP binding 233 2.33E-27 
GO:0003723 RNA binding 116 8.80E-23 
GO:0003924 GTPase activity 71 2.90E-22 
GO:0005525 GTP binding 92 2.24E-21 
GO:0005200 structural constituent of cytoskeleton 45 6.58E-19 
GO:0000166 nucleotide binding 82 2.86E-18 
GO:0051287 NAD binding 26 1.01E-16 
GO:0051082 unfolded protein binding 40 2.10E-14 
GO:0003779 actin binding 63 1.81E-12 
GO:0051015 actin filament binding 41 4.51E-12 
GO:0042802 identical protein binding 109 6.83E-09 
GO:0005516 calmodulin binding 44 2.23E-08 
GO:0019904 protein domain specific binding 45 1.67E-07 
GO:0004298 threonine-type endopeptidase activity 14 2.98E-07 
GO:0008022 protein C-terminus binding 41 3.51E-07 
GO:0005198 structural molecule activity 49 5.25E-07 
GO:0016887 ATPase activity 40 1.53E-06 
GO:0019899 enzyme binding 58 1.93E-06 
GO:0008017 microtubule binding 43 2.00E-06 
GO:0019901 protein kinase binding 62 4.42E-06 
GO:0003729 mRNA binding 31 7.15E-06 
GO:0044325 ion channel binding 29 1.09E-05 
GO:0019003 GDP binding 19 3.84E-05 
GO:0032403 protein complex binding 40 5.04E-05 
GO:0008143 poly(A) binding 10 5.07E-05 
GO:0019900 kinase binding 22 8.55E-05 
GO:0003725 double-stranded RNA binding 19 3.18E-04 
GO:0001948 glycoprotein binding 19 9.11E-04 
GO:0035255 ionotropic glutamate receptor binding 11 0.001125 
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GO:0016616 oxidoreductase activity, acting on the CH-OH group of donors, NAD or 
NADP as acceptor 
10 0.001318 
GO:0031489 myosin V binding 10 0.001318 
GO:0046961 proton-transporting ATPase activity, rotational mechanism 12 0.00135 
GO:0051087 chaperone binding 21 0.001635 
GO:0042803 protein homodimerization activity 89 0.003071 
GO:0008092 cytoskeletal protein binding 15 0.0084 
GO:0051020 GTPase binding 11 0.012085 
GO:0030507 spectrin binding 11 0.012085 
GO:0019001 guanyl nucleotide binding 7 0.016821 
GO:0005388 calcium-transporting ATPase activity 7 0.016821 
GO:0031625 ubiquitin protein ligase binding 43 0.019184 
GO:0043531 ADP binding 12 0.02101 
GO:0005391 sodium:potassium-exchanging ATPase activity 7 0.039441 
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APPENDIX XII 
 
List of RNA binding proteins in the tau interactome of human AD cortex, as detected by 
OrbiTrap LC-MS/MS of Tau IP samples: 
 
Gene ID Protein Name 
AARS alanyl-tRNA synthetase 
ADAR adenosine deaminase, RNA specific 
AHCYL1 adenosylhomocysteinase like 1 
ALYREF Aly/REF export factor 
ANXA2 annexin A2 
C14ORF166 chromosome 14 open reading frame 166 
CAPRIN1 cell cycle associated protein 1 
CELF2 CUGBP, Elav-like family member 2 
CIRBP cold inducible RNA binding protein 
CNP 2',3'-cyclic nucleotide 3' phosphodiesterase 
CPSF6 cleavage and polyadenylation specific factor 6 
CPSF7 cleavage and polyadenylation specific factor 7 
CSDE1 cold shock domain containing E1 
DDX1 DEAD-box helicase 1 
DDX17 DEAD-box helicase 17 
DDX19A DEAD-box helicase 19A 
DDX39A DExD-box helicase 39A 
DDX39B DExD-box helicase 39B 
DDX3X DEAD-box helicase 3, X-linked 
DDX5 DEAD-box helicase 5 
DHX9 DExH-box helicase 9 
EIF2AK2 eukaryotic translation initiation factor 2 alpha kinase 2 
EIF2S1 eukaryotic translation initiation factor 2 subunit alpha 
EIF4A1 eukaryotic translation initiation factor 4A1 
EIF4A2 eukaryotic translation initiation factor 4A2 
EIF4A3 eukaryotic translation initiation factor 4A3 
EIF4H eukaryotic translation initiation factor 4H 
ELAVL1 ELAV like RNA binding protein 1 
ELAVL2 ELAV like RNA binding protein 2 
ELAVL3 ELAV like RNA binding protein 3 
ELAVL4 ELAV like RNA binding protein 4 
EWSR1 EWS RNA binding protein 1 
FBL fibrillarin 
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FBLL1 fibrillarin-like 1 
FMR1 fragile X mental retardation 1 
FUS FUS RNA binding protein 
G3BP2 G3BP stress granule assembly factor 2 
HNRNPA0 heterogeneous nuclear ribonucleoprotein A0 
HNRNPA1 heterogeneous nuclear ribonucleoprotein A1 
HNRNPA2B1 heterogeneous nuclear ribonucleoprotein A2/B1 
HNRNPA3 heterogeneous nuclear ribonucleoprotein A3 
HNRNPAB heterogeneous nuclear ribonucleoprotein A/B 
HNRNPC heterogeneous nuclear ribonucleoprotein C (C1/C2) 
HNRNPCL4 heterogeneous nuclear ribonucleoprotein C-like 4 
HNRNPD heterogeneous nuclear ribonucleoprotein D 
HNRNPDL heterogeneous nuclear ribonucleoprotein D like 
HNRNPF heterogeneous nuclear ribonucleoprotein F 
HNRNPH1 heterogeneous nuclear ribonucleoprotein H1  
HNRNPH2 heterogeneous nuclear ribonucleoprotein H2  
HNRNPH3 heterogeneous nuclear ribonucleoprotein H3 
HNRNPK heterogeneous nuclear ribonucleoprotein K 
HNRNPL heterogeneous nuclear ribonucleoprotein L 
HNRNPLL heterogeneous nuclear ribonucleoprotein L like 
HNRNPM heterogeneous nuclear ribonucleoprotein M 
HNRNPR heterogeneous nuclear ribonucleoprotein R 
HNRNPU heterogeneous nuclear ribonucleoprotein U 
HNRNPUL1 heterogeneous nuclear ribonucleoprotein U like 1 
ILF3 interleukin enhancer binding factor 3 
KHDRBS1 KH RNA binding domain containing, signal transduction associated 1 
KHDRBS2 KH RNA binding domain containing, signal transduction associated 2 
KHDRBS3 KH RNA binding domain containing, signal transduction associated 3 
KHSRP KH-type splicing regulatory protein 
LARP1 La ribonucleoprotein domain family member 1 
MYEF2 myelin expression factor 2 
NCL nucleolin 
NONO non-POU domain containing, octamer-binding 
NOVA1 NOVA alternative splicing regulator 1 
NOVA2 NOVA alternative splicing regulator 2 
NPM1 nucleophosmin 
NUDT21 nudix hydrolase 21 
NUDT5 nudix hydrolase 5 
PABPC1 poly(A) binding protein cytoplasmic 1 
PABPC1L poly(A) binding protein cytoplasmic 1 like 
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PABPC1L2A poly(A) binding protein cytoplasmic 1 like 2A 
PABPC3 poly(A) binding protein cytoplasmic 3 
PABPC4 poly(A) binding protein cytoplasmic 4 
PARK7 Parkinsonism associated deglycase 
PCBP1 poly(rC) binding protein 1 
PCBP2 poly(rC) binding protein 2 
PCBP3 poly(rC) binding protein 3 
PRKRA protein activator of interferon induced protein kinase EIF2AK2 
PRPF8 pre-mRNA processing factor 8 
PSPC1 paraspeckle component 1 
PTBP1 polypyrimidine tract binding protein 1 
PTBP2 polypyrimidine tract binding protein 2 
PTRF polymerase I and transcript release factor 
QKI QKI, KH domain containing RNA binding 
RALY RALY heterogeneous nuclear ribonucleoprotein 
RALYL RALY RNA binding protein-like 
RBFOX1 RNA binding protein, fox-1 homolog 1 
RBFOX3 RNA binding protein, fox-1 homolog 3 
RBM14 RNA binding motif protein 14 
RBM4 RNA binding motif protein 4 
RBMX RNA binding motif protein, X-linked 
RBMXL1 RNA binding motif protein, X-linked like 1 
RBMXL3 RNA binding motif protein, X-linked like 3 
RPL23A ribosomal protein L23a 
RPL7 ribosomal protein L7 
RPS3 ribosomal protein S3 
RPS4X ribosomal protein S4, X-linked 
SAFB scaffold attachment factor B 
SAFB2 scaffold attachment factor B2 
SERBP1 SERPINE1 mRNA binding protein 1 
SFPQ splicing factor proline and glutamine rich 
SNRPA small nuclear ribonucleoprotein polypeptide A 
SNRPA1 small nuclear ribonucleoprotein polypeptide A' 
SNRPE small nuclear ribonucleoprotein polypeptide E 
SNRPN small nuclear ribonucleoprotein polypeptide N 
SON SON DNA binding protein 
SRSF1 serine and arginine rich splicing factor 1 
SRSF10 serine and arginine rich splicing factor 10 
SRSF6 serine and arginine rich splicing factor 6 
SRSF7 serine and arginine rich splicing factor 7 
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SRSF8 serine and arginine rich splicing factor 8 
SSB Sjogren syndrome antigen B 
STRBP spermatid perinuclear RNA binding protein 
SYNCRIP synaptotagmin binding cytoplasmic RNA interacting protein 
SYNJ1 synaptojanin 1 
TAF15 TATA-box binding protein associated factor 15 
TARDBP TAR DNA binding protein 43 
TIMM50 translocase of inner mitochondrial membrane 50 
TRA2A transformer 2 alpha homolog 
TRA2B transformer 2 beta homolog  
TROVE2 TROVE domain family member 2 
U2AF1 U2 small nuclear RNA auxiliary factor 1 
U2AF2 U2 small nuclear RNA auxiliary factor 2 
XPO1 exportin 1 
ZFR zinc finger RNA binding protein 
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